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Complete occlusion of a coronary artery causes myocardial infarction (MI), 
resulting in cardiomyocyte cell death. The surviving myocardium undergoes a deleterious 
remodeling process which causes further injury, and can ultimately result in heart failure. 
Despite therapeutic advances that have prolonged life, MI remains a leading cause of 
death worldwide and imparts a significant economic burden. The advancement of 
treatments to improve cardiac repair post-MI requires the discovery of new targeted 
treatment strategies. Epicardial-to-mesenchymal transition (EMT) occurs post-MI as a 
mechanism to support neovascularization and cardiac healing. However, the endogenous 
EMT is not enough to support sufficient repair. The transcription factor Wilms’ tumor 1 
(Wt1) and the primary cilium regulate EMT by altering gene expression. Furthermore, 
the long non-coding RNA (lncRNA) Malat1 is not only known to regulate EMT, but also 
mitigates cell death from injury. Little is known about the roles of Wt1, primary cilia, and 
Malat1 in relation to neonatal cardiac regeneration and adult cardiac repair post-MI. The 
aim of this thesis was to investigate cardiac repair mechanisms related to EMT, primary 
cilia, and Malat1. To study the effects of Wt1 and Malat1 deficiency, a reproducible 
model of cardiac regeneration using coronary artery ligation to induce MI was developed 
in neonatal mice. We demonstrated the robust capacity for neonatal cardiac regeneration 
as neither Wt1 nor Malat1 deficiency affected the regenerative response. In the adult 
mouse, MI was induced to investigate the role of the primary cilium in EMT and repair 
post-MI, and the effects of Malat1 deficiency on acute MI pathology. We found that 
indeed epicardial cells are ciliated, and primary ciliary disassembly supports EMT post-
MI, which enhances the contribution of epicardium-derived cells (EPDCs) to 
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neovascularization. This reduced deleterious cardiac remodeling and preserved cardiac 
function. Contrastingly, Malat1 deficiency augmented cardiac cell death from MI. Rather 
than affecting apoptosis, Malat1 deficiency enhanced necroptotic cell death post-MI. 
Overall, this thesis is the first to show that in the adult heart, the primary cilium regulates 
epicardial EMT and the lncRNA Malat1 governs the propensity for necroptosis from 
ischemic injury. Both the primary cilium and Malat1 may serve as targets in the 
development of therapeutics to treat MI. 
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Diseases of the heart are the second leading cause of death in Canada and the 
leading cause of death worldwide.1, 2 Specifically, myocardial infarction (MI), often 
caused by coronary artery disease, is the most common form of sudden cardiac injury.3 
There has been significant improvement in therapeutic options for patients to treat MI 
and the subsequent disease associated with post-MI cardiac compensation. As a result, 
the number of Canadians who survive their in hospital stay after acute MI has increased 
from about 70% to over 90% in the last 60 years.4-6 Despite therapeutic advancement, MI 
and post-MI morbidity poses a significant financial burden for the health care system of 
most nations. In Canada, MI is the third leading cause of hospitalization and the largest 
driver of prescription drug use.7 In 2011 the annual estimated direct and indirect cost of 
ischemic heart disease amounted to over $20.9 billion in Canada alone.8 The advent of 
percutaneous intervention as well as the use of vasodilators and thrombolytics has 
reduced the incidence of death from post-MI complications five-fold since the 1950s, 
however, 35% of patients still progress to heart failure.9 Furthermore, the number of 
patients for whom conventional revascularization techniques fail is increasing (due to 
widespread coronary block, immediate post-intervention vessel occlusion, or late 
restenosis). As such, the approach to the treatment of heart failure is continuously 
evolving, and clinical trials continue to investigate emerging treatment options from stem 
cells to gene therapy.  
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The heart is the driving force moving the supply of oxygen and nutrients to meet 
the metabolic demands of every tissue in the body. This fist sized muscular organ pumps 
blood through the large vessels of the circulatory system. The wall of the heart consists of 
three layers: the epicardium, a thin serous membrane on the outer layer of the heart; a 
contractile thick middle muscular layer; and a thin inner layer of endothelial cells called 
the endocardium. Cardiomyocytes are the cells responsible for generating the contractile 
force of the heart. In mice, the middle muscular layer of the heart contains myocytes 
(56%), cardiac fibroblasts (27%), endothelial cells (7%), and vascular smooth muscle 
cells (10%) as well as elastin and connective tissue.10 However, evidence from human 
autopsy tissues indicate that cardiomyocytes occupy about 75% of human cardiac tissue 
by volume, but only 30-40% by cell number.11 The non-myocyte cells in these samples 
are predominantly fibroblasts.  
Every tissue in the body requires a supply of blood to maintain its function – this 
includes the heart itself. As such, the heart not only pumps blood to the rest of the body 
through the aorta and subsequent great vessels, but also pumps blood to its own thick 
muscular walls through the coronary circulation. The heart consumes approximately 5% 
of the total cardiac output, making the coronary circulation essential to maintaining heart 
function.12 When part of this coronary circulation is narrowed, constricted, or blocked, an 
ischemic event occurs where there is inadequate supply of oxygen to the portion of the 
cardiac muscle supplied by that artery. This causes damage and impaired cardiac 
function. A source of oxygen is paramount to allowing oxidative phosphorylation for not 
only continued cardiomyocyte contraction, but also cell homeostasis.  
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A “heart attack,” or acute MI, is a sudden form of cardiac injury, whereby 
obstruction to blood flow results in a perfusion imbalance between supply and demand 
that is long enough (several hours) to invoke myocyte death. Symptoms may present 
immediately, and include severe crushing chest pain, diaphoresis, dyspnea, fatigue, 
nausea and syncope. Many patients experience angina (chest pain) in the weeks to 
months leading up to an ischemic event due to narrowing of the coronary arterial lumen 
from atherosclerosis. However, the MI event is much more severe, resulting in complete 
deprivation of the cardiac tissue from oxygen. 
 The most common cause of MI is the blockage of a coronary artery resulting from 
a primary coronary event such as an atherosclerotic plaque rupture.13 This most often 
affects the left ventricle, with the majority of coronary occlusions occurring in the left 
anterior descending coronary artery (LAD). Importantly, no matter the artery affected, 
coronary artery occlusions typically occur in the proximal third of the coronary vessels, 
unfortunately resulting in higher morbidity and mortality from necrosis of a large 
myocardial territory.14 Thus, occlusion of the LAD is often referred to as the 
“widowmaker” lesion due to the poor prognosis of patients losing blood supply to such a 
large portion of their left ventricle. 
>@J( )166(71&$-(&:$1%(G?(
The acute ventricular molecular response to MI results in tissue damage and 
cardiomyocyte loss. The gravity and duration of the ischemic period, as well as the 
propensity for cell death, determines the extent of tissue loss to infarction. The process 
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begins with a rapid decline of cellular homeostasis and permanent cardiomyocyte cell 
death leading to a cascade of processes involved in infarct healing. Oxidative 
phosphorylation generates over 95% of the energy required for myocyte function.15 
Oxygen depletion in cardiomyocytes decreases the generation of high energy phosphates 
leading to loss of contractility (within 60 seconds) as well as the failure of membrane 
pumps and subsequent electrolyte imbalance.3 Both necrosis (Type I cell death; oncosis) 
and apoptosis (Type II cell death) occur acutely in the infarct region. The onset of passive 
cell death by necrosis, an un-programmed event caused by enzymatic degradation 
(autolysis), marks irreversible tissue injury. Signs of necrosis are evident within 4-6 hours 
after the onset of ischemia as demonstrated by the accumulation of water and electrolytes 
causing rapid swelling, destruction of cellular organelles, and early plasma membrane 
rupture causing inflammation.16 However, coagulative necrosis in the infarct region peaks 
1 day post-infarction and is likely preceded by apoptosis.17 Programmed apoptotic cell 
death is energy dependent and is characterized by nuclear chromatin condensation, DNA 
fragmentation, cell shrinkage, budding of apoptotic bodies, and phagocytosis by 
neighboring cells. This process begins in the ischemic zone as early as 2-3 hours post-
infarction and peaks at 4.5 hours.17 Traditionally, necrosis was viewed as the 
predominant form of cell death from MI. Subsequently, the discovery of the mechanisms 
of apoptosis turned the focus to this regulated form of cell death post-MI.17 However, 
limitations of assays including the annexin V assay, caspase staining, and terminal 
deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) impede the 
ability to definitively distinguish between the types of cell death.18, 19 For example, these 
assays have been developed to detect apoptotic cells, however depending on the timing of 
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use they may also detect late phase necrotic cells due to exposure of the inner plasma 
membrane and cellular contents to the outer environment upon cell lysis. More recently, 
owing to new discoveries surrounding the mechanisms of necrosis, it has been repeatedly 
suggested that necrosis is in fact responsible for the majority of cell death associated with 
the initial infarct.20 
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Programmed apoptotic cell death is a finely regulated process, and proceeds via 
one of several conserved “suicide” mechanisms. Cellular injury triggers the activation of 
cysteine proteases, called caspases, which in turn cause proteolytic cleavage of a 
spectrum of intracellular targets.  Once an initiator caspase (Caspase-8 and Caspase-9) is 
activated, a proteolytic pathway ensues whereby downstream effector caspases (e.g., 
Caspase-3) are cleaved to the active state.  Caspase proteases can be activated by an 
extrinsic (death ligand) or an intrinsic (mitochondrial) apoptotic pathway (Figure 1.1). 
The interaction of extracellular death signal proteins, such as tumor necrosis factor (TNF-
α) and/or Fas-ligand (FasL) (both up-regulated in cardiac ischemia),21 with target 
membrane receptors causes extrinsic pathway activation by recruitment of intracellular 
adaptor proteins. FasL interacts with the Fas-associated death domain protein (FADD), 
whereas TNF-α binds TNF-α receptor 1 (TNFR1) to activate the TNFR-associated death 
domain protein (TRADD). The associated adaptor protein in turn binds caspases and 
adaptor molecules such as receptor interacting protein (RIP1) to create the transient 
death-inducing complex (DISC) or complex I, and activate the proteolytic cascade.22  
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In acute ischemia, however, the intrinsic mitochondrial pathway plays a dominant 
role.23 Intracellular stress such as hypoxia or increased production of reactive oxygen 
species (ROS) results in the loss of mitochondrial membrane potential along with 
increased mitochondrial outer membrane permeabilization by both membrane breakdown 
and mitochondrial apoptosis-induced channel (MAC) formation by proapoptotic 
proteins.24 This causes the release of calcium and mitochondrial membrane protein 
cytochrome c. Cytosolic cytochrome c binds proapoptotic proteins, such as apoptotic 
protease-activating factor 1 (Apaf-1), to proteolytically activate initiator caspases 
(caspase-9).25 Apaf-1 has an ATP-binding site, which may explain why the presence of 
ATP critically important for the apoptotic program.26 
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Figure 1.1. Cell death by apoptosis.  
Apoptosis occurs via either an extrinsic ligand-mediated pathway or an intrinsic pathway. In the 
extrinsic pathway, TNF-α or FasL bind their receptors resulting in the activation of initiator 
caspases such as caspase-8. In the intrinsic pathway, intracellular stress such as hypoxia causes 
membrane destabilization, outer membrane pore opening, and mitochondrial apoptosis-induced 
channel formation (MAC), causing leak of cytochrome c into the cytosol, activation of apoptotic 
protease-activating factor (Apaf-1), and proteolytic cleavage of another initiator caspase, caspase-
9. Caspase cleavage and activation results in protease activation and degrades the cell 
components. 
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Other proteins converge on the intrinsic caspase pathway to amplify or oppose the 
cascade. For example, Bcl-2-associated-X protein (BAX) and BH3 (Bcl-2 homology 
domain 3)-only proteins promote mitochondrial membrane destabilization and release of 
calcium, cytochrome c and other apoptogens by inserting themselves in the outer 
mitochondrial membrane.27 Their natural antagonist and family member, Bcl-2, plays a 
protective role by sequestering and inhibiting pro-apoptotic proteins, thus preserving 
membrane integrity and inhibiting release of pro-apoptotic factors from the 
mitochondria.28 Unfortunately, Bcl-2 is down-regulated in the hypoxic myocardium, 
worsening BAX mediated cell death.29 Furthermore, upregulation of BAX post-infarction 
is also known to contribute to the development of heart failure.30 
>@J@C( K1'%*#.#(
In contrast to the tightly regulated apoptotic pathways, ordinary necrosis is 
relatively uncontrolled and ATP-independent (Figure 1.2). The culminating causal event 
contributing to necrosis is the opening of the mitochondrial permeability transition pore 
(mPTP) at the inner mitochondrial membrane. The formation of the mPTP is regulated by 
a calcium-dependent mechanism. A lack of oxygen during ischemia stimulates anaerobic 
glycolysis in the cardiomyocyte to provide ATP. This type of energy production causes 
the accumulation of H+ ions, which are in turn pumped out of the cell via the Na+/H+ 
exchanger. The increasing Na+ concentration forces the Na+/Ca2+ exchanger into reverse 
mode, thus elevating Ca2+ concentrations in the cytoplasm, and eventually the 
mitochondria through a Ca2+ uniporter. Elevated Ca2+ recruits proteins such as 
cyclophilin D (CypD), a component of the mPTP. The opening of the pore abrogates 
oxidative phosphorylation and ATP synthesis as hydrogen ions leak from the 
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mitochondria dissipating the proton gradient required for the process. Furthermore, the 
mPTP is large enough to allow free flow of water and solutes, thus causing mitochondrial 
swelling and rupture. The initiation of the release of inflammosomes and pro-
inflammatory cytokines from necrotic cells induces inflammation and can trigger an 
immune response. This type of response is important for reactions to viral infection, but 
can be detrimental in cardiac repair. In acute MI, the recruitment of inflammatory cells, 
release of pro-apoptotic cytokines, and vascular dysfunction from inflammation amplifies 
cardiomyocyte destruction.31, 32  
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While programmed cell death by apoptosis and unprogrammed cell death by 
necrosis have been traditionally recognized as causing the majority of cardiac cell loss 
during ischemia, accumulating evidence indicates that a substantial portion of necrotic 
cell death is in fact highly regulated and actively fulfilled. Programmed necrosis, termed 
necroptosis, is a form of necrotic cell death dependent on molecular signaling pathways. 
Like apoptosis, necroptosis can be initiated by both an intrinsic un-programmed pathway 
(as described above), or an extrinsic ligand mediated pathway. The binding of extrinsic 
ligands (ie: TNF-α) to their receptors, as in apoptosis, also induces the formation of 
complex I (transient), and subsequent conversion to complex II with the recruitment of 
receptor interacting protein 3 (RIP3) (Figure 1.2). In the presence of caspase-8, caspase 
activity causes cleavage of RIP1 and RIP3, abolishing their ability to signal necrosis; 
complex II is proteolytically cleaved and apoptosis is induced (Figure 1.1).33 However, 
in the instance that caspase-8 is not present or its activity is inhibited, RIP3 interacts with 
RIP1 through homotypic interaction motif domains (RHIM), forming a RIP1-RIP3 
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pronecrotic complex, a necessary step for necroptosis (Figure 1.2).34, 35 The complex 
causes cross-phosphorylation of both RIP proteins, and phosphorylation of downstream 
kinases such as mixed lineage kinase domain-like protein (MLKL).36 Phosphorylated 
MLKL can oligomerize and translocate to the plasma membrane. This causes pore 
formation, allowing the influx of Ca2+ into the cell, and membrane destabilization by an 
unknown mechanism, which triggers necroptosis.37 Phosphorylation of numerous other 
catabolic enzymes, phospholipases, and sphingomyelinases elicits the production of ROS, 
the permeabilization of lysosomes, and also triggers necrosis.  
RIP1 has been reported to be involved in Fas and TNF-mediated, caspase-8-
dependent apoptosis as well as necroptosis. However, although RIP1 does promote 
caspase-8 activation, it is not necessarily required for apoptosis induced by Fas; RIP1 
serine/threonine kinase activity is dispensable for the activation of apoptosis, but crucial 
in the necroptotic pathway.38 Similarly, RIP3 knockout experiments indicate that its 
activity is not required for apoptosis induction.39 Although RIP3 may be recruited to 
complex II in apoptosis, the complex is quickly degraded. The binding of RIP3 to RIP1 
becomes more stable within a “pro-necrotic” complex II. Upon binding complex II, RIP3 
is thought to act as a scaffold for RIP1 autophosphorylation. RIP3 is then phosphorylated 
at Ser199, activing its kinase activity. RIP1 alone cannot induce programmed necrosis.40 
However, RIP3 kinase activity is specifically implicated in caspase-independent, 
necroptotic cell death, distinguishing the pathways.41 The reduced necroptotic activity in 
RIP3-/- mice demonstrates the essential role of RIP3 as a mediator of necroptosis.34 
Necrostatin-1, a RIP1 inhibitor, is known to inhibit necroptosis, however this likely 
occurs by abolishing the RIP1-RIP3 complex formation, thus affecting RIP3 activity.33  
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Figure 1.2. Cell death by necrosis and necroptosis.!!
Cell death stimuli cause excessive influx of calcium (Ca
2+
) into the mitochondria, recruiting 
cyclophilin D (CypD), which leads to opening of the mitochondrial permeability transition pore 
(mPTP). Protons leak from the pore resulting in a loss of the gradient for oxidative 
phosphorylation. The mPTP also allows the influx of water and solutes into the mitochondria, 
causing swelling and rupture. Necroptosis is a form of regulated necrosis, where in the absence of 
caspase-8, TNF-α binding causes RIP1-RIP3 complex formation. RIP1 and RIP3 cross-
phosphorylate each other. This causes MLKL recruitment and phosphorylation and subsequent 
pore formation at the plasma membrane, allowing Ca
2+
 entry into the cell and membrane 
destabilization by an unknown mechanism, resulting in cell death. 
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Apoptosis, necrosis and necroptosis have all been demonstrated to independently 
play a significant role in myocardial ischemia and the development of heart failure. As 
such, targeting mediators of these processes may contribute to a better understanding of 
their contribution to infarction while providing strategies for therapeutic interventions to 
limit tissue damage. To this end, much research has been conducted to determine the 
importance of mediators of the cell death pathways. The involvement of caspases and 
their contribution to cardiac apoptosis has been confirmed using a specific inhibitor of 
caspase activity, which reduces infarct size, apoptosis and caspase 3 levels in rabbits.42 
However, inhibitors of caspase 1 and caspase 3 have been shown to reduce apoptosis but 
not infarct size in ischemia/reperfusion (I/R) injury, implicating another mechanism of 
cell death.43 Nonetheless, mice lacking the Bax gene (Bax-/-) did exhibit cardioprotection 
and reduced mitochondrial damage when subject to coronary artery ligation.44 Similarly, 
cardiac specific over-expression of Bcl-2 reduced infarct size and apoptosis post-
ischemic injury.45 Mice deficient in Fas also have reduced infarct size as compared to 
WT control mice, indicating the importance of Fas in the response to MI.46 Necrosis is 
also known to affect infarct size as mice lacking cyclophilin D are protected from I/R 
injury.47 Finally, necroptosis has been demonstrated as a critical component of cell death 
in cardiac ischemic injury, which can be mitigated by its inhibition via necrostatin-1 
(RIP1 inhibitor).48 Indeed, knockout animals lacking RIP3 have attenuated cardiac 
damage (measured by troponin T levels). This led to enhanced cardiac function post-MI 
compared to controls, demonstrating the importance of necroptosis not only for infarct 
size but also for long term functional impairment.49 
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Remodeling after MI is a dynamic process whereby the ventricular architecture is 
altered significantly. Myocyte cell death results in cytotoxic spilling and the recruitment 
of inflammatory cells occurs in the first three or four days post-infarction. Injured 
myocytes act as a scaffold for complement activation (C5a) and release cytokines such as 
monocyte chemoattractant protein (MCP)-1 and transforming growth factor (TGF)-β1, 
which attract macrophages and fibroblasts to the infarct region.50 Neutrophils are also 
recruited via upregulation of cytokines such as interleukin (IL)-8.50 Intracellular signaling 
and neurohormonal activation with inflammatory mediators is amplified as the 
inflammatory response is localized.  
As cells are gradually lost in the early phase of remodeling, characteristic mural 
thinning occurs. By days three to five, the process of progressive infarct expansion is 
evident, where wall dilation occurs without additional necrosis. Recruited neutrophils 
release matrix metalloproteases and serine proteases, which digest local collagen.51 
Myocyte alignment and intercellular myocyte connections are dependent on intracellular 
collagen struts and their breakdown results in myocyte sliding, termed “slippage.”52 
Contributing to infarct expansion, myocytes bordering the infarct region (aka: border 
zone or peri-infarct area) exhibit signs of apoptosis beginning three hours after infarction, 
resulting from signaling by inflammatory mediators as well as moderate ischemia and 
changes in pressure load.53 Apoptosis in this region peaks one day post-MI, but remains 
high for up to twelve weeks.54 TUNEL staining in rats indicates that the majority of cell 
death by apoptosis occurs in the peri-infarct area, containing approximately 70% of 
apoptotic cells, while those in the infarct region account for only about 25%.54 
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Over weeks to months, thinning and expansion causes ventricular dilation, which 
is initially beneficial, compensating for a reduced stroke volume. Ejection fraction, 
however is persistently depressed and end diastolic pressure continues to rise. Consistent 
with the Frank-Starling mechanism, reactive compensatory hypertrophy of remaining 
viable cardiomyocytes occurs. Myocytes increase in both diameter and length and alter 
their gene expression profile in response to mechanoreceptor stimulation and in reaction 
to hormonal and cytokine signaling.55 Augmented levels of endothelin-1 (ET-1) and 
norepinephrine (NE) are found in the infarcted myocardium.56, 57 Importantly, release of 
the hypertrophic mediator angiotensin II (Ang II) is stimulated via a variety of 
mechanisms.  
Hypotension post-infarction triggers the renin-angiotensin system (RAS) (both 
local and systemic), while myocyte stretch causes Ang II release from cytoplasmic 
granules.58 These molecules activate Gq-dependent signaling pathways and protein 
kinase cascades which promote transcription factor profile changes conducive to 
hypertrophy and variations in contractile protein production. Myosin heavy chain 
isoforms are altered by increased beta-chain production and down-regulation of alpha-
chains, while there is a general increase in protein production.59, 60 
These cellular profile changes allow individual myocytes to work harder to 
conserve ventricular function, but at a cost of requiring additional blood supply to sustain 
cell metabolism. An essential component of the remodeling process is neoangiogenesis 
within the infarct region. Upregulation of pro-angiogenic agents like vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF) within the ischemic area 
promotes endothelial cell migration and pericyte communication.61 However, without 
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additional therapy the growing capillary network cannot keep pace with the growing 
demands of hypertrophied myocardium; this evokes further myocyte necrosis. 
Later in remodeling, a fibrin-fibronectin matrix forms, attracting myofibroblasts, 
which infiltrate the infarct region, proliferate and deposit collagen.62 Mast cells attract 
myofibroblasts to the infarct region, promote their proliferation and increase collagen 
synthesis. The RAS system is also involved in scar formation as aldosterone stimulates 
collagen type I and type III transcription.63 Gradually, fibrous tissue deposited by 
fibroblasts entirely replaces necrotic myocytes.64 Fibroblasts appear transiently during the 
formation of granulation tissue and undergo apoptosis when a nondistensible scar has 
formed. This entire process is completed within weeks to months. Despite healing, the 
added contractile mass in remaining cardiomyocytes and muscle cell hypertrophy is 
inadequate to compensate completely for the scarring and loss of contractile mass. De-
compensation inevitably occurs; post-infarction cardiomyopathy commonly progresses to 
heart failure.65  
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In the myocardium remote from the ischemic zone, cell death continues for 
months.66 TUNEL staining indicates that in a normal human heart the prevalence of cell 
death is between 0.001 and 0.01%. However, in heart failure, the prevalence of cell death 
increases to about 0.12-0.70%, significantly contributing to its pathogenesis.67 
Progressive loss of cardiomyocytes plays a major contributing role in the development of 
this chronic disease. Spurring this is continued volume overload and persistent elevated 
end-diastolic left ventricular pressure. While impaired left ventricular function is the 
primary abnormality contributing to heart failure, the fall in cardiac output leads to 
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activation of multiple compensatory mechanisms aimed at improving function. As heart 
failure progresses, the neural sympathetic system is stimulated by baroreceptor 
activation; the sympathetic system attempts to maintain cardiac output and blood pressure 
by increasing heart rate and contractility (ionotropic support) while vasoconstricting 
peripherally. Not only is the response to catecholamines blunted in a failing heart, but 
worse, excessive sympathetic activity at the beta adrenergic receptor can provoke 
additional cardiomyocyte apoptosis and necrosis.68, 69 Furthermore, prolonged NE 
intensifies generalized sympathetic tone, thereby increasing both cardiac afterload and 
preload. A failing heart cannot respond to this increase as the Frank-Starling curve is 
flattened, and there is a lack of increased contractile force in response to afterload. This is 
a result of abnormal calcium cycling and an altered myofilament response to calcium in 
the failing ventricle.70 Indeed, patients who have raised plasma NE concentrations in 
congestive heart failure have a worse prognosis.71 The stiffness of the ventricular wall 
continues to increase, eventually causing diastolic dysfunction by impaired relaxation.  
The renin-angiotensin-aldosterone system (RAAS) is also activated to cause 
vasoconstriction by Ang II and increase blood pressure by provoking water retention with 
aldosterone. This natural compensatory elevation in Ang II levels also provokes 
cardiomyocyte hypertrophy by binding angiotensin II receptors (AT1). Although the 
elevation in Ang II levels is a natural physiologic response to provoke hypertrophy and 
protect homeostasis in the setting of reduced cardiac output, this is to the detriment of the 
cardiomyocyte as activity at AT1 eventually provokes further apoptosis.
72  
There are also many beneficial cytokines and hormones released from the heart 
post-MI and through the progression into heart failure. Atrial natriuretic peptide (ANP) 
  
 
18 
and brain natriuretic peptide (BNP), for example, are released from stretched atrial and 
ventricular cells respectively, and oppose the effects of Ang II on the vasculature and 
kidney.73 As mentioned above, TGF-β is a secreted cytokine up-regulated post-MI. TGF-
β is involved in many cellular functions, and its upregulation not only supports 
recruitment of inflammatory mediators, but also exerts a cardioprotective effect by 
limiting myocardial necrosis.74 TGF-β promotes myogenic differentiation of pools of 
stem cells, further implicating it in cardiac repair.75 bFGF is also increased in the peri-
infarct area, contributing to angiogenesis. bFGF supports endothelial cell migration and 
proliferation, while also inhibiting oxidative injury and attenuating left ventricular 
contractile dysfunction post-MI.76, 77 Similarly, hepatocyte growth factor (HGF) and 
insulin-like growth factor 1 (IGF-1) are cardioprotective factors released in the infarct 
region post-MI. These factors reduce ventricular dilation and wall stress and are thought 
to regulate anti-apoptotic signaling.78, 79 The chemokine stromal cell-derived factor 1 
(SDF-1) is also up-regulated post-MI and impedes myocyte death, promotes 
angiogenesis, and recruits stem cells for repair.80 Unfortunately, patients who do not 
express adequate levels of these factors are at increased risk of developing the 
unrelenting clinical symptoms of heart failure.81 
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The most optimal and common initial treatment post-MI is to re-open a perfusion 
pathway for oxygen delivery to the ischemic cardiac muscle by reperfusion therapy with 
fibrinolysis, percutaneous coronary intervention (PCI), or in rare cases, an urgent 
coronary artery bypass graft (CABG).82 Reperfusion therapy reduces the relative 
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incidence of death from acute MI by over 25% by restoring oxygen delivery to 
cardiomyocytes and reducing initial infarct size from ischemia.83 The in-hospital fatality 
rate for MI has dropped to 10.6% due to these immediate treatments.84 
>@P@C( D-&%2&'*6*8.'(2&3&81213$(/*#$+G?(&37(:*%(-1&%$(:&.6,%1 
Beyond the acute MI, patients who survive are often prescribed antithrombotic 
(glycoprotein IIb/IIIa inhibitor/antagonist; e.g., abciximab) and antiplatelet (e.g., aspirin) 
agents to prevent rethrombosis. Within 24 hours post-MI, oral beta-adrenergic receptor 
blockers (β-blockers), adjunct calcium channel blockers (e.g., verapamil) to reduce 
oxygen demand, and anti-anginal drugs such as nitroglycerin (nitrates) are prescribed. 
Statins are also initiated to lower cholesterol and reduce risk of recurrent MI from 
atherosclerosis.85 
Despite optimal management, over 35% of patients with acute MI begin to 
develop symptoms of heart failure, a chronic disease requiring life-long management.9 
Beyond lifestyle modification suggestions, these patients receive pharmacotherapy to 
improve long term prognosis by limiting cardiac remodeling. The first line 
pharmacologic therapy is an angiotensin-converting-enzyme inhibitor (ACEi), which 
reduces the multiple pathophysiological effects of Ang II on both systemic pressure and 
the heart.86 Angiotensin receptor blockers (ARBs) may be used for patients who are 
intolerant to ACEis (often due to cough). Depending on the patient’s volume status, they 
may receive loop diuretics (e.g., furosemide) to reduce dyspnea and edema, or β-
blockers, which both reduce mortality and reverse ventricular remodeling.87 For patients 
with class II heart failure, the addition of a mineralocorticoid receptor antagonist (MRA; 
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e.g., spironolactone) to compete with aldosterone at the MR has been demonstrated to 
provide survival benefit.88 In patients who progress to class II to IV heart failure despite 
optimal therapy, the addition of digoxin, a sodium-potassium ATPase inhibitor, may be 
required to increase contractility of the heart while reducing heart rate by prolonging the 
cardiac action potential. Finally, in patients who continue to worsen, hydralazine 
(antihypertensive) and/or nitrates (vasodilator) may be required to reduce hypertension. 
Although the current optimal treatments have extended patients’ lives by reducing 
in-hospital mortality from heart failure complications by more than 2%, and 5 year 
mortality by over 9%, epidemiologic evidence, such as that from the Framingham study, 
has demonstrated no change in overall death rate from heart failure.89, 90 Thus, innovative 
approaches to limit cardiomyocyte loss from MI and impede deleterious cardiac 
remodeling are needed to improve prognosis for cardiac patients and create effective 
therapies for heart failure in the future. 
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Over the last 50 years, major efforts in cardiac research have focused on 
minimizing infarct expansion, fibroblast collagen deposition, and cardiac hypertrophy 
following MI. Methods such as inhibiting inflammation, reprogramming cardiac 
fibroblasts, activating cell cycle reentry, transferring skeletal myoblasts to the infarct 
region, and transplanting progenitor cells have been tested.91-93 These methods have been 
met with conflicting results in in vivo models and in the clinic. Early studies in murine 
models suggested that bone marrow-derived haematopoietic stem cells (BMSCs) 
introduced into the myocardium following MI could differentiate into cardiomyocytes 
and aid in repair.93 However, these cells did not differentiate or incorporate into the 
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myocardium in subsequent studies.93 Furthermore, Loffredo et al. demonstrated that 
transplantation of BMSCs enhances cardiac repair, but not by engraftment; they could not 
discern the mechanism of action.94 Results regarding the long-term efficacy and safety of 
transfer of bone marrow stem cells in human trials are inconsistent.93 Also, the ability of 
these cells to differentiate into new muscle cells is limited.95 A similar trend followed 
with experiments in mobilization of haematopoietic stem cells using granulocyte-colony 
stimulating factor (G-CSF); G-CSF was associated with improved stem cell recruitment 
and cardiac functionality post-MI in animal models, but was unable to demonstrate 
improvement in human trials.96 Many traditional therapies were also directed at 
increasing infarct zone microvascularity and promoting angiogenesis. It is thought that if 
blood flow can be restored to the infarcted or “hibernating” myocardium, fewer 
cardiomyocytes will be lost. For example, augmented infarct zone angiogenesis has been 
demonstrated in animal models using VEGF and bFGF therapy,97 however this was not 
associated with benefit in human trials.98  
Adult mammalian cardiomyocytes have classically been viewed as post-mitotic, 
and thus incapable of proliferating to replace damaged myocardium due to their 
terminally differentiated state.99 Complete recovery from injury would be impeded by the 
replacement of lost cardiomyocytes with a fibrotic scar. To combat this deleterious 
response, research directed at blunting fibrosis and minimizing infarct expansion has 
been the primary focus in the field of cardiac repair. However, recent discoveries 
indicating a potential for cardiac regeneration have shifted the fundamental underlying 
assumptions around cardiac healing, deflecting research efforts towards regenerative 
strategies.100 Normally, adult cardiac cells display little cell-cycle activity. Although 
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approximately 50% of cardiomyocytes are replaced in one’s lifespan (0.45 - 1% 
annually),101 cardiac homeostasis after embryogenesis and initial neonatal maturation is 
mostly preserved by hypertrophic growth. However, resident cardiac progenitor cells are 
activated after cardiac injury, and these cells are able to proliferate and differentiate into 
fibrous cells, endothelial cells, smooth muscle cells and potentially even 
cardiomyocytes.102 This discovery is the cornerstone of current cardiac regeneration 
research as it offers the potential for stem cell induction therapy to promote infarct 
healing by directly replacing the injured myocardium. Isolated and purified resident 
cardiac progenitors can be injected after an ischemic event and differentiate into 
myocardial tissue in the region of necrosis.103 While this form of cellular therapy seems 
an attractive option, techniques for isolating these types of cells remain to be optimized, 
and the relatively small number of cells available for autologous transplantation makes 
cell therapy too arduous for clinical use. Furthermore, results from conflicting clinical 
trials call into question the ability of transplanted cells to functionally integrate with the 
remaining viable myocardium and contribute to enhancing left ventricular function in the 
long term.104 While cell replacement may not be the most realistic approach, therapeutic 
enhancement of the regenerative capacity of resident stem cells could provide a feasible 
non-invasive therapy.  
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To understand the biological mechanisms underlying any human disease, reliable 
models that mimic both typical disease pathogenesis and symptoms are required. An 
ideal model is physiologically very similar to the tissue of interest or recapitulates the 
human pathology, is inexpensive and reproducible, can be easily manipulated, and offers 
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large turnover in a short period of time (i.e., rapid gestation period, large litter size and 
relative quick growth). As summarized by Garbern et al., cardiac disease has been 
studied using many different models ranging from computational to cell culture to large 
animal models.105 
The advancement in genomic editing and biotechnology has brought about the 
increasing availability of genetically manipulated mice, making the mouse a desirable 
animal to model various diseases. The most common murine models of cardiac disease 
include permanent or temporary occlusion of the left coronary artery (myocardial 
infarction or ischemia/reperfusion), aortic banding (pressure overload), electrocautery 
(focal infarctions), isoproterenol administration (diffuse myocardial necrosis), and 
genetic knock-in and knock-out mutations (arrhythmia, hypertrophy, congenital cardiac 
abnormalities). Surgical coronary ligation has been demonstrated to be a useful 
experimental technique in many animal models.106, 107 Originally used on dogs, and first 
applied in small animals by Johns and Olsen in 1954,108 the coronary ligation model has 
become the most widely used in the field of heart failure.  
While the types of murine injury listed above have served as prototypical models 
for the study of cardiac healing post-MI, each model results in permanent cardiac injury, 
without cardiac regeneration. Until recently, the dogma dictating an incapacity for 
complete mammalian cardiac healing left the study of in vivo regeneration to non-
vertebrate models, such as that demonstrated by teleost fish from cardiac apex 
resection.109 Recently, however, two groups have presented surgical models of 
mammalian cardiac regeneration in the neonatal mouse. First, Porrello et al. 
demonstrated complete cardiac regeneration after apex resection in mice at postnatal day 
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1 (P1).110 Subsequently, Haubner et al. presented complete cardiac regeneration after MI 
by coronary occlusion.111 Unfortunately, in the first week of postnatal life, the tissue 
progenitor cell composition declines rapidly, and previously proliferative cells 
permanently exit the cell cycle.112 As a result, the regenerative capacity in neonatal mice 
was retained only in the early neonatal period, and was lost shortly after birth by P7. 
Elucidating the mechanistic differences between the response to myocardial injury in the 
neonate and the adult could lead to novel targets which may be manipulated to 
therapeutically recapitulate neonatal regenerative capabilities in the adult human heart. 
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The principles of tissue repair and regeneration are similar for almost any organ 
system, offering similar therapeutic targets for the treatment of disease. These are the 
fundamental processes affecting pathophysiological changes post-infarction and post-
wounding. As summarized above, at the time of infarction, cell death occurs followed by 
an inflammatory cell response. In the long term, the infiltration of inflammatory cells, as 
well as collagen deposition and angiogenesis causes the development of a form of 
granulation tissue, a connective tissue matrix typically formed at the wound healing 
surface. Finally, a scar is produced and the surrounding tissue must compensate for the 
loss of this functional area. The mechanisms which could support regeneration include 
altering processes involved in wound healing response. Inhibiting apoptosis and necrosis 
are of primary importance to limit initial wounding. Secondly, the polarization of the 
inflammatory response contributes to the aggravation of wounding or improvement of the 
healing process. Neutrophils and macrophages are the first immune cells to arrive at the 
site of wounding. These immune cells engulf damaged tissue and cellular debris, but also 
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both respond to and secrete a variety of cytokines. Macrophages have been categorized 
into two major subtypes: pro-inflammatory M1 cells secrete mediators such as ROS 
which aggravate inflammation, while cells of the pro-regenerative M2 phenotype secrete 
cytokines which reduce inflammation and aid in angiogenesis. Thirdly, the ability to 
produce new vasculature is of utmost importance. Neovascularization supports cells at 
the wound site with nutrition and oxygen. Blood vessel growth occurs by three major 
mechanisms: angiogenesis, the formation of endothelial cell derived capillary sprouts 
from pre-existing capillary vessels; arteriogenesis, the remodeling of pre-existing 
arteriolar collaterals by increasing their size and caliber; and vasculogenesis, the 
formation of blood vessels de novo from progenitor cells (mesoderm derived) or 
angioblasts. Another important factor is the propensity for proliferation or cell replication 
to replace damaged tissue. A pro-proliferative microenvironment stimulates the division 
of existing viable cells to aid in the repopulation of the tissue. Finally, both resident stem 
cells and bone marrow derived stem cells are activated by cytokines and recruited to the 
site of injury. The differentiation of these cells into tissue resident cells, as well as their 
signaling for growth of resident healthy tissue is important for repair.  Determining which 
of these mechanisms are up-regulated in the neonatal heart will provide a mechanistic 
framework for cardiac regeneration. Interestingly, many of these processes are hallmarks 
of cancer and metastasis.113 Thus, it may be prudent to learn from studies in cancer to 
direct therapies for cardiac repair. 
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Numerous studies have demonstrated the new myocardium post-injury in the 
neonate is derived from dividing cells. Recent insight into the mechanism of this process 
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comes from studies on lower vertebrates, such as urodele amphibians and teleost fish, 
which are known to possess the ability to regenerate organs following injury. Like in the 
zebrafish, cardiomyocytes of the vertebrate neonate are able to de-differentiate and 
proliferate to contribute to heart regeneration.109, 110 In fact, it has been demonstrated that 
cardiomyocytes are replaced throughout the human lifespan; however this replacement is 
at a rate of 5% per year in childhood and 0.5% per year in adulthood.101 This inherent cell 
division ability is not enough to compensate for injury. Thus, researchers have focused on 
inhibiting cell cycle arrest and up-regulating the proliferative potential.100  
Investigators have also demonstrated a polarized inflammatory response, and 
increased stem cell recruitment in the neonatal mouse contributing to its regenerative 
capacity.114, 115 Certainly, the importance of the regeneration of the contractile tissue 
cannot be undermined. However, the ability of cells to survive and proliferate is 
intimately linked with proponents for a vascular supply. This newly generated contractile 
tissue must retain a source of nutrients and oxygen; the regenerated cardiac tissue must 
also contain newly formed blood vessels. The source of this vasculature remains elusive. 
In the zebrafish, ample evidence indicates that the epicardium is the cellular 
source of the regenerated vasculature after cardiac injury.116 Indeed, fetal epicardial 
markers are also re-expressed after MI in adult mice. This is particularly important in 
subsets of epicardium-derived cells (EPDCs) that express Wilms’ tumor 1 (Wt1) and T-
box transcription factor 18 (Tbx18), markers of embryonic cardiovascular progenitors.117 
These cells are thought to contribute to angiogenesis and stem cell recruitment post-MI 
through paracrine effects by up-regulating molecules such as MCP-1, FGF and retinoic 
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acid (RA).118, 119 More importantly, EPDCs are able to recapitulate their embryonic 
profile and undergo a process called epithelial-to-mesenchymal transition (EMT).  
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EMT plays a critical role in early development. Beyond its role in the invasion of 
the uterine lining and the formation of the three germ layers, EMT is also responsible for 
cardiac formation. Originating in the proepicardial organ, cells that express Wt1 in 
development migrate to the surface of the myocardium to become the epicardial layer (at 
about E9-E10.5 in mice).120 Many of these cells then undergo EMT to delaminate from 
the epicardium and form EDPCs which migrate into the myocardium as the precursors of 
the cardiac structures (at about E11.5-12.5).120 Specifically, EPDCs contribute to the 
subendocardial and atrioventricular cushion, cardiac interstitial fibroblasts, and the 
coronary vasculature (coronary smooth muscle cells and endothelial cells).121 This 
dormant fetal growth program is reactivated after adult MI by stimuli such as increased 
wall stress, which activates mechanical stretch receptors, triggering immediate early 
genes such as c-jun, c-fos, c-myc and Egr-1.122 Hypoxia from injury induces hypoxia-
inducible factor-1 alpha (HIF-1α), which is responsible for the upregulation of VEGF and 
other pro-angiogenic factors that are implicated in epicardial EMT in coronary vascular 
development.123  
Epicardial EMT involves cell junction disassembly, loss of epithelial cell polarity, 
and cytoskeletal reorganization via suppression of epithelial genes, and activation of a 
mesenchymal gene signature. The upregulated local expression of TGF-β and FGF-2 
activated kinases and GTPases facilitates degradation of the basement membrane and 
promotes actin rearrangement and cell movement.124 TGF-β stimulates the expression of 
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Snail and Slug transcription factors, which directly repress transcription of endothelial 
genes.121 For example, epithelial E-cadherin, a transmembrane protein that forms 
epithelial cellular junctions, is cleaved and its production suppressed in favor of N-
cadherin and vimentin (mesenchymal proteins).121, 125 The cell assumes a mesenchymal 
phenotype and migrates away from the basement membrane. As discussed later, 
wingless-type integration site (Wnt) signaling and associated β-catenin nuclear 
translocation also contribute to this process. This embryonic reprogramming is 
responsible for detachment, inward movement and mitosis, which also occur in 
transitioning epicardial cells post-MI. Once transitioned, differentiated EPDCs lose Wt1 
expression;126 post-MI, epicardial cells express mesenchymal markers rather than 
epicardial ones, implying their mesenchymal transition.121  
Many of the factors which promote EMT are also implicated in maintaining 
survival and integrity of cells for this newly formed vasculature. For example, TGF-β, a 
cytokine integral to the initiation of EMT, also promotes endothelial survival via 
phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
signaling.127 Platelet-derived growth factor (PDGF) is critical for epicardial EMT in 
development, but also participates in the recruitment of progenitors for angiogenesis and 
enhances survival of endothelial cells.128, 129 Additionally, bFGFs induce mesenchymal 
characteristics in endothelial cells and support epithelial migration and transition while 
inhibiting endothelial cell apoptosis via upregulation of the antiapoptotic proteins Bcl-2 
and survivin.130-132 
While genes for epicardial EMT are activated post-MI in the adult mammal, 
perhaps this activation is exacerbated in the neonate, contributing to its superior 
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regenerative response. Indeed, EMT genes are upregulated post-cardiac apex resection in 
the neonate.110 Data from zebrafish models designates the epicardium as the cellular 
source of the regenerated vascular compartment, corroborating this hypothesis.116  
Enhancing the EMT process in the neonate and adult may augment infarct and 
peri-infarct angiogenesis, and by extension, cell division. Our laboratory recently 
demonstrated that the contribution of EPDC progenitors can be augmented in the adult by 
other factors related to embryogenesis, including stem cell factor (SCF).133 The 
breakdown of the epicardial basement membrane post-MI allowed SCF expressed by the 
myocyte to interact with the c-kit receptor on the epicardium. This induced the expression 
of the key EMT regulator, TGF-β, enhancing epicardial activation and production of 
EPDCs, contributing to arteriogenesis.  
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The involvement of Wt1 in promoting the EMT phenotype makes it a potential 
candidate to target EMT for regeneration. Wt1 is an epicardial transcription factor 
enriched in the embryonic heart, and is required for embryonic coronary artery formation 
and essential for EMT of EPDCs.126, 134 The Wt1 gene is located on chromosome 11p13, 
and codes for the Wt1 mRNA transcript, which is about 3.5 kb long.135 Wt1 contains a 
DNA binding domain with a proline-glutamine rich region capable of regulating 
transcription. Early studies of Wt1 identified many potential target DNA binding sites 
including promoters of genes that encode IGF, PDGF-A, and TGF-β1.135 Subsequently, 
two of the major mediators of EMT, Snail (Snail) and E-cadherin (Cdh1), were both 
determined to be controlled through direct transcriptional regulation by Wt1, thereby 
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affecting cell differentiation.136 After MI, Wt1 marks the activation of the epicardium and 
is expressed in the coronary vasculature.137 However, the role of Wt1 in neonatal cardiac 
regeneration has not been elucidated. 
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Receptors for cytokines that govern multiple signaling pathways integral to the 
initiation of EMT are found on small microtubule based sensory organelles called 
primary cilia.138 Primary cilia are non-motile hair-like protrusions that emanate from the 
cell surface in an antenna-like fashion. Primary cilia are located on almost all polarized, 
and most non-polarized cell types.139 Once considered vestigial organs, the function of 
the primary cilium is still being elucidated; the major function of primary cilia was 
hypothesized to be in calcium-responsive mechanical force sensation, however the 
involvement of calcium in this process was recently disproved.140 Nevertheless, the 
hypothesis that primary cilia sense extracellular cues (chemical and mechanical) and 
transmit signals required for tissue homeostasis and tissue development persists. These 
organelles possess unique antenna-like properties which allow them to detect mechanical 
and sensory cues and transmit these signals from the cell surroundings to its interior. 
>@>F@>( 0$%,'$,%1(*:($-1(/%.2&%E('.6.,2(
Primary cilia are immotile organelles comprised of microtubules in a structure 
called the axoneme, and a surrounding ciliary membrane (Figure 1.3A). The primary 
cilium grows to the outer surface of the cell from the centriole, which transforms into the 
base of the ciliary organ called the basal body. The requirement of the centriole to form 
the basal body makes the presence of the primary cilium mutually exclusive with 
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progression through the cell cycle; during mitosis the basal body detaches from the cell 
membrane region to enter the interior of the cell as the mother centriole of the 
centrosome.141 Centrioles are composed of nine microtubule triples, which give rise to 
microtubule doublets of acetylated α-tubulin to nucleate the axoneme of the primary 
cilium. For this reason, the basal body dictates the position and orientation of the 
cilium.142 At this transition zone between the basal body and axoneme are axonemal 
microtubules, transition fibers, and ciliary rootlets which anchor the basal body to the 
membrane and act as a barrier for selective passage of materials into the cilium; this 
region is known as the “ciliary necklace”.143 During its formation, the primary cilium 
grows outward from the mother centriole to become encased by the lipid bilayer of the 
plasma membrane.144 The plasma membrane of the cilium, however, is changed to 
contain an altered set of ion channels and membrane receptors which pass through the 
ciliary necklace by harboring specific ciliary targeting motifs.145, 146 Unlike the motile 
cilium which is comprised of a 9 + 2 microtubule structure (nine outer doublets with a 
central pair), the primary cilium lacks the central doublet, making a 9 + 0 structure 
(Figure 1.3B).  
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Figure 1.3. Structure of the cilium. 
The primary cilium emanates from the basal body under the plasma membrane. The structure is 
membrane bound and composed mainly of the ciliary axoneme (A). Intraflagellar transport 
proteins (IFT) containing cargo are transported up the cilium with active kinesin. Ciliary turnover 
takes place in the ciliary tip, and inactive cargo is transported retrogradely on IFT particles by 
dynein. The ciliary axoneme differentiates the motile cilium from the primary cilium. In the 
motile cilium (C), a 9+2 arrangement of doublet microtubules surrounds a central microtubule 
pair. Attached to these microtubules are accessory structures involved in motility. On the other 
hand, the primary cilium (B) is also arranged with 9 outer doublet microtubules, however it does 
not contain the central pair or any accessory motility structures. 
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The machinery for protein synthesis does not reside within the cilium, thus all 
proteins necessary for ciliary function must be transported into the cilium from the 
cytoplasm. The ciliary axoneme is elongated, and continuously turned over via the 
process of intraflagellar transport (IFT). IFT is a bi-directional transport system which 
allows the trafficking of large protein complexes (IFT particles) along polarized 
microtubules in the axoneme.147 Kinesin-2 motors carry particles along the outer doublet 
of microtubules from the base to the tip, and cytoplasmic dynein 2 returns the recycled 
products (e.g., inactive receptors) back to the cell body in a retrograde fashion (Figure 
1.3A).148, 149 There are two distinct subcomplexes of IFT; IFT complex B is required for 
anterograde transport from the ciliary base to the axoneme tip, while IFT complex A 
allows retrograde movement from the axoneme tip back down to the ciliary base.150, 151 
The IFT complexes serve as rafts for ciliary cargo such as tubulin, G protein coupled 
receptors (GPCRs), ion channels, and protein kinases.152 Dysregulation of IFT 
polypeptides leads to a plethora of human diseases, demonstrating the importance of 
these molecules for proper ciliary function. These “ciliopathies” are often pleiotropic 
disorders and include defects in numerous organ systems including the liver, kidney, 
airway, brain, pancreas, retina, adipose, and heart.139  
Intraflagellar transport protein 88 (Ift88) (Tg737; Polaris protein) is a complex B 
protein required for primary cilia formation. This requirement was discovered in 
Chlamydomonas, and subsequently determined to contribute to the failure of ciliary 
function in polycystic kidney disease.151 Tg737 functionality was also shown to be 
required for various ciliary related processes including proper ependymal cell function in 
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brain ventricles and node cilia functioning in left-right patterning for embryonic 
development.153 Tg737 knock-out mice die at embryonic day 11.5 due to a variety of 
developmental abnormalities beyond those associated with left-right axis patterning 
defects, including cardiac insufficiency with pericardial sac ballooning.154 
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IFT allows the transport of signaling molecules and receptors, turning the cilium 
into a repository that can harbor proteins and coordinate signaling pathways. As a cell 
signaling center, the primary cilium integrates components of numerous signaling 
pathways, including Hedgehog (Hh), Wnt and PDGF (Figure 1.4), all molecules related 
to EMT.125, 155-157  
The Hh signaling pathway is required for adult tissue homeostasis, and is essential 
for axis determination and organ development during embryogenesis.158 Gradients of Hh 
signal transduction dictate the developmental patterning of numerous tissues including 
the neural tube and limb bud. The primary modulator of the Hh pathway is Sonic 
hedgehog (Shh), which binds to its 12-transmembrane protein receptor Patched (Ptch) to 
initiate signaling.159 Shh induces the expression of transcription factors required for 
cardiac development.160 Ift88-null mice develop hearts with ventricular dilation, reduced 
myocardial trabeculation, and outflow tract abnormalities.161 Clement et al. demonstrated 
that Hh signaling is associated with the cilium in cardiomyocytes, and suggested its loss 
could be responsible for the observed cardiac phenotype of these Ift88-null mice. 
However, these authors also showed that Hh signaling is required for cardiac 
differentiation in pools of stem cells, suggesting that inhibition of Ift88 (and consequently 
Hh) may allow for maintenance or return to a stem cell like phenotype. The downstream 
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positive mediator of Hh signaling is a seven-transmembrane GPCR protein called 
Smoothened (Smo), which modulates Gli transcription factors. Gli1 and Gli2 function as 
transcriptional activators while Gli3 is a repressor. Ptch, Smo, and Gli transcription 
factors are all present within the primary cilium and this localization of Ptch and Smo is 
mutually exclusive.162, 163 In a basal state, Ptch is localized to the primary cilium. In the 
absence of Shh, Ptch tonically inhibits Smo from its entrance into the cilium, thereby 
repressing Hh mediated transcription. In this instance, Smo cannot act on the Gli factors, 
and Gli2 is degraded while Gli3 is processed to its repressive form. Alternatively, in the 
presence of Shh, Ptch is internalized, allowing Smo to enter the primary cilium (Figure 
1.4A). Within the cilium, Smo sends Gli3 to the proteasome for degradation, and 
activates the Gli2 transcription factor, which enters the nucleus to promote transcription. 
The involvement of the primary cilium in this process is demonstrated by the requirement 
of IFT for both Gli2 activator and Gli3 repressor processing. Loss of IFT results in 
reduced Gli2 activators and Gli3 repressors, causing aberrantly active low level Hh 
signaling.162, 164 During development, at which time high levels of Hh are required, this 
low level signaling results in apparent loss of function.155 However, in the adult, Hh 
signaling plays a limited role, and reduced inhibition with abnormal low level activation 
results in a gain of function phenotype which may contribute to tumorigenesis.165 Shh 
targets which may propagate tumor development include genes related to cell survival 
(Bcl2), self-renewal (Nanog), angiogenesis (Vegf), and EMT (Snail1).166 
Wnt signaling also contributes to normal mammalian development and adult 
tissue homeostasis. Wnts act through activation of two separate pathways: the canonical 
(β-catenin dependent) and non-canonical (β-catenin independent) pathway. In the 
  
 
36 
canonical pathway, Wnt ligands interact with the Frizzled (Fz) class of cell surface 
receptors, which in turn recruit the downstream signal mediator Dishevelled (Dvl) 
(Figure 1.4B). In the absence of Wnt ligand, β-catenin is constitutively phosphorylated 
and targeted for destruction. Conversely, when Wnt activates the canonical pathway, Dvl 
is recruited to Fz, and the β-catenin destruction complex is disassembled, allowing for β-
catenin nuclear transport and subsequent activity as a transcription factor.167 This type of 
Wnt/β-catenin signaling is required for endocardial cushion formation during cardiac 
development.168 Various lines of evidence indicate that the primary cilium plays an 
inhibitory role in Wnt signaling. Knockout mice for proteins required for primary cilia 
assembly exhibit hyperactive β-catenin- dependent signaling as compared to wild type 
controls.169 It is thought that the β-catenin- positive regulator Jouberin (Jbn) is spatially 
sequestered in the cilium, constraining movement of β-catenin to the nucleus.157 β-
catenin is a known transcriptional activator of several EMT related genes, including 
Twist and ZEB1.170 
In the non-canonical (β-catenin independent) pathways, Wnts bind to either Fz or 
another transmembrane receptor, Vangl2, to activate small GTPases Rac1 and RhoA, 
which control planar cell polarity (PCP) pathways, resulting in cytoskeletal-actin 
rearrangements causing changes in cell shape.171 The PCP pathway causes polarized 
localization of proteins required for the establishment of polarized cell morphology. 
Unlike the canonical pathway, the primary cilium is thought to be required for PCP (non-
canonical Wnt signaling).172 For example, conditional mutation of Ift88 in the inner ear 
results in disorganization of the planar-polarized orientation of stereocilia.173 Several core 
PCP proteins have been shown to localize to the primary cilium. For example, Vangl2 is 
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localized along the axoneme, likely contributing to its localization on the apical 
membrane in epithelia.174 The interaction of Vangl2 with the ciliary/ basal body protein 
Bardet-Biedl syndrome 8 (BBS8) has been shown to be required for the establishment of 
left-right asymmetry.175 On the other hand, it has been demonstrated that mediators of 
noncanonical Wnt/PCP signaling are required for primary cilia formation.176 Regardless 
of whether the primary cilium is required for noncanonical Wnt signaling, or vice versa, 
the two appear to be closely connected, perhaps via various molecules. In either case, 
mutations in ciliary proteins attenuate Wnt/PCP signaling, resulting in loss of cell 
polarity – a feature of EMT.125  
Cell survival, proliferation, migration, and, importantly, angiogenesis are all also 
crucially regulated by PDGF signaling.177, 178 These pathways critically contribute to 
wound healing in adult tissues. Interestingly, Schneider et al. demonstrated that the 
primary cilium is essential for PDGF signaling in growth arrested cells through its 
receptor PDGFRαα, the homodimer of PDGFRα.156 PDGFRαα localized to the primary 
cilium, and in Tg737 knockout mutants, embryonic fibroblast cell cycle entrance was 
blocked, delineating a role for the primary cilium and PDGF signaling in growth control. 
The same group also demonstrated the importance of this signaling pathway for 
directional wound healing, indicating that the primary cilium is required for chemotaxis 
towards PDGF-AA.179 Defects in PDGF signaling are implicated in a range of diseases 
including epithelial cancers and vascular disorders.178 Specifically, aberrant PDGF causes 
EMT and supports cancer metastasis.180 PDGF signaling also plays a role in EMT of 
mesenchymal cells during cardiac development and the growth of the coronary 
vasculature.181 However, these authors demonstrated the importance of PDGF-B and 
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PDGFRββ, rather than PDGFRαα in EMT for coronary artery development. Although 
Schneider et al. demonstrated that PDGF-AA signaling through PDGFRαα is associated 
with the cilium, signaling through PDGFRββ was unaffected by loss of the cilium 
(Figure 1.4C).156 Interestingly, activation of PDGFRββ has been shown to promote 
deciliation, a phenotype associated with ciliopathies.182 Furthermore, isolated deletion of 
PDGFRβ results in an impairment of coronary vascular smooth muscle generation in 
development, while knockout of PDGFRα alone inhibits the generation of cardiac 
fibroblasts, differentiating the two PDGF receptors.128 Thus, the type of PDGF may be an 
important consideration when determining the role of the cilium in PDGF signaling; 
specifically, it has been suggested that signaling through PDGFαα requires the presence 
of the cilium, while PDGFββ leads to activation of the downstream MEK/ERK mediators 
independent of the cilium.161 
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Figure 1.4. Signaling associated with the primary cilium.  
A) Primary cilium harbors sonic hedgehog (Shh) signaling factors, and its degradation decreases 
Shh signaling. B) Wnt receptors are associated with the base of the primary cilium. In the absence 
of the cilium, Jouberin (Jbn) binds β-Catenin in the cytoplasm and its nuclear transport is 
uninhibited, causing hyperactive signaling. C) PDGFα receptors are associated on the cilium and 
PDGFβ receptors on the plasma membrane. Loss of the cilium attenuates PDGFα mediated 
responses, but has no effect on PDGFβ signaling.
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Given the association between cilia and EMT related signaling, it is not surprising 
that altered ciliary function is associated with the progression of multiple types of cancer 
that require EMT for invasion and growth.165 For example, EMT is a fundamental 
process in breast cancer development, and cilia loss is associated with breast carcinoma 
invasiveness and severity.183 Specifically, genes related to intraflagellar transport proteins 
are downregulated in human breast cancer tissue as compared to tissue from normal 
patients. Similarly, cilia are lost in pre-invasive and invasive prostate cancer, leading to 
increased Wnt signaling.184 Furthermore, as mentioned above, the presence of the cilium 
is also associated with cell cycle arrest, and ciliary resorption precedes cell cycle entry in 
many cell types, which may be associated with tumour growth.185 
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Ciliary function is also important for signaling during organogenesis and 
development.186 Normal ciliary function is required for proper left-right patterning 
leading to proper situs and heart positioning in development.187 Multiple human 
ciliopathies have related cardiac abnormalities such as dextrocardia, aortic stenosis, and 
septum defects.138 Furthermore, mutations in cilia proteins in animal models result in 
congenital heart defects.161, 188 In concordance with this finding, patients with Bardet-
Biedl syndrome, an autosomal recessive ciliopathy with multi-organ involvement, present 
with congenital heart defects, and echocardiography of adult patients demonstrated 
development of dilated cardiomyopathy.189 Interestingly, FGF, the cardioprotective 
growth factor expressed post-MI, downregulates Ift88 expression and reduces the ciliary 
length during development.190 In the heart, both endocardial and epicardial cells are 
ciliated. However, under the influence of high shear stress (as in cardiac development, as 
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well as post-MI conditions), cells become devoid of cilia as the pressure signals the 
microtubules in these organelles to dissociate.191 In 2013, Rozycki et al. demonstrated that 
the resorption of the primary cilium is involved in regulating TGF-β mediated 
myofibroblast transition.192 Furthermore, the absence of ciliary Ift88 function in the 
embryonic mouse heart coincides with endocardial–to–mesenchymal transition 
(EndMT).193 Therefore, stimulating ciliary disassembly by targeting the Ift88 protein may 
prove efficacious in recapitulating an embryonic phenotype conducive to promoting EMT 
for angiogenesis and cardiac regeneration post-MI. 
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To target any regenerative mechanism, a suitable approach that is specific, 
efficient, efficacious, and cost effective with minimum side-effects is required. Protein 
expression can be up-regulated with the addition of recombinant proteins or adenoviral 
constructs containing the gene of interest, or silenced using gene-based interference 
technology. To enhance EMT, it is possible to prevent assembly of the primary cilium by 
inhibiting the translation of proteins necessary for the intraflagellar transport process. The 
understanding of the structure and function of ribonucleic acid (RNA), along with 
profiling of the mammalian transcriptome, has made knock-down or gene inhibition 
possible using RNA interference (RNAi). For example, short hairpin RNA (shRNA) can 
be used to inhibit messenger RNA from transcribed genes, or even other non-coding 
RNAs (to be discussed later). This is of particular importance in accessing targets for 
which conventional pharmaceutical agents such as small molecule agonists, antagonists 
or antibodies are currently not available.  
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Genome wide analysis studies have determined that although the majority of the 
human (and mouse) genome is transcribed (80%), the bulk (62-75%) of these transcripts 
do not code for proteins.194, 195 RNA molecules that do not encode a molecular protein 
have been termed functional RNA (fRNA) or non-coding RNA (ncRNA). The advanced 
resolution with which data from genome wide analysis studies can be scrutinized along 
with careful examination of the transcriptome has led to an unprecedented understanding 
of the genomic organization of human life. Questioning the doctrine of the “central 
dogma” theory, ncRNA genes produce RNA molecules that are functional in and of 
themselves and are not merely intermediary molecules that encode proteins. 
Early studies in biochemistry identified three RNAs involved in protein synthesis: 
messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA), two of 
which are ncRNAs. However, the study of genomic organization through transcriptome 
analysis has allowed for the identification of several other forms of ncRNA. Broadly, 
these ncRNAs can be divided into two classes: small non-coding RNAs, less than 200 
nucleotides in length, and longer non-coding RNAs, greater than 200 nucleotides in 
length. The types of small ncRNA include: piwi-interacting RNA (piRNA), involved in 
RNA destabilization and the formation of heterochromatin; small nucleolar RNAs 
(snoRNA), which are involved in rRNA modification; small cajal body specific RNA 
(scaRNA), a subset of the snoRNAs which guide biochemical modifications of rRNAs 
and snoRNAs; small nuclear RNAs (snRNA), which are involved in splicing; micro RNA 
(miRNA), which regulate (typically suppress) gene expression; and circular RNA 
(circRNA), which antagonize miRNA.196 Longer ncRNAs include rRNA and other long 
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non-coding RNA (lncRNA), and these have heterogeneous biological functions such as 
mediating epigenetic modifications, transcription and post-transcriptional processing.197  
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A number of molecular RNA tools have been developed in the research setting to 
exogenously alter gene expression, of which small interfering RNA (siRNA) and short 
hairpin RNA (shRNA) are of utmost interest for treatment of disease because they can 
cause gene silencing by RNA interference. These RNAs are advantageous as they are 
thought to have the ability to act on “non-druggable” targets which are inaccessible via 
typical means due to lack of enzymatic function, atypical protein conformation, or their 
presence inside the cell (beyond the plasma membrane). Furthermore, these molecules 
are typically more specific and potent than classical drugs, thereby reducing off-target 
side effects.198 
siRNA and shRNA are processed from either a double stranded (dsRNA) or 
hairpin RNA sequence. siRNAs are designed to have an almost perfect complementarity 
sequence to one mRNA, causing cleavage and degradation, rather than just repression of 
translation as occurs with endogenous miRNA. The specificity and efficiency of siRNA 
makes it a useful synthetic tool for gene silencing in vitro. However, the short half-life of 
siRNA makes in vivo use problematic; siRNAs are rapidly degraded by nucleases and 
quickly eliminated by renal glomeruli.199 To solve this delivery conundrum, shRNA has 
been developed as an alternative which can be delivered via a viral delivery vector. The 
delivered vector bearing the short DNA sequence enters the nucleus and is transcribed to 
a hairpin loop structure by the endogenous RNA polymerase machinery. As a result, 
shRNA is constantly synthesized, leading to enduring gene silencing (lasting weeks) in 
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host cells, as compared with onetime transient siRNA complementarity. This process 
offers the advantage of stable prolonged silencing over the long-term, which is 
advantageous for chronic diseases such as heart failure. Furthermore, optimized delivery 
systems also demonstrate the superior silencing efficacy of shRNA over siRNA.200 These 
delivery systems also offer additional control at the level of the promoter; organotropic 
vectors with cardiac specific promoters can be used for transcriptional confinement to 
reduce off-target effects.201 
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The lncRNAs comprise the largest portion of the non-coding transcriptome, with 
more than twice the number of protein-coding genes in the human.195 lncRNAs are 
suggested to comprise 6.5% of transcripts in the human transcriptome, as compared to 
mRNA which accounts for less than 2%.202, 203 These endogenous transcripts have been 
reported to be involved in a diverse range of regulatory roles, including remodeling of 
chromatin, shaping of nuclear structure, and transcriptional, translational, and post-
translational processing. For example, the lncRNA XIST is required for histone 
trimethylation and gene silencing of the inactive X chromosome.204, 205 lncRNAs can 
compete for the binding of miRNAs, inhibiting miRNA induced mRNA 
destabilization.195 Other lncRNAs, such as NEAT1, possess the capacity to bind both 
DNA and protein, and thus aid in the concentration of both in nuclear bodies 
(paraspeckles) within the nucleus.206 lncRNA can interact with and modulate protein 
activity and protein-interactions, by competing with protein DNA-binding domains and 
providing a scaffold binding surface to assemble proteins.207 Several lncRNAs have been 
reported to interact with transcription factors, regulating their binding and activity, 
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thereby amplifying or attenuating transcription. For example, the dihydrofolate reductase 
pre-initiation complex assembly is controlled by a lncRNA transcript from an up-stream 
promoter.208  Others indirectly affect transcription factors by modulating their shuttling 
into the nucleus.209 The versatility of mechanisms by which lncRNA regulate biological 
processes is continuing to be defined; while the mechanisms of many lncRNAs have been 
uncovered,206, 207 the functions of the vast majority of lncRNAs are still unknown, leaving 
a great mystery of growing scientific interest. 
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ncRNA has been used to alter mRNA to affect cardiac disease in numerous pre-
clinical studies. For example, shRNA has been used to augment activity of HIF-1α for 
angiogenesis in ischemic heart disease by inhibiting translation of its regulator, prolyl 
hydroxylase-2.210 The sarcoplasmic reticulum Ca2+ ATPase pump (SERCA2a) is often 
dysfunctional in the progression of heart failure, and typical pharmacological approaches 
have failed to modulate this target. In 2009, Suckau et al. demonstrated that adenoviral 
shRNA mediated-inhibition of SERCA2a regulator phospholamban normalized cardiac 
hypertrophy and restored cardiac function in a rat model of heart failure.211 Clinical trials 
using RNAi have demonstrated some efficacy in other disease settings (including 
targeting angiogenesis in ocular disease),212 however to the best of our knowledge, there 
has yet to be a clinical trial using RNAi therapy for cardiovascular disease of a non-
genetic cause. 
While RNA interference may revolutionize treatments, endogenous ncRNAs that 
play a significant role in cardiovascular disease have also come under the spotlight as 
both biomarkers which may be used in screening for disease, as well as therapeutic 
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targets to regulate pro-regenerative events post-cardiac injury. Many miRNA levels are 
significantly altered after MI and changes correlate with the progression of cardiac 
hypertrophy and fibrosis.196, 213  
Although many studies have been conducted on the activity of inhibitory RNAs in 
cardiovascular disease, the role of lncRNAs has been less well explored.  In early 2015, 
Ounzain et al. identified hundreds of lncRNAs with potential roles in cardiogenesis and 
pathological remodeling after MI that could be used as candidate biomarkers in 
cardiovascular diseases.214 Several lncRNAs are required for proper cardiogenesis, such 
as H19, which regulates cell proliferation and apoptosis during development.215 More 
recently, analysis of cardiac progenitor cells from human fetal hearts supports the role for 
lncRNAs such as CARMEN (Cardiac Mesoderm Enhancer-associated Non-coding RNA) 
in cardiac differentiation.216 Additionally, He et al. used RNA sequencing to report the 
differential lncRNA expression profiles of fetal and adult hearts, indicating lncRNA may 
be a candidate target for recapitulation of fetal gene expression post-MI.217 
Yang et al. have further suggested that lncRNA expression profiles more 
accurately discriminate failing hearts of different etiologies as compared to miRNAs.218 
Circulating lncRNA LIPCAR, for example, is indicated as a novel predicting biomarker 
of heart failure and death post-MI.219 An association study identifying myocardial 
infarction associated transcript (MIAT) found single nucleotide polymorphisms (SNP) in 
lncRNAs that are associated with increased risk of cardiac disease.220 Other candidate 
lncRNAs include cardiac hypertrophy related factor (CHRF), which regulates cardiac 
hypertrophy, and cardiac apoptosis-related lncRNA (CARL) which suppresses cardiac 
apoptosis.221, 222 As this is a relatively new area of study, the first step towards clinical 
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application using lncRNA is to identify lncRNAs that are dysregulated in disease, and 
determine which are appropriate targets for therapeutic action. To this regard, Viereck et 
al. demonstrated that Chast (cardiac hypertrophy-associated transcript) is upregulated in 
cardiac hypertrophy; upon inhibition of Chast using antisense oligonucelotides, TAC-
induced cardiac hypertrophy is prevented.223 The authors also discovered a human 
homolog, CHAST, which caused hypertrophy in human cells in vitro. 
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The lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) 
has been described as a regulator of EMT, apoptosis, cell cycle progression, and 
angiogenesis.224-226 MALAT1 (also known as nuclear enriched abundant transcript 2; 
NEAT2), is a highly conserved lncRNA with a length of about 8000 nucleotides (two 
splice variants of 8352nt and 8110nt) transcribed from human chromosome 11q13.227 
Malat1 is also found in the mouse, with a length of about 6700 nucleotides located on 
chromosome 19A.228 Like NEAT1 (described above), MALAT1 has been shown to 
localize to nuclear bodies (nuclear speckles) within the nucleus, where it is suggested to 
regulate alternative splicing of several pre-mRNAs.229 MALAT1 is highly expressed in 
many tissues, including those of the respiratory system, liver and biliary system, visual 
system, and importantly, the cardiovascular system. 
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While murine knockout mouse models demonstrate that loss of Malat1 is 
compatible with normal development, its requirement becomes apparent under conditions 
of stress or disease.230, 231 Indeed, MALAT1 was originally identified as a marker for non-
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small cell lung cancers with metastatic propensity.227 MALAT1 transcripts have also been 
found to be upregulated in numerous cancer types and it is thought to contribute to the 
maintenance of EMT for cell migration and invasion.232, 233 Inhibition of MALAT1 in both 
in vivo and in vitro models of squamous cell carcinoma reduced cell migration and 
invasion, expression of EMT makers Slug and β-catenin, and the appearance of 
mesenchymal markers N-cadherin and Vimentin.233 Furthermore, Yang et al. 
demonstrated a direct link between MALAT1 and TGF-β-induced EMT in human cell 
cultures in which knockdown of MALAT1 suppressed TGF-β-mediated morphological 
changes, α-SMA expression, as well as the down-regulation of E-cadherin.234    
MALAT1 also plays a role in tumor driven angiogenesis, and siRNA for MALAT1 
in vitro reduces pro-angiogenic factor expression in tumour cells.235 In vivo, Malat1 plays 
a role in hypoxia related responses in the kidney, and genetic ablation of Malat1 reduces 
neonatal retinal vascularization and post-ischemic angiogenesis in the hindlimb.226, 236 
Similarly, evidence from ocular membranes from diabetic retinopathy patients (involving 
abnormal blood vessel proliferation) and mouse diabetic retinopathy models indicate 
augmented expression of Malat1.237 Furthermore, MALAT1 expression is responsive to 
HIF-1α in pulmonary artery smooth muscle cells, and GapmeR (antisense 
oligonucleotide) mediated reduction of Malat1 reduced smooth muscle cell proliferation 
and ameliorated heart hypertrophy in mice with pulmonary hypertension.238  
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MALAT1 is also a known regulator of cell proliferation and cell death. Along with 
EMT, MALAT1 contributes to cancer progression by promoting cell cycle advancement 
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and inhibiting p53 activation.239 MALAT1 has been shown to mediate progression through 
the G1/S phase of the cell cycle by interacting with unmethylated chromatin and 
relocating repressive complexes to support a gene activation milieu.224 Furthermore, 
siRNA mediated knockdown of MALAT1 promotes apoptosis of glioma cells and 
increases caspase-3 and Bax expression while attenuating Bcl-2 expression in human 
cervical cancer cells.225, 240 In human non-small-cell lung cancer, Bcl-2 expression 
depended on MALAT1 status.241 Silencing MALAT1 also modulated cell proliferation in 
esophageal squamous cell carcinoma cells.242 In more direct relation to the cardiovascular 
system, MALAT1 has been shown to protect endothelial cells from oxidative injury by up-
regulating CXCR2 and AKT, which in turn promote cell proliferation, protect from 
apoptosis, and enhance angiogenesis.243 Malat1 is thought to play a protective role in 
ischemic stroke; its expression is increased after ischemic stroke in mice, and Malat1-/- 
mice experience larger brain infarct sizes, augmented cell death and enhanced caspase-3 
activity.244 Importantly, plasma MALAT1 levels are increased in human MI patients.245 
However, the role of MALAT1 in MI has not been elucidated.  
>@>O(L&$.*3&61(&37(-E/*$-1#.#(
MI and subsequent heart failure are both life threatening and extremely costly 
ailments. Despite scientific advances and optimized current treatment, this is still a 
deadly disease, and breakthroughs in innovative disease treatment are needed. It has now 
been demonstrated that mammalian neonates possess the capacity to completely 
regenerate their hearts, turning treatment innovation towards augmenting strategies 
employed by neonatal hearts for regenerative repair. The recent developments in and 
understanding of ncRNA and RNAi technology has led to the study of their potential in 
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promoting or inhibiting tissue repair, however these methods have yet to show 
development in clinical trials, likely due to direction towards unsuitable targets. Ideal 
candidates to direct treatment strategies would enhance the endogenous repair processes 
that are demonstrated by neonates, such as EMT, and attenuate factors associated with 
adverse outcomes, such as cardiac damage and heart failure. Indeed, we and others have 
demonstrated that augmenting EMT mediated angiogenesis improves cardiac function 
and attenuates hypertrophy.133 A new target which may affect the EMT capacity is the 
primary cilium, a small microtubule based organelle on the cell surface which is thought 
to play a role in regulating EMT processes. 
Although hypertrophy, angiogenesis, and cytokine expression post-MI are 
important mediators in cardiac repair, the magnitude of the acute infarct is perhaps the 
most critical determinant of the development of contractile dysfunction.246 It is important 
to preserve existing cardiac mass given the hearts’ limited capacity for regeneration. This 
is vital since current pharmacologic treatments can attenuate remodeling and preserve 
function post-MI, but have limited effects on the size of the initial infarct. Research 
directed at limiting infarct size by reduction of apoptosis has yielded positive results in 
animal models. Indeed, Yaoita et al. and others were able to attenuate infarct size and 
improve cardiac function using caspase inhibitors in rat models of ischemia.247, 248 
However, no caspase inhibitors have advanced to clinical trials for cardiac disease 
because of poor pharmacologic properties.249 Among other mediators of cell death are the 
lncRNAs. Specifically, Malat1 is a lncRNA implicated in both augmenting EMT and 
mitigating apoptosis. The overall aim of this thesis was to assess the capacity for 
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cardiac regeneration in neonatal mice and study the role of the primary cilium in 
EMT and the lncRNA Malat1 in cell death post-myocardial infarction. 
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Unlike adult mammals which undergo minimal regeneration after cardiac injury, 
the capacity for cardiac regeneration is transiently retained in the mammalian heart in 
early neonatal life. The regenerative capacity is critically dependent on a vascular supply. 
Coronary artery development during embryogenesis and neovascularization post-MI in 
the adult are dependent upon epicardial EMT for both a source of cells and cytokines for 
growth.121 Wt1 and MALAT1 are both known to support the EMT process.136, 234 
However, the importance of Wt1 and Malat1 in the neonatal regenerative response have 
not been clarified. Thus, the first aim of this thesis was to develop a reproducible model 
of cardiac regeneration in neonatal mice with which to test the importance of both Wt1 
and Malat1 in cardiac regeneration. We hypothesized that a reproducible model of 
cardiac regeneration would be developed in neonates, and deficiency of Wt1 and 
Malat1 would abolish the regenerative capacity of the neonatal mouse.  
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It has been demonstrated that EMT genes are upregulated in the regenerating 
neonatal heart.110 EMT is a critical regulator of coronary artery development and 
neovascularization post-MI.121 To the best of our knowledge, the primary cilium has 
never before been targeted for healing post-MI, however its role in EMT has been 
demonstrated in numerous cancer metastases.165 Furthermore, several important EMT 
signaling mediators are known to be harbored within the primary cilium.186 Thus, the 
second aim of this thesis was to determine the role of the primary cilium in EMT and 
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cardiac repair post-MI. We hypothesized that downregulation of Ift88 using 
adenoviral shRNA would potentiate primary cilium disassembly and promote 
epicardial EMT leading to neovascularization and cardiac repair post-MI.  
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Finally, the exploration of lncRNA in the modulation of recovery from 
myocardial infarction has only recently begun. The lncRNA MALAT1 has been shown to 
promote EMT, prevent cell apoptosis and support tissue repair. The role of MALAT1 in 
EMT for metastasis has been demonstrated in several different types of cancer.232 
Similarly, MALAT1 has been shown to play a role in ischemic angiogenesis.226 The role 
of MALAT1 in cardiac ischemia, however, has been less well explored. The third aim of 
this thesis was to assess the role of Malat1 in cardiac damage using a Malat1-/- mouse. 
We hypothesized that silencing of the lncRNA Malat1 would result in augmented 
cardiac injury post-MI. 
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Myocardial infarction induced by coronary artery ligation has been used in many 
animal models as a tool to study the mechanisms of cardiac repair, and to define new 
targets for therapeutics. For decades, models of complete heart regeneration existed in 
amphibians and fish, but a mammalian counterpart was not available. The recent 
discovery of a postnatal window during which mice possess regenerative capabilities has 
led to the establishment of a mammalian model of cardiac regeneration. A surgical model 
of mammalian cardiac regeneration in the neonatal mouse is presented herein. Briefly, 
postnatal day 1 (P1) mice were anesthetized by isoflurane and placed on an ice pad to 
induce hypothermia. After the chest was opened, and the left anterior descending 
coronary artery (LAD) was visualized, a suture was placed around the LAD to inflict 
myocardial ischemia in the left ventricle. The surgical procedure took 10-15 minutes. 
Visualization of the coronary artery is crucial for accurate suture placement and 
reproducibility. This protocol can be used to as a tool to elucidate mechanisms of 
mammalian cardiac regeneration after myocardial infarction. Using this model, the role 
of Wt1 and Malat1 in cardiac regeneration after myocardial infarction was investigated 
with Wt1CreER knock-in (or Wt1+/-) and Malat-/- mice. Our data indicate that indeed the 
neonatal mouse possesses a robust capacity for cardiac regeneration and this was not 
affected by changes in gene expression of Wt1 or Malat1.  
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Myocardial infarction (MI) is a leading cause of death worldwide, and remains 
responsible for about one third of heart failure cases.1 While the advent of percutaneous 
intervention and continuous optimization of the use of thrombolytics has increased 
reperfusion following MI, cardiomyocyte death and loss of contractile myocardium 
nevertheless occurs. There also remain large numbers of “no-option” patients who are not 
candidates for or do not see benefit from these interventions. These patients continue to 
experience disabling ischemia leading to scar formation and deleterious ventricular 
remodeling as a mechanism of infarct healing. This process ultimately results in heart 
failure, for which prognosis remains poor despite best available pharmacologic 
management with angiotensin-converting enzyme inhibitors (ACEi) and beta blockers. 
Unfortunately, the one-year mortality rate for patients with severely impaired left 
ventricular function still remains as high as 26%.2 Heart transplant is the final treatment 
option for patients with heart failure. However, the limited donor pool for heart 
transplantation does not make this a viable option for most patients. Thus, the discovery 
of novel therapeutic agents to restore the damaged myocardium remains paramount to 
solving the cardiac disease problem. Reliable animal models of cardiac injury are 
therefore required as a critical component of this process.  
Traditional dogma has dictated that adult cardiomyocytes are post-mitotic, 
terminally differentiated cells, incapable of dividing or de-differentiating to replace the 
damaged myocardium.3 As such, an adult mammalian heart could never completely 
recover from injury, and lost cardiomyocytes would be replaced with fibrous tissue. 
Thus, research has focused primarily on therapeutic agents to minimize infarct expansion 
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and reduce scar formation. More recently however, a paradigm shift has occurred from 
promoting cardiac healing to focusing on the potential for cardiac regeneration.4  
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Until recently, in vivo study of cardiac regeneration was restricted to non-
vertebrate models, such as those in urodele amphibians and teleost fish.5-7 However, the 
discovery of the capacity for cardiac regeneration in the neonatal mouse has led to the 
development of two surgical models of mammalian cardiac regeneration: resection of the 
cardiac apex and coronary artery occlusion to induce myocardial infarction.8, 9 In 2011, a 
mouse apex resection model was used to demonstrate that complete cardiac regeneration 
is possible at postnatal day 1 (P1). However, this capacity declines rapidly after the initial 
neonatal period. The mammalian heart loses its regenerative potential shortly after birth 
at P7 as progenitor cell numbers decline, and cardiomyocytes become binucleated, lose 
their proliferative competency, and permanently exit the cell cycle.10, 11 Understanding 
the fundamental differences between the neonatal and adult mammalian heart may lead to 
novel insights into cardiac regeneration.  
While apex resection indeed offers insight into re-growth of contractile tissue, the 
model does not simulate typical human cardiac injury, and thus does not lend itself as 
well to extrapolation for the development of therapeutics. The coronary artery occlusion 
model, however, more directly simulates the pathophysiologic aspects of MI pathology, 
and thus may provide more useful insights into mechanisms that may be applicable to 
therapeutic advancement for human use.  
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Surgical coronary ligation has been used as a useful experimental technique in 
many animal models.12-14 In the adult coronary artery ligation model, animals are 
anesthetized and intubated to allow opening of the chest cavity while maintaining 
respiration. The heart continues to beat regularly, permitting visualization of the coronary 
vasculature and allowing for accurate suture placement. Furthermore, the heart remains 
pink as perfusion continues, and after ligation the ischemic myocardium appears pale, 
indicating successful coronary artery ligation. The protocol described for neonatal mice, 
however, is less reliable as the coronary artery is not visualized and the surgeon must 
estimate where to place the suture.15 Although the general anatomy of the coronary 
vasculature is the same, individual animal variability in the direction and branching of the 
LAD exists.16 Thus, when “going in blind,” the artery could be easily missed. Other 
techniques such as echocardiography are then required to confirm successful induction of 
MI, and to ensure all surgeries result in a similar infarct size. Described here is an 
improvement on the recently published method where the position of the LAD can be 
established and thus the LAD may be ligated to reproducibly induce MI.  
As described previously, this technique does not require endotracheal intubation 
or mechanical ventilation, as thoracotomy in a hypothermic state in the neonatal mouse 
does not result in lung collapse.15 However, in the method described previously, severe 
hypothermia must be induced to the point of both complete apnea and cessation of the 
cardiac rhythm. The major limitation of this approach is that the coronary artery is no 
longer perfused and the heart appears pale even before LAD ligation.15 In the approach 
described herein, coronary artery visualization is possible at a point of torpor before deep 
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hypothermia and cardiac rhythm cessation, with full recovery of the neonatal mouse after 
the surgery. This method offers a major advantage of 100% reproducibility. 
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The protocol described above can be used to as a tool to elucidate mechanisms of 
mammalian cardiac regeneration after myocardial infarction. Mechanisms which support 
tissue repair are similar across tissue types. These include reducing the magnitude of cell 
death upon tissue injury, polarizing the inflammatory response to a more M2 type pro-
regenerative response, increasing cell proliferation to replace damaged tissue, recruiting 
resident and bone marrow stem cells, and supporting neovascularization in the wounded 
region.17 Several studies indicate that like regeneration in the zebrafish, cardiomyocyte 
proliferation is vital to the mammalian neonatal regenerative response. Specifically, fate 
mapping indicates that the majority of new cardiomyocytes come from pre-existing 
cardiomyocytes, and this can be altered by regulators of the ERBB2 and Hippo families 
which support dedifferentiation and proliferation.4, 8, 18 However, the ability of 
cardiomyocytes to replace damaged tissue is intimately linked with the formation of new 
supportive blood vessels. Indeed, numerous studies indicate that neovascularization is 
required for wound repair, and impaired angiogenesis results in delayed or defective 
wound healing.19, 20 While evidence from coronary corrosion casts indicates that a 
vascular response does restore perfusion during neonatal heart regeneration, the source of 
this regenerative vasculature is unknown.21  
In lower vertebrates, such as the zebrafish, regeneration primarily occurs through 
cardiomyocyte proliferation. However, a crucial component of zebrafish regeneration is 
activation of the epicardium as it acts as a multipotent cardiac progenitor cell, both 
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providing a cellular source of the regenerated perivascular cells, and acting as a paracrine 
mediator of cell proliferation.22 During cardiac development, the coronary arteries arise 
from an epicardial cell source; epicardium derived cells (EPDCs) contribute to coronary 
vascular smooth muscle cells, perivascular fibroblasts, and potentially vascular 
endothelial cells.23 Beyond direct cellular contributions, the epicardium is also a critical 
signaling source during cardiac formation, secreting retinoic acid (RA), fibroblast growth 
factor (FGF), and other pro-mitogenic and angiogenic paracrine signals.24 The 
epicardium becomes quiescent in the adult mammal, but it re-adapts its embryonic 
phenotype following myocardial injury contributing to myocardial healing, albeit this 
contribution is not enough to support full regeneration.25 As in the zebrafish, epicardial 
cells are activated post-injury in the neonatal mouse heart, evidenced by upregulation of 
embryonic epicardial gene expression.8, 9  
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Wilm’s tumor 1 (Wt1) is a transcription factor expressed in the epicardium during 
development.26 Specifically, it marks EPDCs which undergo EMT during embryonic 
coronary artery formation. Wt1 knockout is embryonic lethal, partially due to impaired 
coronary plexus formation.27 Interestingly, not only is Wt1 expressed in endothelial cells 
in development, it is also up-regulated in the infarct and peri-infarct area after MI.28 
Several of the major mediators of EMT are controlled by Wt1 including, Snail (Snail), E-
cadherin (Cdh1), β-catenin (Ctnnb1), and RALDH2 (Raldh2).27, 29 Specifically, after MI 
Wt1 marks the activation of the epicardium and is expressed in the coronary 
vasculature.30 It is thought that post-MI hypoxia triggers Wt1 expression and activates 
EMT and angiogenesis. The importance of Wt1 for angiogenesis has been confirmed in 
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matrigel plugs and aortic rings from Wt1 knockout mice which displayed reduced 
sprouting capacity.31 To date however, the role of Wt1 in the neonatal mouse cardiac 
regenerative response has not been elucidated. 
 Transcriptome analysis of human tissue indicates that long non-coding RNA 
(lncRNA) accounts for more than double the number of protein coding transcripts in the 
human transcriptome, and plays numerous diverse regulatory roles in transcription, 
translation, and post-translational processing.32, 33 Metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1; aka nuclear enriched abundant transcript 2, 
NEAT2) is a highly conserved lncRNA associated with poor progression, and metastasis 
of numerous cancers.34 In fact, increasing levels of MALAT1 are associated with worse 
prognosis.35 Molecularly, MALAT1 is suggested to promote EMT, owing to its ability to 
support Slug and β-catenin expression, and TGF-β-mediated mesenchymal change.36, 37 
Downstream, Malat1 also causes tumor angiogenesis and post-ischemic angiogenesis, as 
demonstrated in a hindlimb ischemia model.38, 39 The role of Malat1 in myocardial 
angiogenesis has not been elucidated. Specifically, the role of Malat1 in neonatal cardiac 
regeneration has never been studied.  
In the zebrafish, disruption of epicardial signaling abates regeneration,40 thus, we 
hypothesized that disruption of epicardial EMT in the neonatal mouse would diminish its 
regenerative capacity. Specifically, we hypothesized that a reproducible model of cardiac 
regeneration would be developed in neonates, and deficiency of Wt1 and Malat1 would 
attenuate murine neonatal cardiac regeneration. 
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Animals used in this study were handled in accordance with the guidelines of the 
Canadian Council on Animal Care, and study protocols were approved by the Animal 
Use Subcommittee at Western University, London, Canada.  
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Breeding pairs of C57BL/6 (wild type; WT) and CD-1 IG-S mice were purchased 
from Charles River. To investigate the role of Wt1 in the cardiac regenerative response, a 
mouse heterozygous for Wt1 expression was used to emulate Wt1 knockdown. The 
Wt1CreER mouse was designed using a “knock-in” allele strategy, which abolishes Wt1 
homologous gene function. Homozygous Wt1 deletion is embryonic lethal by E13.5 due 
to numerous developmental abnormalities, including those of the heart.27 However, 
heterozygous Wt1CreER are viable, fertile and phenotypically normal.41 Wt1CreER mice 
were generated by crossing Wt1CreER males with WT females, to ensure heterozygosity. 
To investigate the role of Malat1 in the cardiac regenerative response, a Malat1 knockout 
mouse line (Malat1-/-)42 was obtained from Dr. David L. Spector, Cold Spring Harbor 
Laboratory, New York. This mouse was generated via homologous recombination in 
ESCs, and shown to be both viable and fertile.42 
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Genotyping was carried out to identify Wt1CreER positive and Malat1-/- by PCR 
using genomic DNA from tail biopsies. Primer sequences can be found in Table 2.1. 
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Table 2.1. Genotyping PCR primer sequences. 
Gene Forward Reverse 
Wt1
CreER
 tgccacgaccaagtgacagc ccaggttacggatatagttcatg 
Malat1-WT gggaggcaatggtctaacactggacctcca tcgcacacggcctggcggcaccgtcctgct 
Malat1
-/-
 gggaggcaatggtctaacactggacctcca cattcttctttctgggccttggcagtcagc 
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After birthing was complete and pups were initially breast-fed by their mother for 
a few hours, they were placed in a different cage with a CD-1 foster mother. CD-1 
mothers display a calmer phenotype with a strong fostering instinct, and have a lower 
tendency to cannibalize injured pups.15 
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The following surgical protocol was used to reproducibly cause myocardial infarction 
(MI) in neonatal mice.  
1.( Anesthesia was induced by placing the pup in a sealed isoflurane chamber 
(approximately 500 µl of 100% v/v isoflurane allowed to dissipate over 1300 cm3 
chamber). The mouse was kept in the chamber until cessation of movement 
(about 30 sec). 
2.( The mouse was removed from the isoflurane chamber and hypothermic anesthesia 
induced by placing mouse on wet ice.  
3.( To avoid frostbite, ice was placed inside a sterile surgical glove, the mouse was 
wrapped within the glove and the glove covered with ice OR the mouse was 
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wrapped in sterile wet gauze and placed on ice.  
 
NOTE: Mice cool faster when contact with ice is over a larger surface area, and as 
such melted ice can shorten hypothermia induction time.  
 
4.( Anesthesia was confirmed by lack of movement response to toe and tail pinch.  
 
NOTE: Cessation of provoked movement occurs at a body temperature between 
15 °C and 8 °C. (Cooling time to this temperature approximately 1 minute). 
Complete apnea and asystole is NOT required for LAD ligation.  
 
5.( The ice bed was moved to the surgical area equipped with an operating 
microscope. The mouse pup remained on ice during the whole surgical procedure. 
 
NOTE: The surgical area, gauze and surgical instruments were sterilized. The 
sterile field was maintained throughout the procedure, and single use, sterile 
surgical gloves were worn. Opthalmic ointment is not required as mice are born 
with their eyes closed.43 
 
 
6.( The mouse pup was placed in the right lateral decubitus position. 
7.( The chest was disinfected by gently wiping with betadine solution followed by an 
ethanol swab. 
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8.( A skin incision was performed on the left chest along the mid-axillary line by 
cutting the skin between the xyphoid and left axilla a few millimeters below the 
left foreleg. Scissors were also used to cut through the underlying pectoral muscle 
layer. 
9.( A left thoracotomy was performed in the 4th intercostal space by separating the 
ribs and intercostal muscles with forceps.  
 
NOTE: Neonatal ribs are very fragile and can be easily broken. To avoid this, ribs 
were gently separated by opening forceps along the intercostal muscle (rather than 
grasping ribs). 
 
 
10.(The left anterior descending coronary artery (LAD) was visualized emerging from 
the left auricle behind the pulmonary vein and descending beyond the great 
cardiac vein. 
 
NOTE: In this early neonatal window, the thymus is often visualized and may 
cover part of the cardiac base. The LAD can be seen emerging beside the position 
of the thymus, depending on the angle of thoracic incision.  
 
11.(The LAD was ligated by passing a 11-0 nylon suture (0.007 mm diameter needle) 
below the artery through the mid ventricle below the left auricle (Figure 2.1C). 
Ischemia was confirmed with blanching of the myocardium below the suture site 
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(Figure 2.1G). 
12.(The thoracic incision was closed using 8-0 nylon sutures (0.15 mm diameter 
needle).  Two sutures were used to close the ribs. Both rib sutures were placed 
before ligating to ensure the needle did not puncture the lungs when passing 
through the body cavity.  
13.(After closing the ribs, the mouse was removed from the ice bed. The mouse was 
kept within the surgical area and placed directly on the sterile surgical towel over 
a warm heating pad at 37 °C to begin warming.  
14.(Once on the sterile heated area, the muscle and skin layers were closed using 8-0 
nylon sutures (0.15 mm diameter needle). One suture for the muscle layer and two 
sutures for the skin incision were used.  
 
NOTE: Muscle and skin layers may be closed on a heating pad to reduce 
hypothermia exposure time. Mouse temperature begins to rise once placed on the 
heating pad, but remains sufficiently low enough for anesthesia maintenance 
during muscle and skin closure. 
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1.( Rapid warming on a warm heating pad was continued until return of spontaneous 
movement. Animals were not left unattended until they had regained sufficient 
consciousness to maintain sternal recumbency. 
2.( Betadine and blood were removed by gently wiping injury site with an ethanol 
swab. 
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3.( After sufficient recovery from anesthesia, neonates were removed from the sterile 
surgical area, smeared with bedding from foster mother’s cage, and returned to 
the foster mother. This helped prevent maternal rejection or cannibalization. Mice 
recovered from surgery with no apparent complications and were breast fed 
alongside their littermates with no observable difficulty. 
 
NOTE: Pups were not returned to a cage with other animals until fully recovered. 
If an entire litter was not used, and littermates remained with the foster mother, 
recovered pups were placed in the middle of the litter. If performing more than 
one surgery, all surgeries required for an individual litter were completed before 
returning mice to their foster mother. 
 
4.( Behavior of foster mother toward the pup was observed every 10-15 minutes for 
2-3 hours to ensure acceptance of the pup. If the mother displayed aggression 
towards the injured pup, the pup was removed and euthanized by isoflurane 
overdose (>5%; until cessation of breathing), followed by decapitation. 
 
NOTE: Perioperative analgesia medications are not required as the centralized 
pain reflexes are not fully developed at this early age.15 
 
5.( Surgical instruments were wiped clean with water and then ethanol followed by 
sterilization in a bead sterilizer before the next procedure. 
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To study the role of Wt1, two entire Wt1CreER/WT litters were subject to MI at P1, 
and neonates were genotyped for the Cre allele after the procedure (to ensure blinding to 
the surgeon). Mice from each group (4 Cre positive and 7 WT) were collected 21-days 
post-MI for tissue analysis. To investigate the role of Malat1 in cardiac regeneration, 
three litters of Malat1-/-  and two litters of WT mice were subjected to CAL. Tissues from 
12 Malat1-/- and 12 WT mice were collected 21-days post-MI for analysis. 
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To ensure induction of an infarction event, the following protocol was used to 
determine myocardial infarct size in 13 WT neonatal mice.  
1.( Pups were allowed to recover in the care of a CD-1 foster mother for a period of 
4-6 hours.  The pup was removed from the cage with the mother and euthanized 
by isoflurane overdose followed by decapitation with large scissors. 
2.( The heart was excised under a dissecting microscope, with care not to rip the 
myocardium.  
i.( The skin from the xyphoid process to the top of the thorax was cut. 
ii.( The abdominal wall was opened below the ribcage. 
iii.( The lower rib cage was grasped and cut through the ribs and musculature 
longitudinally along the left mid-axillary line from the diaphragm to the 
axilla. 
iv.( Scissors were held in the transverse plane and carefully cut through the 
diaphragm from the left to the right side. ** Scissors were placed below 
the level of the heart so as to avoid any damage to the apex. 
v.( The rib cage was grasped and cut on the right side of the ribs and the 
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musculature along the right mid-axillary line. 
vi.( All vascular connections to heart were removed with scissors. 
vii.( The heart was removed from the chest cavity by grasping the base. 
3.( The heart was sectioned into three pieces using a surgical carbon steel razor blade. 
The first cut was made along the short-axis of the heart at the midpoint between 
the suture and the cardiac apex.  The second cut was made at the level of the 
suture (Figure 2.5A).  
 
NOTE: This left an apex section approximately 0.75 mm diameter, weighing 
0.0018 g; a mid-base section approximately 1mm diameter, weighing 0.0065 g; 
and the base of the heart.  
 
4.( The heart sections were placed in 1% 2,3,5-triphenyltetrazolium chloride (TTC) at 
room temperature for 10-15 minutes. The specimen was carefully watched to 
avoid over-staining. 
5.( To increase contrast, stained heart slices were fixed with 4% paraformaldehyde 
overnight at 4 °C. 
6.( To calculate % infarct area, heart sections were photographed and infarct area 
measured on imaging software. The viable myocardium stains red while the 
infarct area is demarcated as white.44 
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To ensure MI resulted in reduced cardiac function, the following protocol was 
used to assess cardiac function in 25 WT neonatal mice.  
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1.( Pups were allowed to recover in the care of a CD-1 foster mother for a period of 
24 – 48 hours.  Anesthesia was induced by placing the pup in a sealed isoflurane 
chamber (approximately 5% isoflurane). The mouse was kept in the chamber until 
cessation of movement (about 30 seconds). 
2.( The pup was secured in the supine position on a heated dock (temperature 37 °C) 
with its nose in a cone to deliver 0.5-1% isoflurane (for anesthesia maintenance).  
3.( Pre-warmed echo gel was placed on the left thoracic area. 
4.( A parasternal long-axis view of the left ventricle (LV) was obtained, and M-mode 
echocardiography images were recorded using Vevo 2100 system with a MS 400 
transducer. The images were obtained below the level of the suture in the LV. 
Once the correct position was acquired, the echocardiography probe was turned 
90° to obtain a parasternal short-axis view, and record M-mode echocardiography 
images. 
5.( The end diastolic left ventricular internal diameter and end systolic left ventricular 
internal diameter were measured from the short-axis M-mode images. Ejection 
fraction and fractional shortening were calculated.  
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To ensure induction of a reproducible infarct size, the following protocol was 
used to determine myocardial infarct size per area at risk in 4 WT neonatal mice.  
1.( Pups were allowed to recover in the care of a CD-1 foster mother for a period of 
24 hours. The pup was removed from the cage with the mother and euthanized by 
isoflurane overdose followed by decapitation with a large scissors. 
2.( The chest cavity was opened as in steps 2.2.4 1 - 5. Before excising the heart, the 
88 
 
thoracic aorta was carefully grasped just above the diaphragm with fine forceps. 
Fine scissors were held in the coronal plane, flat against the thoracic wall, and the 
thoracic aorta was cut off the posterior thoracic wall moving scissors in the cranial 
direction. The aorta was cut free from the thoracic wall and any other connections 
until it reached the heart. The heart was excised by grasping the superior vena 
cava and removing all other vascular connections to the body.  
3.( The heart was rinsed (with aorta attached) in saline. 
4.( The thoracic aorta was carefully cannulated with a 30 gauge needle and the aorta 
tied to the cannula with 8-0 nylon suture thread. The heart was perfused with 1 
mL of saline through the aorta via a 30 gauge needle at a rate of 1 mL/min. 
5.( The heart was perfused with 150 µL of 2% Evans-Blue solution at a rate of 1 
mL/min. 
6.( The heart was removed from the cannula, sectioned into three pieces and stained 
with TTC as described in 2.2.4 3 – 4. 
7.( To calculate infarct size, heart sections were photographed and infarct area 
measured on imaging software. The viable myocardium stains blue, the area at 
risk stains red, and the infarct area is demarcated as white. 
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The myocardial infarction procedure can be completed in 10-15 minutes and has a 
mortality rate of 7%. After surgery, mice recover from hypothermic anesthesia within the 
next 5-20 minutes (time of recovery depends on body temperature reached during 
anesthesia and speed of surgeon). When using P7 pups (for comparison with a non-
regenerative myocardium), a longer period of cooling is required to reach torpor. P7 pups 
89 
 
are much larger and have more difficulty recovering from both cardiac injury and 
hypothermia, resulting in a much higher mortality rate of 30%.  
Results from previous studies are confirmed herein, indicating induction of 
hypothermic anesthesia at close to 10 °C (between 8 °C and 15 °C).45 Within this 
temperature window, heart rate is slow, but rhythm continues at rates of between 24 bpm 
and 11 bpm. The low heart rate at this level of cooling significantly reduces 
intraoperative bleeding. The LAD can be easily visualized and ligated at these 
temperatures (Figure 2.1). The LAD remains visible until body temperatures reach 
between 9.6 °C and 4.9 °C, causing lowering of heart rate to 2 bpm or asystole.  
Post-MI, pups recover fully and grow to a body size comparable to that of 
littermate controls. Once placed back with their foster mother, pups regain awareness and 
feeding capabilities comparable to littermates within 5-10 minutes. Upon histological 
examination 3 days post-MI, there is evidence of a pale infarct area, with infiltrating 
inflammatory cells, a typical post-infarction response (Figure 2.2). At day 7 post-MI, 
there is evidence of regeneration with left ventricular tissue appearing normal. By day 21 
post-MI, complete cardiac regeneration has occurred. 
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Figure 2.1. Coronary artery is visible during neonatal CAL procedure.  
P1 neonatal mouse after hypothermic anesthesia, skin incision, muscle incision and lateral 
thoracotomy in the fourth intercostal space. A) Left anterior descending coronary artery (LAD) is 
visible. B-D) 11-0 nylon suture is passed through the mid ventricle. E) LAD is ligated and 
blanching observed below the suture site. F) and G) are magnifications of A) and E) respectively. 
Occ. LAD, occluded left anterior descending artery. LA, left atrium. LV, left ventricle. GCV, 
great coronary vein.  White arrow, LAD. Black arrow head, glare from lighting. Scale bars are 1 
mm. 
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Figure 2.2 Evidence of complete cardiac regeneration after neonatal LAD ligation.  
Masson’s trichrome staining after LAD ligation in P1 neonatal mice. Whole hearts and 
magnifications at the infarction areas are shown on day 3, 7 and 21 post-LAD ligation. Note 
myocyte loss and inflammatory cell infiltrate in infarct region at day 3 post-MI (white arrow). 
Complete infarct zone regeneration beginning at day 7 post-MI. Little evidence of fibrosis noted 
at day 21 post-MI. Scale bars are 200 µm, 100 µm and 50 µm for 40x, 200x, and 400x 
magnification respectively. 
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There are multiple methods that can be used to confirm infarct induction and 
determine myocardial infarct size. These include echocardiography, troponin T level 
measurement, and 2,3,5-triphenyltetrazolium chloride (TTC) staining. Assessing troponin 
T levels requires a significant blood volume and with present techniques would not be 
possible for individual neonatal mice without sacrificing them. Instead, echocardiography 
was performed at both 24 hours and 48 hours post-infarction to confirm successful LAD 
ligation (Figures 2.3 and 2.4 respectively). At 24 hours post-MI, ejection fraction (EF) 
was significantly reduced from 84% to 74%, and fractional shortening (FS) significantly 
reduced from 50% to 40% (Figure 2.3). By 48 hours post-infarction, EF was further 
reduced to 46%, as compared to 80% in controls. At 48 hours FS was also reduced 
significantly to 25%, as compared to 50% in controls. Furthermore, there was a 
significant increase in systolic left ventricular internal diameter at 24 and 48 hours. 
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Figure 2.3. Neonatal LAD ligation results in cardiac damage at 24 hours post-MI. 
Assessment of cardiac function by echocardiography at 24 hours post-infarction. A) 
Representative cine-loop images at end-diastole and end-systole for both SHAM operated and 
LAD ligated mice. B) Cardiac functional measurements by echocardiography including fractional 
shortening (FS), ejection fraction (EF), left ventricular internal diameter (LVID) at both diastole 
and systole, and anterior wall thickness at both diastole and systole. Data are mean ± SEM. n = 8 
& 7 mice for SHAM and coronary artery ligation (CAL) respectively. * P < 0.05. 
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Figure 2.4. Neonatal LAD ligation results in cardiac damage at 48 hours post-MI.  
Assessment of cardiac function by echocardiography at 48 hours post-infarction. A) 
Representative cine-loop images at end-diastole and end-systole for both SHAM operated and 
LAD ligated mice. B) Cardiac functional measurements by echocardiography including fractional 
shortening (FS), ejection fraction (EF), left ventricular internal diameter (LVID) at both diastole 
and systole, and anterior wall thickness at both diastole and systole. Data are mean ± SEM. n = 4 
& 6 mice for SHAM and coronary artery ligation (CAL) respectively. * P < 0.05, ** P < 0.01. 
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TTC staining is low cost, reproducible and reliable, and easily performed with 
high throughput. For these reasons, TTC staining 4-6 hours post-infarction was used as a 
confirmation of consistent induction of MI. The red area represents viable myocardium 
and the white area represents ischemic dead tissue. In a total of 13 LAD ligation 
surgeries, 100% of the hearts were infarcted, with an average infarct size of 36% (Figure 
2.5). TTC staining with Evans blue was also performed at 48 hours post-infarction to 
demonstrate persistence of infarcted tissue and measure infarct size based on area at risk 
(Figure 2.6). In these hearts, viable myocardium stains blue, the area at risk stains red, 
and the infarct area is demarcated as white.  Infarct size was calculated as a percent of the 
area at risk. In 4 LAD ligation surgeries, 100% of the hearts were infarcted, with an 
average infarct size of 49% of the area at risk (Figure 2.6). 
To determine the capacity of cardiac regeneration in Wt1CreER and Malat1-/- 
neonatal mice, these mice were subjected to MI at P1. Hearts collected 21 days post-MI 
(P22) were sectioned and stained with Masson’s trichrome staining to detect the presence 
of any residual scarring. Wt1 heterozygosity did not affect the cardiac regenerative 
capacity, as indicated by robust regeneration and lack of scarring in hearts day 21 post-
MI (Figure 2.7A). Similarly, there was no evidence of scarring in any of the 12 Malat1-/- 
hearts at P22 (Figure 2.7B), suggesting Malat1 is not required for the neonatal cardiac 
regenerative response. 
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Figure 2.5. Neonatal LAD ligation is 100% reproducible.  
A) Lines of sectioning of whole heart to create a 0.75 mm apex piece and a 1 mm mid-base piece 
for TTC staining. B) Representative images of TTC stained SHAM control and LAD ligated 
hearts. Scale bars are 1 mm. C) Infarct size in 13 LAD ligations in P1 neonatal mice. Hearts 
collected 4-6 hours post-infarction and infarct size measured after TTC staining. Red indicates 
viable myocardium; white indicates necrosis. Data are mean ± SEM. 
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Figure 2.6. Neonatal LAD ligation results in reliable infarct area percentage.  
A) Infarct size as % of ischemic area in 4 LAD ligations in P1 neonatal mice. Hearts collected 48 
hours post-infarction and infarct size measured after Evans blue and TTC staining. Blue indicates 
viable myocardium; red indicates area at risk; white indicates necrosis. Data are mean ± SEM. B) 
Representative images of Evans blue and TTC stained LAD ligated hearts. Scale bar is 1 mm. 
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Figure 2.7. The neonatal mouse maintains a robust propensity for cardiac regeneration. 
Wt1
CreER 
mice and WT littermate controls underwent coronary artery ligation (CAL) at P1. 
Similarly, Malat1
-/-
 and corresponding WT mice received CAL at P1. Hearts from all mice were 
collected 21 days post-MI (P22), sectioned and stained with Masson’s trichrome staining. As with 
WT controls, both Wt1
CreER
 (A) and Malat1
-/-
 (B) mouse hearts were completely regenerated 21 
days post-MI (indicated by lack of blue scar). Shown are representative images from n = 4 for 
WT1
CreER
 and n = 12 for Malat1
-/-
 mice. Scale bars are 0.5 mm. 
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The surgical LAD ligation demonstrated herein is a reliable method to produce MI 
in neonatal mice. This model provides researchers with a reproducible model with which 
to study mammalian heart regeneration. Visualization of the coronary vasculature is a key 
component of this method, ensuring correct suture placement and thus guaranteeing 
reproducibility. While adult mice do not possess capabilities of poikilotherms, the body 
temperature and metabolic rate of neonatal mice is closely associated with ambient 
temperature. Furthermore, the small size of neonatal mice makes them ideal for 
hypothermic induction by surface cooling. The timing of surgery and mouse body 
temperature are crucial for accuracy in replicating this procedure and thus must be 
monitored carefully. Ligation as soon as possible after torpor is reached provides the 
opportunity to visualize blanching of the myocardium post-ligation, confirming surgical 
success.  
The reproducibility of this technique may be confirmed by functional analysis 
such as echocardiography, viability TTC staining, or immunohistochemistry. If the 
investigator is experiencing difficulty visualizing the LAD (likely due to deep 
hypothermia induction), the left auricle may be lifted slightly with forceps, as the main 
root of the LAD is larger than the more distal segments and may be more easily 
appreciated. If the LAD cannot be visualized, the investigator should not presume artery 
location. This pup should not be used for experimental ligation and could rather be used 
as a sham operated control. Difficulty may arise if entry into the chest cavity is not 
performed at the 4th intercostal space. This space is easily found by visualizing the lower 
edge of the left lung beneath the 4th intercostal space musculature. If a minor amount of 
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bleeding occurs during the procedure, remove blood with sterile gauze. If bleeding is 
significant, however, the surgeon has likely not cooled the mouse sufficiently before 
beginning the procedure, and further cooling is required. Due to the small size of neonatal 
mice, obtaining clear images for echocardiographic analysis may prove difficult. For best 
results, ensure heart rate maintenance with light anesthesia (0.5-1% isoflurane inhalation) 
and maintenance of body temperature (heated dock and warmed echo gel). Images are 
best acquired if the body is tilted slightly downwards towards the right shoulder (~ 5° 
cranially and 5° rightward). Ensure sufficient echo gel is applied to minimize noise. 
Although this approach does offer 100% reproducibility, the size of the infarct 
may be somewhat variable depending on the coronary artery branching anatomy of the 
individual neonate (Figure 2.2). As a result, higher n numbers may be required to reach 
statistical significance in determining the effects of different treatments or genetic 
manipulations on cardiac regeneration.  
From the time of this publication, cryoinjury has also been demonstrated to cause 
reproducible cardiac injury.46 However, the approach presented here holds major 
advantages over both neonatal apex resection and cryoinjury as the pathophysiology of 
these mechanisms of injury may be entirely different from MI and thus may not 
accurately represent human MI.8, 47 This approach more directly mimics typical human 
injury, and may be used to study cardiac regeneration in the setting of mammalian MI.  
This model is unique as it allows for the study of the differences in the 
mechanisms of recovery from cardiac injury between the non-regenerative (adult) and the 
regenerative (neonatal) mammalian myocardium. For example, the adult mouse MI 
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model results in permanent scar formation. Ventricular rupture often occurs as a result of 
infarct expansion. In our experience with this model (>100 surgeries), complete 
regeneration is evident 21 days post-infarction and ventricular rupture has not been 
observed.  
The information accrued from use of this model may offer novel insights into 
mechanisms that may promote cardiac regeneration in the adult. For example, recent 
evidence indicates cardiomyocyte proliferation is a major contributor to cardiac 
regeneration.9 This is in contrast to previous thinking suggesting substantial contributions 
from progenitor cell pools. This has directed research efforts to determining methods of 
promoting cardiomyocyte proliferation rather than progenitor cell activation. For 
example, Meis1 and Neuregulin 1 signaling have already been identified as critical 
regulators of cardiomyocyte proliferation and neonatal cardiac regeneration.4, 48  
Our study indicates that neonatal mice retain a remarkable capacity for cardiac 
regeneration. The role of Wt1 in both coronary artery development and 
neovascularization post-MI has been confirmed by numerous groups.26, 30, 49 Here we 
show that, like their WT counterparts, Wt1CreER mice heterozygous for the Wt1 allele are 
able to recover from myocardial infarction injury at P1 without scarring or phenotypic 
consequences three weeks after injury. These results suggest that high level Wt1 
expression is not required for this regenerative response. The pitfall of using 
heterozygous mice is that the remaining allele may produce sufficient Wt1 to achieve 
cardiac regeneration in neonates. To test this, Wt1 protein expression levels can be 
measured by Western blotting. Other methods to achieve sufficient knockdown of Wt1 
include conditional knockout mouse lines (homozygous deletion is embryonic fatal),27 
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shRNA administration with a viral construct, or by targeted genome editing using the 
CRISPR/Cas 9 system. 
Malat1 is a lncRNA known to promote hypoxia-mediated angiogenesis, and 
support EMT.37, 39 Similar to our neonatal Wt1CreER mice, homozygous deletion of the 
lncRNA Malat1 (Malat-/-) did not affect the regenerative capacity in the neonatal stage. 
This was surprising since Malat1 has also been suggested to support cardiomyocyte 
proliferation, which is required for the neonatal regenerative response.50 Malat1 does not 
appear to be critical to embryonic development, since Malat1-/- mice develop and 
reproduce normally.51 This lack of necessity for Malat1 may apply to the neonatal 
transition period after birth, where some embryonic responses and expression of some 
embryonic genes are still present.52, 53 However, alterations in Malat1 may become 
increasingly important in the adult during situations of stress or disease.54 Thus, it may be 
important to test the effects of Malat1 deficiency on cardiac injury in the adult heart. 
Together, the results presented herein confirm the robust regenerative capacity of 
the neonatal mammalian heart, and that this regenerative response is not sensitive to 
perturbations in Wt1 or Malat1 expression. This intrinsic regenerative capacity has even 
recently been demonstrated in a newborn human child who spontaneously recovered 
normal cardiac function after massive cardiac damage from severe MI.55 Although 
alterations in Wt1 and Malat1 in the early neonatal stage did not affect cardiac 
regeneration, this does not negate their importance in the adult healing response. 
Continued research in this field may elucidate the mechanisms supporting neonatal 
cardiac regeneration, an understanding of which may aid in the development of 
therapeutic targets for post-MI repair.  
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Primary cilia disassembly promotes epicardial epithelial-to-
mesenchymal transition, neovascularization, and cardiac repair post-
myocardial infarction 
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Pathological ventricular remodeling following ischemic cardiac injury is a leading 
cause of death. Typical pharmaceutical approaches to treat this disease have extended life 
but have not improved mortality. Augmenting angiogenesis is considered a promising 
therapeutic target for supporting healing after ischemic cardiac injury. The epicardium is 
a potential source of vascular cells to support healing. Primary cilia are increasingly 
being recognized as hubs of cellular signaling, and their presence can alter traditional 
signaling pathways. Here, we report on the involvement of primary cilia as modulators of 
epicardial epithelial-to-mesenchymal transition (EMT) post-myocardial infarction (MI). 
We demonstrate that mouse epicardial cells are ciliated, and that inhibition of ciliary 
assembly using an adenoviral vector encoding short-hairpin RNA for the mouse 
intraflagellar transport protein-88 (Ad-shIft88) enhances epicardial EMT in vitro. 
Concomitantly, Ad-shIft88 treatment in the myocardium supports a regenerative response 
in a post-regenerative state in a mammalian neonatal mouse (postnatal day 7), 
demonstrated by reduced infarct size and improved cardiac function after MI. Finally, 
treatment with Ad-shIft88 promotes epicardial EMT and neovascularization in the peri-
infarct area, which results in improved cardiac function three weeks post-MI in adult 
mice. This study suggests that the primary cilium may serve as a therapeutic target to 
improve cardiac repair and function post-MI. 
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Ischemic heart disease is the leading global cause of death.1 After surviving from 
acute myocardial infarction (MI), a deleterious remodeling process takes place whereby 
the infarct expands, a fibrous collagen scar replaces lost myocardium, and the remaining 
viable cardiomyocytes hypertrophy in effort to compensate for lost contractile tissue. 
This deleterious remodeling post-MI often causes heart failure, a debilitating and deadly 
disease with a 5 year mortality of 60-75%.2 The current treatment options for heart failure 
can moderately extend life, however the end stage disease remains a major cause of 
death, and is associated with approximately one in eight deaths in the United States.3 
Collectively, heart failure is a major economic burden, with a current global economic 
cost of about $108 billion per annum.4 
It has recently been demonstrated that the neonatal mouse possesses the capacity 
to completely regenerate its heart, however, this response is lost by postnatal day 7 (P7).5 
Neovascularization in the infarct and peri-infarct area is critical to a cardiac regenerative 
response. Cardiac progenitor cells have been demonstrated to be involved in healing post-
MI, and may contribute to angiogenesis and arteriogenesis for vascularization.6 
Specifically, epicardium derived cells (EPDCs) are endogenous multipotent cardiac 
progenitors which support coronary artery development during embryogenesis. During 
cardiogenesis, these epicardial cells begin to express the transcription factor Wilms’ 
tumour 1 (Wt1), and undergo the process of epithelial-to-mesenchymal transition (EMT) 
to invade the myocardium and contribute perivascular and interstitial fibroblasts, 
epithelial cells and smooth muscle cells for vascularization.7 Typically, the adult 
epicardium is dormant; however, after MI, many epicardial cells express markers of 
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embryonic progenitors (including Wt1, Tbx18, c-kit and CD34), and are activated to 
undergo EMT and form EPDCs to promote neovascularization.8, 9 Unfortunately, this 
endogenous EPDC response is insufficient, and does not support adequate vascularization 
necessary for recovery post-MI. However, EMT genes are upregulated post-cardiac apex 
resection in the neonate, implicating epicardial EMT in neovascularization contributing 
to regeneration.10 
The primary cilium is an immotile specialized organelle protruding from the 
apical surface of most vertebrate cells. It is thought to integrate numerous sensory 
signaling pathways from extracellular signals, affectionately earning the name the 
cellular “antenna.” Included in the signaling pathways associated with the cilium are 
sonic hedgehog (Shh), wingless-type integration site (Wnt; canonical & non-canonical), 
and platelet-derived growth factor (PDGF), which are all integrated in the network 
related to EMT activation.11 Shh, Wnt and PDGF pathways support the loss of E-
cadherin, gain of N-cadherin, and induce expression of other pro-EMT mediators such as 
TGF-β.12 Interestingly, it has been proposed that primary ciliary disassembly primes 
endothelial cells to shear-stress induced EMT during heart development.13 Loss of the 
primary cilium is also suggested to be responsible for EMT based metastatic invasion in 
numerous cancer cell types.14 Finally, in association with tissue wounding, TGF-β 
provokes deciliation along the wound edge, which incites EMT-type transitions.15 
However, the effects of primary ciliary disassembly on epicardial EMT and post-MI 
angiogenesis are not known. Intraflagellar transport protein 88 (Ift88) is a transport 
protein required for both the assembly and structural maintenance of the primary 
cilium.16 In the present study, we hypothesized that knockdown of Ift88 using an 
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adenoviral construct encoding a short hairpin RNA against Ift88 (Ad-shIft88) would 
potentiate primary cilia disassembly and promote epicardial EMT, myocardial 
neovascularization, and cardiac repair post-MI.  
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All protocols were approved by the Animal Use Subcommittee at the University 
of Western Ontario, London, Ontario Canada, and animals were handled in accordance 
with the guidelines of the Canadian Council on Animal Care.  
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To inhibit ciliary signalling, an adenoviral construct (Type 5 dE1E3) encoding 
short-hairpin RNA for the mouse intraflagellar transport protein-88 (Ad-shIft88) (shRNA 
sequence: ccgg-gcaggaagactgaaagtgaatctcgagattcactttcagtcttcctgc-tttttg),17 driven by the 
human RNA polymerase III U6 promoter, and tagged with eGFP (cytomegalovirus 
promoter driven; CMV), was obtained from Vector Biolabs (Malvern, PA). An 
adenoviral construct containing CMV-driven green fluorescent protein (GFP) was used as 
control. Adenoviruses were propagated using HEK 293 cells, purified, and titered using 
an AdEasy viral titer kit according to the manufacturer’s instructions (Agilent 
Technologies, Santa Clara, CA).  
F@F@F( )*%*3&%E(&%$1%E(6.8&$.*3(&37(*+&,*,-(&713*=.%&6(.3T1'$.*3(
 Coronary artery ligation (CAL) to induce MI in postnatal day 7 mice (P7) was 
performed as previously described.18 Briefly, mice were anesthetized using isoflurane and 
then cooling on an ice bed. A left thoracotomy was performed at the 4th intercostal space, 
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and an 11-0 suture was used to ligate the left anterior descending coronary artery (LAD). 
The thoracic cavity was closed using 8-0 sutures and mice were warmed to 37 °C on a 
heating pad. For sham operations, a left thoracotomy was performed without ligation of 
the LAD. Similarly, adult LAD coronary occlusion was performed as described 
previously.19 Mice were anesthetized with an IP injection of a ketamine (50 mg/kg) and 
xylazine (12.5 mg/kg) mixture, intubated endotracheally, and ventilated with positive 
pressure by a respirator (Model SAR-830, CWE Inc, Ardmore, PA) at a rate of 90 
breaths/min. A left thoracotomy was performed, and the coronary artery was ligated with 
an 8-0 suture. Both neonatal and adult mice were randomly assigned to injection of either 
Ad-GFP or Ad-shIft88 (109 PFU in 3 µL saline for neonates, and 1010 PFU in 5 µL saline 
for adults). Immediately after CAL, viruses were injected intramyocardially into 3 sites of 
the peri-infarct area, just below the epicardium using a 29 Gauge needle connected to a 
25 µL Hamilton gastight syringe. The surgeon was blinded to the virus group. Hearts 
were collected 3, 5 and 21 days post-MI. Adenoviral infection was confirmed by 
visualization of GFP fluorescence in heart sections; only those mice whose hearts 
expressed GFP upon visualization, indicating adenoviral infection, were used for 
subsequent analysis.  
Neonatal hearts were serially sectioned, and fibrosis was detected by Masson’s 
trichrome staining as per the manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO). 
The fibrotic area was expressed as a percentage of left ventricular surface area, averaged 
from 5 sections across the heart, evenly spaced from the suture site to the apex.20 Adult 
heart weight and body weight was recorded at the time of euthanasia. Infarct size of the 
adult heart was measured and expressed as a fraction of the total cross-sectional 
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endocardial circumference.19 Finally, LV thickness, evaluated at the ventricular septum at 
the level of the suture was determined. 
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 Neonatal heart function was measured at P28 (21 days post-MI or sham surgery) 
using Vevo 2100 system with a MS 400 transducer (VisualSonics, Toronto, Ontario).21, 22 
For adult mice, echocardiographic imaging was performed prior to surgery, as well as 5 
and 21 days post-MI. Mice were anesthetized by inhalation of isoflurane, and fur was 
removed from the chest using hair-removal cream (Nair). Two-dimensional images were 
obtained in both the long-axis and short-axis views. M-mode image recordings on short 
axis were used to measure the left ventricular internal diameter (LVID) at systole and 
diastole.  
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 Primary epicardium derived cells (EPDCs) were cultured as described 
previously.23 Briefly, fetal hearts at embryonic day 13.5 (E13.5) were dissected and 
ventricles were cut into four pieces. After brief washing in warm PBS, ventricle pieces 
were plated onto 1% gelatin-coated dishes in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin 
(Wisent Inc, Canada), and covered with a glass coverslip to promote adherence. 
Epicardial cells migrated outward from the cardiac explant, forming a monolayer across 
the gelatin surface. After EPDCs were allowed to grow outward for a period of 7 days, 
ventricle explants were removed using sterile forceps and epicardial cells were 
trypsinized and re-plated for further experiments. To avoid inclusion of non-EPDC cell 
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types from the culture, only cells from an initial (approx. 4 minute) wash with trypsin 
were used. To test purity of EPDCs in culture, first passage EPDCs were plated onto 1% 
gelatin-covered glass coverslips, fixed, and stained with rabbit anti-mouse Wt1 (1:800, 
Calbiochem, San Diego, CA), goat anti-rabbit Cy3 conjugated secondary antibody 
(Jackson ImmunoResearch, PA, USA), and Hoechst 33342 (Invitrogen, Carlsbad CA) to 
mark nuclei. For validation of Ift88 knockdown, first passage EPDCs were plated onto 
either 1% gelatin-covered glass coverslips or 24-well plates (approx. 105 EPDCs per 
well). Cells were grown to confluence and treated with 107 PFU (approx. 100 MOI) Ad-
shIft88 or Ad-GFP. After 48 hours, medium containing virus was replaced with fresh 
serum-free medium for 24 hours (serum starvation has been shown to induce cilia 
formation and elongation in culture).24, 25 Cells grown on coverslips were then fixed in 
80% methanol and 20% acetone mixture at -20 °C for 10 minutes and air dried. Cells 
grown in 24-well plates were used for analysis of mRNA levels by RT-qPCR. 
Immunocytochemistry was performed on cells fixed on coverslips. Cells were rinsed with 
PBS, and permeabilized with 0.1% Triton for 12 minutes. After blocking with 2% BSA 
for 30 minutes, cells were stained with acetylated α-tubulin primary antibody (1:2000, 
Sigma-Aldrich, St. Louis, MO) in 2% BSA for 90 minutes, followed by 45 minute 
incubation with Cy3 conjugated anti-mouse secondary antibody (1:600, Jackson 
ImmunoResearch, PA, USA). Nuclei were stained with Hoechst 33342. A minimum of 
30 cells were examined for each culture using a fluorescent microscope (Observer D1, 
Zeiss, Germany) at 630x magnification to quantify the cells containing a cilium, and to 
measure the length of cilia. To quantify the percentage of cells containing a cilium, cells 
containing a cilium equal to or greater than 1.5 µm were considered ciliated. 
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 When embryonic day 12.5-13.5 hearts are explanted on a collagen gel, epicardial 
cells grow outward and by about 12 hours, they begin to undergo epithelial-to-
mesenchymal transition (EMT).26 Collagen (1 mg/ml, type I rat tail collagen, VWR 
CanLab) was solidified to a gel in 24-well plates and hydrated with OPTI-MEM media 
containing 1% FBS and insulin-transferrin-selenium (ITS) for 30 minuts at 37 °C. To 
determine the effect of ciliary disassembly on EMT, ventricles of E13.5 embryos were 
harvested as described above and plated on the hydrated collagen gel.23, 26 M199 medium 
(Sigma-Aldrich, St. Louis, MO) containing Ad-GFP or Ad-shIft88 (107 PFU) was then 
added to the culture. After three days, the number of spindle shaped cells grown outward 
from the explanted ventricles was quantified. Images were captured using phase contrast 
microscope (Observer D1, Zeiss, Germany). 
 
F@F@P( A.#$*6*8.'&6(&3&6E#.#(
 Both adult and neonatal samples were fixed in 4% paraformaldehyde at 4 °C 
overnight, dehydrated in ethanol, and paraffin embedded. Hearts were cut into 5 µm 
sections (Leica RM2255 microtome) and mounted on positively charged microslides. All 
images for histological analysis were obtained using a light microscope and Axiocam ICc 
5 camera (Zeiss, Germany). Cardiac tissue sections from adult mice 21 days post-MI 
were stained with hematoxylin and eosin (H/E) for analysis of myocyte cell size.27 
Myocyte diameter was measured as shortest cross sectional diameter at nuclei level in a 
minimum of 5 sections and 50 cells per heart. 
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To assess the number of Wt1 positive cells,  heart sections were immunostained 
using rabbit anti-mouse Wt1 antibody (1:800, Calbiochem, San Diego, CA) following 
antigen retrieval in citrate buffer 10 mM pH 6.0 for 12 minutes at 94 °C using a 
microwave oven (BP-111; Microwave Research & Applications, Inc., Carol Stream, IL).6 
EMT is thought to result in coronary artery formation and neovascularization post-MI.28, 
29 Thus, capillary and arteriole abundance was quantified in the peri-infarct area 5 days 
post-MI, the time when EPDCs begin to re-differentiate, and 21 days post-MI, to ensure a 
long-lasting effect on vascularization. To quantify capillary abundance, heart sections 
were stained with biotinylated Griffonia (Bandeiraea) simplificolia lectin I (1:200, 
Vector Laboratory, CA). Arteriole abundance was analyzed by staining smooth muscle 
cells with α-smooth muscle actin antibody (α-SMA; 1:1000, Sigma-Aldrich, St. Louis, 
MO). Primary antibodies for Wt1 and α-SMA were followed by goat anti-rabbit IgG 
secondary antibody (1:500, Vector Laboratories) and rabbit anti-mouse IgG secondary 
antibody (1:500, Vector Laboratories) respectively. All signals were visualized using 
avidin and biotinylated HRP (Santa Cruz) followed by 3-3’diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich St. Louis, MO). Nuclei were counterstained with  
modified Mayer’s hematoxylin (Thermo Scientific, Waltham, MA). The abundance of 
positive signal was analyzed in at least 5 individual heart sections per sample, and at least 
4 fields in each section. For quantification of Wt1 positive cells, arteriole abundance, and 
capillary abundance, the number of positive cells/vessels were quantified and normalized 
to the myocardial area in each section.6 
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For analysis of expression of Ift88 and E-cadherin in cells, EPDCs grown as 
discussed above were rinsed twice with PBS, and total RNA collected in 150 µL of 
Trizol (Ambion, Foster City, CA). For in vivo expression analysis, the peri-infarct area of 
hearts was collected three days post-MI. Tissue was rinsed in PBS and homogenized (Pro 
Scientific homogenizer) in Trizol. Moloney murine leukemia virus (M-MLV) reverse 
transcriptase was used to synthesize cDNA (from a minimum total RNA of 0.35 µg for 
cells and 0.55 µg for tissue) in 20 µL reactions. EvaGreen qPCR MasterMix (ABM, 
Vancouver, BC) was used for real-time PCR amplification with 2 µL cDNA, as per the 
manufacturer’s instructions. Samples were amplified for 35 cycles using an Eppendorf 
Realplex2 Real-Time qPCR machine and analyzed using cycle threshold (Ct) analysis. 
Primer sequences for expression analysis are listed in Table 3.1. The mRNA levels in 
relation to murine glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal 
control were determined using a comparative CT method.
27  
118 
 
Table 3.1 Real-time RT-PCR primer sequences 
Gene Accession # Forward Reverse 
Ift88  NM_009376 gcgtttcttggttcgtctct cactcccctctcgtttgct 
E-Cadherin (Cdh1) NM_009864 actgtgaagggacggtcaac ggagcagcaggatcagaatc 
Snail1 NM_011427.2 cacacgctgccttgtgtct ggtcagcaaaagcacggtt 
Slug NM_011415.2 caacgcctccaagaagccca gagctgccgacgatgtccat 
β-Catenin NM_001165902 cttggctgaaccatcacagat agcttcctttttggaaagctg 
Wnt1 NM_021279 ctggaactgccccactgct gccaaagaggcgaccaaaat 
Tbx18 NM_023814 gagcagcaacccgtctgtga gggactgtgcaatcggaagg 
HIF-1α NM_001313919 cagcctcaccagacagagca  gtgcacagtcacctggttgc 
bFGF NM_008006 caagggagtgtgtgccaacc tgcccagttcgtttcagtgc 
Aldh1a2 NM_009022.4 ggcagcaatcgcttctcaca cagcactggccttggttgaa 
Tgf-β1 NM_011577 gcccgaagcggactactatg cactgcttcccgaatgtctg 
GAPDH NM_001289726 gatgggtgtgaaccacgaga agtgatggcatggactgtgg 
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 Data are means ± SEM. A one- or two-way ANOVA followed by a Bonferroni 
test was performed for multiple group comparisons (GraphPad Prism program, version 
6.0). An unpaired Student’s t-test was used to detect significance between two groups. 
All tests were two sided, using a significance level of P<0.05. 
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When grown in culture, EPDCs can grow outward from E13.5 heart explants to 
form a cobblestone monolayer of cells (Figure 3.1A). After passage 1 EPDCs were 
plated on gelatin coated coverslips, and EPDC purity was confirmed by detecting Wilms’ 
Tumour 1 (Wt1) expression; 100% of cells outgrown from heart explants were Wt1 
positive, indicating all cells exhibited traits of EPDCs (Figure 3.1B).  
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Figure 3.1 In vitro culture of EPDCs. 
After heart explant culture, epicardium derived cells grow in a cobblestone shaped cell monolayer 
around the explant. A) Cobblestone cells observed three days after explant. Passage 1 EPDCs 
grown outward from heart explants can be used for future experiments.. B) Passage 1 EPDCs 
were 100% positive for Wt1 (red). Nuclear counterstain with Hoechst (blue).  
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To determine the direct effects of ciliary knockdown on EPDCs, two different in 
vitro assays were used. First, passage 1 EPDCs were grown on gelatin coated 24-well 
plates, and treated with 107 PFU of an adenoviral construct containing shRNA for 
Intraflagellar transport protein 88 (Ad-shIft88), a protein vital to ciliary assembly, or a 
green fluorescent protein adenovirus control (Ad-GFP). Two days after treatment, 
medium was changed to virus free, serum free medium to elucidate the presence of the 
cilium in culture. Ift88 mRNA from these cells was quantified by real time RT-qPCR. 
Treatment with Ad-shIft88 significantly reduced Ift88 transcript levels as compared to 
Ad-GFP treated cells (P<0.05, Figure 3.2C). Additionally, a significant reduction in E-
cadherin (Cdh1) mRNA levels, a characteristic of EMT, was observed (P<0.05, Figure 
3.2C). Notably, the primary cilium was revealed in cultured EPDCs using 
immunostaining of acetylated α-tubulin (with dense localization in the primary cilium) 
(Figure 3.2A). Ad-shIft88 treatment significantly reduced cilia length (P<0.01) as well as 
the percent of ciliated cells (P<0.05) (Figure 3.2B). 
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Figure 3.2. Ad-shIft88 reduces Ift88 expression, ciliary number, cilia length, and cellular E-
cadherin mRNA in EPDCs. 
Epicardium derived cells (EPDCs) isolated from E13.5 cardiac explants were grown on a gelatin 
coated dish. Cells were treated with 10
7
 PFU Ad-GFP or Ad-shIft88 for 48 hours followed by 24 
hours serum starvation. A) Representative image of EPDCs stained with acetylated α-tubulin 
(red; white arrow head). Control and treatment adenovirus infection indicated by GFP expression 
(green). Each image shows a single cell. B) Cilia length and percentage of cells with the primary 
cilium longer than 1.5 µm. C) Ift88 and E-Cadherin mRNA levels measured by real-time qPCR. 
Data are presented as mean ± SEM from 3 independent experiments. *P<0.05, **P<0.01.  
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 To investigate whether Ift88 knockdown supports epicardial EMT, E13.5 hearts 
were cultured on a collagen gel to allow epicardial cell outgrowth, and cell EMT to 
become spindle shaped cells.30 The number of spindle shaped cells was quantified and 
normalized to heart explant area. Ad-shIft88 treated cultures had a significantly higher 
number of spindle shaped EPDCs as compared to Ad-GFP controls (P<0.05, Figure 3.3). 
These data indicate that Ift88 knockdown supports EMT of epicardial cells. 
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Figure 3.3. Inhibition of Ift88 promotes EPDC EMT. 
Epicardial cells migrate from cardiac explant culture to become EPDCs and undergo EMT to 
become mesenchymal like (white arrow). A) E13.5 heart explants were cultured on collagen 
coated dishes with Ad-GFP or Ad-shIft88 (10
7
 PFU) treatment. B) Three days post-treatment the 
number of spindle shaped cells (the cells that have undergone EMT) was quantified. Data are 
mean ± SEM from 9 independent experiments. *P<0.05.  
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 To investigate the effect of primary ciliary disassembly on cardiac function after 
injury in a post-regenerative state, myocardial infarction (MI) or sham surgery was 
performed on postnatal day 7 (P7) C57BL/6 mice, followed by intramyocardial injection 
of Ad-shIft88 or Ad-GFP (109 PFU). Cardiac function was assessed by echocardiography 
21 days-post infarction (P28) (the time required for full cardiac regeneration in the 
neonatal mouse).18 Representative M-mode images of echocardiographic measurements 
are shown in Figure 3.4A. Measurements of ejection fraction (EF) and fractional 
shortening (FS) indicate that MI significantly reduced cardiac function as compared to 
aged matched sham operated animals (P<0.01, Figure 3.4B). The left ventricular internal 
diameter during systole was also significantly increased after MI in the Ad-GFP group 
(P<0.05). Notably, mice that received Ad-shIft88 treatment had a significantly higher EF 
and FS than the Ad-GFP treated group (P<0.05 for both). Importantly, both EF and FS of 
mice treated with Ad-shIft88 were restored to similar levels as sham operated mice. 
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Figure 3.4. Inhibition of Ift88 attenuates cardiac functional impairment post-myocardial 
infarction in neonatal mice. 
Postnatal day 7 (P7) mice were subjected to MI by coronary artery ligation, and hearts were 
injected with Ad-GFP or Ad-shIft88 (10
9
 PFU) in the peri-infarct area. Echocardiography was 
performed 21 days post-MI (P28). A) Representative M-mode images. B) Measurements of 
ejection fraction (EF), fractional shortening (FS) and left ventricular internal diameter (LVID) at 
systole and diastole. Data are mean ± SEM, n = 8-9 mice per group. *P<0.05, **P<0.01. 
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 Next, fibrotic scar development was assessed 21 days post-MI as an indicator of 
the propensity for contractile tissue regeneration. Masson’s trichrome staining of heart 
sections revealed the formation of a significant scar post-P7 MI (Figure 3.5A). This data 
is in agreement with the published demonstration of loss of the regenerative phenotype 
by P7.5 Notably, there was a significantly smaller scar in Ad-shIft88 treated hearts as 
compared to Ad-GFP controls (P<0.05, Figure 3.5B), indicative of enhanced cardiac 
repair post-MI.   
 
Figure 3.5. Inhibition of Ift88 attenuates infarct size post-myocardial infarction in neonatal 
mice. 
Postnatal day 7 (P7) mice were subject to MI by coronary artery ligation, and hearts were injected 
with Ad-GFP or Ad-shIft88 (10
9
 PFU) in the peri-infarct area. A) Hearts were collected 21 days 
post-MI (P28) and stained with Masson’s trichrome stain. Red indicates cytoplasm & muscle; 
blue indicates collagen. B) The fibrotic area in the heart calculated as % of left ventricular 
myocardium area. Data are mean ± SEM, n = 13-15 mice per group (6-7 litters). *P<0.05. 
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To determine whether ciliary disassembly affects the capacity for cardiac repair 
post-MI in the adult, coronary artery ligation was performed in adult mice (2 – 4 months 
of age). Cardiac function was assessed by echocardiography before MI (baseline), and 5 
and 21 days post-MI. Representative images are shown in Figure 3.6. MI significantly 
reduced EF and FS (P<0.01, Figure 3.7), however this reduction was abrogated by Ad-
shIft88 (P<0.01). Furthermore, MI resulted in a significant increase in the left ventricular 
internal diameter (LVID) in both groups (P<0.001 for Ad-GFP, P<0.05 for Ad-shIft88), 
however this increase was significantly lower after Ad-shIft88 treatment (P<0.05, Figure 
3.7C & D). 
 
Figure 3.6. Inhibition of Ift88 attenuates cardiac functional impairment post-myocardial 
infarction in adult mice.
Mice were subjected to MI by coronary artery ligation and injected with Ad-GFP or Ad-shIft88 
(10
10
 PFU) in the peri-infarct area. Shown are representative M-mode images of 
echocardiography performed before infarction (baseline), and at 5 days and 21 days post-MI.  
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Figure 3.7. Inhibition of Ift88 attenuates cardiac functional impairment post-myocardial 
infarction in adult mice. 
Mice were subjected to MI by coronary artery ligation and injected with of Ad-GFP or Ad-
shIft88 (10
10
 PFU) in the peri-infarct area. Echocardiography was performed before infarction 
(baseline), and at 5 days and 21 days post-MI. Measurements of A) ejection fraction (EF), B) 
fractional shortening (FS), C) left ventricular internal diameter during systole (LVID;s) and D) 
left ventricular internal diameter during diastole (LVID;d). Data are mean ± SEM, n = 10-11 mice 
per group. *P<0.05, **P<0.01, ***P<0.001 vs. baseline. #P<0.05, ##P<0.01 vs. Ad-GFP group.  
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To investigate the mechanisms responsible for preserved cardiac function in the 
Ad-shIft88 treated group, the involvement of EMT was evaluated 3 days post-MI. Both 
epicardial and myocardial Wt1 expression was assessed by immunohistochemistry 
(Figure 3.8A). Quantitative analysis demonstrated that there were significantly more Wt1 
positive cells both on the epicardium in the peri-infarct area as well as in the myocardium 
of the peri-infarct area in Ad-shIft88 treated mice compared to Ad-GFP treated mice 
post-MI (P<0.05, Figure 3.8B).  
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Figure 3.8. Inhibition of Ift88 augments Wt1 expression in the peri-infarct area post-MI. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) intramyocardially in the peri-infarct area. Hearts were collected 3 days 
post-MI. A) Representative images of Wt1 staining. Wt1 positive cells show dark brown nuclear 
staining. Black and red arrow heads point to Wt1 positive cells in the epicardium and 
myocardium, respectively. Quantification of Wt1 positive cells in B) epicardium and C) 
myocardium of the peri-infarct area. Data are mean ± SEM, n = 8-9 mice per group. *P<0.05 vs. 
Ad-GFP.  
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To further understand the effect of primary ciliary disassembly on EMT in the 
peri-infarct area post-MI, expression of key molecular regulators of EMT was measured 
by RT-qPCR. Tbx18 is also a known epicardial transcription factor enriched in the 
embryonic heart, and marks epicardial activation after injury.31, 32 Tbx18 has been shown 
to upregulate Snail and Slug expression, which are involved in EMT and critically 
modulate E-cadherin expression.33, 34 Wnt1 and β-catenin are also critical to EMT and aid 
in epicardial activation via both canonical Wnt (β-catenin-dependent) and non-canonical 
Wnt signaling (β-catenin-independent).35 There has also been a direct role established 
between Wt1 expression and both β-catenin and retinoic acid signaling pathways 
(aldehyde dehydrogenase 2, Aldh1a2 gene).36 Importantly, Tbx18, Snail, Slug, Wnt1, β-
catenin, and Aldh1a2 are all known to be expressed by transitioning EPDCs. Ad-shIft88 
treatment significantly increased the mRNA expression of Tbx18, Snail, Slug, Wnt1, and 
β-catenin in the peri-infarct area post-MI (P<0.05, Figure 3.9). A trend also indicates an 
increase in Aldh1a2 expression, however this was not statistically significant (Figure 
3.9F). Additionally, hypoxia-inducible factor 1-alpha (HIF-1α) is a master regulator of 
vasculogenesis, which induces growth factors to provoke both EMT and blood vessel 
development.37 For example, HIF-1α is increased in the peri-infarct region post-MI, and 
it promotes the expression of basic fibroblast growth factor (bFGF) and platelet derived 
growth factor –B (PDGFB), well known pro-angiogenic growth factors.38-40 Not only are 
bFGF and PDGFB suggested to play a role in activing EPDCs, they also support 
cardiomyocyte survival, function, and proliferation via a paracrine mechanism.41, 42 
Expression of HIF-1α, bFGF, and PDGFB were all significantly higher in the Ad-shIft88 
treated group as compared to controls (P<0.05, Figure 3.10). Finally, EMT of EPDCs is 
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regulated by TGF-β.43 Although not significant, there was a trend of an increase in TGF-
β mRNA expression in the Ad-shIft88 treated group (P=0.059, Figure 3.10D). Together, 
these results indicate that Ad-shIft88 enhances the expression of transcription and growth 
factors that promote epicardial EMT post-MI. 
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Figure 3.9. Expression of EMT markers is upregulated post-MI in hearts treated with Ad-
shIft88. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) intramyocardially in the peri-infarct area. Tissues from peri-infarct area 
were collected 3 days post-MI. mRNA levels were analyzed by real-time qPCR for A) Snail, B) 
Slug, C) β-Catenin, D) Wnt1, E) Tbx18, and F) Aldh1a2. Data are mean ± SEM, n = 6 mice per 
group. *P<0.05 vs. Ad-GFP.  
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Figure 3.10. Ad-shIft88 treatment increases myocardial expression of HIF-1α and its 
downstream targets that are implicated in neovascularization and EMT. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) intramyocardially in the peri-infarct area. Tissues from peri-infarct area 
were collected 3 days post-MI. mRNA levels were analyzed by real-time qPCR for A) HIF-1α, 
B) bFGF, C) PDGFB, and D) TGFβ1. Data are mean ± SEM, n = 6 mice per group. *P<0.05, 
**P<0.01 vs. Ad-GFP.  
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EPDCs are essential for the development of endothelial cells of the coronary 
vasculature.44 Given the observed increase in EPDC activation post-MI, we hypothesized 
that Ad-shIft88 treatment would augment angiogenesis in the peri-infarct region. To 
investigate these effects, lectin staining was employed to specifically stain endothelial 
cells and quantify myocardial capillary density (Figure 3.11A). As early as 5 days post-
MI, myocardial capillary density was significantly higher in the Ad-shIft88 treated group 
as compared to the Ad-GFP group (P<0.05, Figure 3.11B). This difference was 
maintained to day 21 post-MI (P<0.05, Figure 3.11C).  
As with endothelial cells, EPDCs are thought to contribute to the development of 
the smooth muscle cell compartment of the coronary circulation.44 To determine whether 
enhanced epicardial activation affected arteriogenesis in the peri-infarct region, α-SMA 
staining was employed to stain smooth muscle cells. The number of arterioles (between 
10-150 µm in diameter) in the peri-infarct area 5 days post-MI was quantified. Arteriole 
density was significantly higher in Ad-shIft88 treated hearts as compared to Ad-GFP 
mice (P<0.05, Figure 3.12B). This difference was maintained in the long term to the 21 
day time point post-MI (P<0.05, Figure 3.12C). These data suggest that knockdown of 
primary cilia function supports EMT and neovascularization post-MI. 
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Figure 3.11.Inhibition of Ift88 improves myocardial capillary density in the peri-infarct 
area post-MI. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) in the peri-infarct area. A) Representative images of lectin staining 
(brown). Quantification of capillary density in the peri-infarct area B) 5 days and C) 21 days post-
MI. Data are mean ± SEM, n = 5-6 mice per group for day 5 and 8-9 mice per group for day 21. 
*P<0.05 vs. Ad-GFP.  
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Figure 3.12. Inhibition of Ift88 improves arteriolar density in the peri-infarct area post-MI. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) in the peri-infarct area. A) Representative images of α-SMA staining. 
Arterioles were identified as small vessels 10-150 µm in diameter surrounded by α-SMA positive 
cells. Black arrows indicate arterioles. Quantification of arteriole density in the peri-infarct area 
B) 5 days and C) 21 days post-MI. Data are mean ± SEM, n = 5-6 mice per group for day 5 and 
8-9 mice per group for day 21. *P<0.05 vs. Ad-GFP.  
Ad-GFP Ad-shIft88
0
10
20
30
40
50
M
y
o
c
a
rd
ia
l 
a
rt
e
ry
 
a
b
u
n
d
a
n
c
e
/
p
e
ri
-i
n
fa
rc
t 
a
re
a
 m
m
2
*
Ad-GFP Ad-shIft88
0
10
20
30
40
M
y
o
c
a
rd
ia
l 
a
rt
e
ry
 
a
b
u
n
d
a
n
c
e
 /
 p
e
ri
-i
n
fa
rc
t 
a
re
a
 m
m
2
*
!
"
#$
%
&
!
"
#'
(
)*
+,
,
-./01 -./023!
4 5
16078
139 
 
F@J@P( )&%7.&'(-E/1%$%*/-E(C>(7&E#(/*#$+G?(.3(&7,6$(2.'1(
Hypertrophy of the left ventricular (LV) myocardium is indicative of detrimental 
cardiac remodeling post-MI and can be assessed by the heart weight/body weight ratio 
and the thickness of the ventricular septum. Both Ad-GFP and Ad-shIft88 treatment 
groups had a similar infarct size measured at 21 days post-MI (39.5 ± 5.3% vs. 35.6 ± 
3.7%, P= n.s.). However, although there were no significant differences in body weight 
(Figure 3.13A), a trend of a lower heart weight/body weight ratio was seen in the Ad-
shIft88 treated group as compared to the control Ad-GFP treated group (P=0.06, Figure 
3.13B). Furthermore, the ventricular septum measured at the level of the suture was 
significantly thinner in the Ad-shift88 group as compared to the Ad-GFP group,  
indicating an attenuated hypertrophic response by Ad-shIft88 treatment (Figure 
3.13C/D). To further assess cardiac hypertrophy, cardiomyocyte cell size in the peri-
infarct area was studied by measuring the minimum cross-sectional transverse diameter at 
the nuclear level of hematoxylin/eosin stained heart sections. Treatment with Ad-shIft88 
significantly lowered cardiomyocyte cross-sectional diameter as compared to the Ad-
GFP treated group (P<0.05; Figure 3.13E/F).  
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Figure 3.13. Inhibition of Ift88 attenuates cardiac hypertrophy 21 days post-MI. 
Adult mice were subjected to MI by coronary artery ligation and injected with either Ad-GFP or 
Ad-shIft88 (10
10
 PFU) in the peri-infarct area. A) Body weight and B) heart weight / body weight 
ratio at 21 days post-MI. C) Representative heart sections 21 days post-MI. D) Quantification of 
ventricular septum thickness. E) Representative photomicrographs of hematoxylin and eosin 
stained sections showing cross-sections of cardiomyocytes. F) Analysis of cardiomyocyte 
diameter. Data are mean ± SEM, n = 8-10 mice per group. *P<0.05 vs Ad-GFP.  
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The importance of epicardial activation for neovascularization post-MI has been 
established previously,6 however we demonstrate here a novel role for the primary cilium 
in modulating this process. The results presented herein indicate that knockdown of the 
required ciliary transport protein Ift88 promotes EMT and neovascularization post-MI, 
reduces the deleterious remodeling process and improves long-term cardiac function. 
These data show for the first time that the primary cilium can alter the healing response 
post-MI, and that primary ciliary disassembly increases EMT in the adult heart. Previous 
studies demonstrate the ability of Wt1 positive EPDCs to migrate into the infarct and 
peri-infarct area post-MI to contribute to neovascularization.6 However, this activation is 
not enough to completely salvage the ischemic myocardium post-MI. It is likely that the 
enhanced Wt1 expression in the epicardium and myocardium in the Ad-shIft88 treated 
hearts in our study is indicative of increasing numbers of active EPDCs which migrate 
into the myocardium. Our study suggests that this response improves neovascularization, 
a hypothesis supported by our observation of increased capillary and arteriole density in 
the peri-infarct area in the Ad-shIft88 treated group (summarized in Figure 3.14). Ad-
shIft88 significantly reduced left ventricular chamber dilation, thereby preserving cardiac 
function. Furthermore, Ad-shIft88 significantly attenuated hypertrophic responses which 
typically contribute to the deleterious cardiac remodelling process causing 
cardiomyopathy.  
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Figure 3.14. Schematic diagram of enhanced epicardial EMT via Ift88 inhibition post-
myocardial infarction (MI). 
A) Adult epicardial cells are inherently dormant under normal physiological conditions, however 
after MI, epicardial cells are activated to undergo EMT. B) Epicardium-derived cells migrate into 
the myocardium and become mesenchymal cells in support of reparative vasculature. EPDCs also 
secrete paracrine mediators which aid in cardiac repair. C) Ift88 knockdown by Ad-shIft88 
inhibits primary cilium assembly and augments epicardial EMT post-MI. 
  
!"#$%$&' ()&*+,-&
.,/,)0
12344
!"5'#16+44
!"#$%&'%()*+,
78,*9%",)0
:%,09%;<*,/,)0
!%+$%,-/$
.98,//9%;
78,*9%",9/< 7=3
>?@=!A<B7!@3 :?C35=1<@7:!1@
:9%9*%,&$<766$*+'
! D
.
143 
 
Interestingly, cilia are required for proper situs during development, and 
mutations in ciliary proteins cause congenital heart defects.45 Specifically, the primary 
cilia cannot endure high levels of shear stress, and the loss of cilia actually primes the 
endocardium to shear-stress induced endothelial-to-mesenchymal transition, which is 
critical to endocardial cushion formation and compact myocardium development.13 
Slough et al. demonstrated the presence of cilia on the epicardium, but they did not 
determine the function of these cilia; it was noted however, that epicardial cells from 
mutant mice without cilia did not exhibit the typical flattened epithelial shape, making 
them less distinct from the myocardium.46 This loss of epicardial phenotype is a feature of 
EMT. Here we confirm that mouse epicardial cells are indeed ciliated, and that loss of the 
functional primary cilium supports a transformation from an epithelial phenotype to a 
mesenchymal phenotype.  
Primary cilia are known to modulate Shh, Wnt, and PDGF signalling, and have 
recently been demarcated as an important site modulating TGF-β mediated responses.47 
The downstream molecular events regulating the EMT-like effects seen in our study were 
not investigated, however we postulate that cells without IFT ciliary components may 
lose inhibition of EMT processes. RT-qPCR analysis demonstrates that several mediators 
of EMT including Snail, Slug, and β-catenin are indeed higher after Ad-shIft88 
treatment. Other groups have established the EMT effects of Shh, Wnt/β-catenin, and 
PDGF in epicardial cells after cardiac injury.35, 48, 49 Furthermore, β-catenin mediated 
upregulation of Slug has been demonstrated to be responsible for mesenchymal 
transformation of aortic endothelial cells lacking primary cilia.17 Rozycki et al. also 
determined that the combination of TGF-β with deciliation supports EMT, whereas TGF-
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β alone was not sufficient to cause EMT in tubular epithelial cells.15 These data confirm 
the observation in our study of the ability of the cilium to modulate cellular EMT 
responses. 
Interestingly, studies from zebrafish embryos indicate that endothelial primary 
cilia are essential in developmental vascular integrity, and embryos with mutant 
intraflagellar transport genes have leaky vasculature.50 It is possible that primary cilia 
disassembly indeed supports vascular permeability via endothelial junction disassembly, 
leading to cell migration and movement; thus, primary cilia knockdown would be 
disadvantageous under normal conditions, and advantageous after postnatal injury. 
Sánchez-Duffhues et al. also demonstrated that cilia are present in endothelial cells of the 
vasculature. In this study, lack of functional primary cilia potentiated β-catenin and Slug 
signaling, sensitizing the endothelium to undergo EMT in aortic endothelial cells.17 
In the work presented here, adenoviral mediated shRNA delivery was used to 
knockdown the Ift88 transport protein. There are several pitfalls to this experimental 
approach. Intramyocardial adenoviral injection imparts adenovirus in specific point areas 
of the myocardium, rather than allowing diffuse expression throughout the heart. To 
ensure delivery to the area of interest, care was taken to inject within the peri-infarct area 
at the time of MI. Furthermore, using this approach, we also observed GFP expression in 
the myocardium, suggesting that some of the observed effects could be attributed to 
reduction in cardiomyocyte primary cilia function. Cardiomyocytes are ciliated, and 
knockdown of primary cilia have been demonstrated to support maintenance of a cardiac 
stem cell like phenotype.51 Defects in primary cilia have been demonstrated to promote 
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postnatal cardiomyocyte replication.52 Indeed, primary ciliary disassembly is required for 
progression through the cell cycle.53 However, no difference was observed in the number 
of proliferating cells in the peri-infarct area in this study (data not shown), suggesting the 
observed effects are not a result of enhanced cell proliferation. For these reasons, it would 
be interesting to determine the effects of epicardial specific cilia knockout in the setting 
of MI in future work. Nevertheless, our study is the first to uncover the importance of 
primary cilia for cardiac healing.  
In summary, intrinsic epicardial activation in response to MI is inadequate to 
promote sufficient healing. The present investigation showed that Ad-shIft88 treatment to 
induce primary cilia disassembly potentiated responses to EMT signaling in the 
epicardium, promoting EMT and neovascularization, and improving cardiac function 
post-MI. These data reveal the physiological significance of the primary cilium in 
mediating EMT signaling pathways and highlight the primary cilium as a possible 
therapeutic target post-MI. This is particularly important since patient mortality post-MI 
remains high despite current available pharmacological treatments and there is a pressing 
need for new effective drug therapies. 
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Malat1 protects the heart from myocardial infarction via inhibition of 
necroptotic cell death 
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The lncRNA Malat1 is ubiquitously expressed, and has been shown to prevent 
endothelial cell apoptosis. In patients with myocardial infarction (MI), plasma MALAT1 
levels are elevated. However, the exact role of MALAT1 after acute MI has not been 
investigated. Here, we tested the hypothesis that Malat1 protects the myocardium from 
ischemic injury. We demonstrated that Malat1-/- mice were more susceptible to ischemic 
damage, evidenced by larger infarct sizes and reduced cardiac function post-MI. 
Expression of cardioprotective factors, including bFGF, TGF-β and SDF-1, were 
reduced in Malat1-/- mice. Notably, myocardial caspase-3 and caspase-8 activities were 
not significantly different between knockout and control mice post-MI. However, 
Malat1
-/- mice did display increased necrosis in the infarct area as compared to WT 
controls. Furthermore, expression of both TNF-α and RIP3 was increased in the infarct 
area of Malat1-/- mice, suggesting augmented necroptotic cell death. Our study suggests 
that Malat1 protects the heart from MI injury via inhibition of necroptosis. 
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Cardiovascular disease is the leading cause of death worldwide, accounting for 
over 17.3 million (>30%) deaths per annum.1 Specifically, myocardial infarction (MI) is 
a leading cause of death in the industrialized world, with more than 7 million people 
experiencing MI each year.2, 3 It has been argued that the most important contributing 
event to injury from MI is the initial cell death caused by the infarction. In fact, patients 
with a larger initial infarct suffer worse outcomes including reduced long-term survival, 
and higher rates of heart failure.4, 5 Thus, to maintain proper function, it is important to 
study the mechanisms of cell death in the setting of MI in effort to reduce the extent of 
injury and preserve existing cardiac mass. 
In 2002, Okazaki et al. revealed that the vast majority of the mammalian 
transcriptome is non-coding.6 Specifically, long non-coding RNAs (lncRNA) represent a 
significant portion of the non-coding transcriptome. lncRNAs are longer than 200 
nucleotides in length and, although present in both the nucleus and cytoplasm, they lack a 
sufficient open reading frame for protein coding.7 However, accumulating evidence 
indicates that a significant number of lncRNAs are implicated in a diverse array of 
molecular phenomena including transcriptional, translational and epigenetic regulation.8 
Recent studies have demonstrated significant changes in lncRNA expression profiles in 
patients post-MI, suggesting a potential pathological role.9 
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), also known as 
nuclear enriched abundant transcript 2 (NEAT2), is a nuclear residing, ubiquitously 
expressed lncRNA with a length of about 8000 nucleotides.10 Expression of MALAT1 is 
associated with cancer progression and metastasis, and is involved in regulating cell 
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migration, epithelial-to-mesenchymal transition (EMT), and cell proliferation.11 Malat1 
has also been shown to suppress apoptosis in several cell types. Specifically, MALAT1 
has been demonstrated to support PI3K and AKT phosphorylation, and reduce caspase-3 
activity.12 Furthermore, silencing the lncRNA using siRNA or shRNA increases the rate 
of apoptosis mediated cell death in glioma and endothelial cells.13, 14 Similarly, in cervical 
cancer cells, downregulation of MALAT1 induced the expression of B-cell lymphoma 2 
(Bcl-2)-associated x protein (BAX; pro-apoptotic), as well as caspase-3 and caspase-8, 
while repressing Bcl-2 expression (anti-apoptotic).15 
Hypoxia upregulates Malat1 expression.16 Furthermore, expression of MALAT1 is 
increased in the plasma of MI patients, possibly resulting from hypoxia in the ischemic 
myocardium.17 Based on these findings, and its role in apoptosis, it is likely that Malat1 
may control cellular responses to affect cell death in the setting of MI. The aim of this 
study was to investigate the role of Malat1 in cardiac damage from acute MI. We 
hypothesized that silencing of the lncRNA Malat1 would augment apoptosis and cardiac 
injury post-MI. Our results indicate that deficiency in Malat1 increases cell death from 
infarction, causing increased infarct size and reducing cardiac function. However, to our 
surprise, these results indicate that in the setting of acute MI, Malat1 does not affect 
apoptosis, but rather potentiates another regulated mechanism of cell death, necroptosis. 
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Animal protocols used in this study were approved by the Animal Use 
Subcommittee at Western University, Canada. A Malat1-/- mouse line was provided by 
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Dr. David L. Spector from Cold Spring Harbor Laboratory, New York.18 These mice 
have a homozygous ~3kb deletion in the 5’ end and promoter of the Malat1 gene. The 
deletion is not conditional, and results in a global knockout with complete depletion of 
Malat1 transcript expression in all tissues. To identify Malat1-/- mice, genotypes were 
confirmed by PCR using DNA from tail biopsies. The following primer pairs were used: 
WT Malat1 forward: gggaggcaatggtctaacactggacctcca, reverse: 
tcgcacacggcctggcggcaccgtcctgct; Malat1-/- forward: gggaggcaatggtctaacactggacctcca, 
reverse: cattcttctttctgggccttggcagtcagc. 
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Male C57Bl/6 and Malat1-/- mice (8-12 weeks) underwent left coronary artery 
ligation as previously described.19 Briefly, mice were anesthetized by IP injection of a 
ketamine (50 mg/kg) and xylazine (12.5 mg/kg) mixture. The chest cavity was entered 
via an anterolateral approach, and MI was induced by surgical occlusion of the left main 
coronary artery. The surgeon was blinded to the genotype of the mice during surgery. All 
further experimental procedures were carried out 24 hours post-MI. 
J@F@F( A12*7E3&2.'(G1&#,%1213$#(
One day post-MI, mice were anesthetized by IP injection of ketamine (50 mg/kg) 
and xylazine (12.5 mg/kg) mixture, and placed on a heat pad. Temperature was 
monitored to ensure stability at 37 °C. A Millar pressure-conductance catheter (Model 
SPR-839, Size 1.4F) was inserted into the right carotid artery and baseline arterial 
pressure was measured. The catheter was then advanced retrograde into the left ventricle 
through the aorta. The signal was recorded continuously to measure LV pressures, 
volumes and heart rate. Data was analyzed with a cardiac pressure-volume analysis 
155 
 
program (PVAN 3.2; Millar Instruments, TX).20 After hemodynamics, hearts were 
excised for use in future experiments. 
J@F@J( ?3:&%'$(0.Q1(
Hearts were excised 24 hours post-MI, and the aorta was cannulated to perfuse 
Evans blue dye solution (1% in PBS) through the coronary arteries. Hearts were then cut 
into four transverse sections and incubated in 1.5% triphenyl-tetrazolium chloride in PBS 
(TTC; Sigma-Aldrich, St.Louis, MO) for about 10 minutes at room temperature. Evans 
blue distinguished the ischemic (white) and non-ischemic (blue) areas of the heart, while 
TTC stained viable tissue red. Heart sections were weighed and infarct size was 
calculated by ratio of infarct area (white) to ischemic area (white + red) normalized by 
tissue weight.21 
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To determine the involvement of apoptosis, both caspase-3 and caspase-8 activity 
assays were carried out using a caspase-3 and caspase-8 cellular activity assay kit 
(BIOMOL, Plymouth Meeting, PA). Cardiac tissue from the ischemic area was collected 
24 hours post-MI and homogenized. Protein concentrations were measured and a 
minimum of 115 µg protein was loaded into a 96-well plate. Protein was incubated in the 
presence of the caspase substrate Ac-DEVD-AMC (4 µM) with or without the inhibitor 
for caspase-3 (Ac-DEvD-CHO) or caspase-8 (Ac-IETD-CHO) at 37 °C for 17.5 hours. A 
Spectra-Max M5 micro-plate reader (Molecular Devices, Sunnyvale, CA) was used to 
measure fluorescence intensity (excitation at 360 nm and emission at 460 nm). Data are 
expressed as amount of AMC substrate cleaved per 100 µg protein.  
156 
 
Propidium iodide was used to assess necrotic cell death in the infarct area. To 
label the necrotic cells, animals received an IP injection of 10 mg/kg propidium iodide 
(PI; Invitrogen, Grand Island, NY) 2 hours before tissue collection (22 hours post-MI). 
After collection, hearts were snap-frozen, then embedded in FSC22 frozen section media 
(Leica) at -20 °C. Hearts were sectioned in the transverse plane at 10 µm thickness, and 
frozen tissue sections were counterstained with Hoechst 33342 (Invitrogen, Grand Island, 
NY) to mark nuclei. PI positive cells were quantified and normalized to mm2 infarct area. 
J@F@O( ],&3$.$&$.=1(L9+[D)L(
Total RNA was isolated from the left ventricular infarct or peri-infarct area using 
Trizol reagent (Ambion, Foster City, CA) 24 hours after infarction. A minimum of 0.55 
µg total RNA was used to synthesize cDNA with Moloney murine leukemia virus (M-
MLV) reverse transcriptase in 20 µL reactions. 2 µL cDNA was used for real-time PCR 
amplification with EvaGreen qPCR MasterMix-S (ABM, Vancouver, BC). An Eppendorf 
Realplex2 Real-Time qPCR machine was used to amplify samples and after 35 cycles, 
samples were analyzed using cycle threshold (Ct) analysis. Primer sequences for 
expression analysis are listed in Table 4.1. The mRNA levels were determined using a 
comparative CT method in relation to murine glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as internal control. 
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Table 4.1. The PCR primer sequences. 
Gene Accession NM Forward Reverse 
Malat1 EF177380 ctttgcgggtgttgtaggtt acaggagtgaggcttgtggt 
bFGF NM_008006 caagggagtgtgtgccaacc tgcccagttcgtttcagtgc 
TGF-β1 NM_011577 gcccgaagcggactactatg cactgcttcccgaatgtctg 
SDF-1 
(CXCL12) 
NM_021704 tcagcctgagctaccgatgc tcttcagccgtgcaacaatc 
HIF-1α NM_001313919 cagcctcaccagacagagca gtgcacagtcacctggttgc 
RIP3 AF178953 acacggcactccttggtatc ccgaactgtgcttggtcata 
TNF-α M13049 ccgatgggttgtaccttgtc gggctgggtagagaatggat 
GAPDH NM_001289726 gatgggtgtgaaccacgaga agtgatggcatggactgtgg 
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Total RIP3 expression from the infarct area 1 day post-MI was measured by 
Western blot analysis. Briefly, 50 µg of protein from isolated left ventricular tissue was 
separated by 10% SDS-Page gel and transferred onto a polyvinylidene difluoride 
membrane (PVDF; 0.45µm pore size; Bio-Rad, Hercules, CA). For immunodetection, the 
following primary antibodies were used: anti-RIP3 (1:100, eBioscience, San Diego, CA) 
and anti-GAPDH (1:2000, Santa Cruz, Dallas, TX). Blots were then washed and probed 
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with horseradish peroxidase conjugated secondary antibodies (1:5000, Bio-Rad, 
Hercules, CA), and detected by using an ECL detection method. Signal quantification 
was performed by densitometry (AlphaEase FC, Alpha Innotech Corporation, San 
Leandro, CA). 
J@F@R( 0$&$.#$.'&6(!3&6E#.#(
Data are presented as mean ± SEM. Differences between groups were analyzed using 
an unpaired Student’s t-test. A one-way ANOVA followed by a Bonferroni test was 
performed for multiple group comparisons. All tests were two sided using a significance 
level of P<0.05. 
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Plasma MALAT1 levels are increased in patients post-MI.17 To assess Malat1 
expression in the mouse heart, RT-qPCR analysis was employed. Malat1 was expressed 
in the mouse heart, and myocardial Malat1 expression was significantly higher in the 
infarct area 1 day post-MI as compared to normal hearts (P<0.05, Figure 4.1).  
 
  
 
Figure 4.1. Malat1 expression is significantly increased in the infarct area post-MI. 
Real-time qPCR measurements of Malat1 expression from hearts of control and infarcted WT 
mice. Data are mean ± SEM. n = 4 mice per group. *P<0.05. 
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To determine the role of Malat1 in infarction, both WT and Malat1-/- adult mice 
were subject to MI by coronary artery ligation. Hearts were collected one day post-MI 
and perfused with Evans blue dye followed by staining with triphenyl-tetrazolium 
chloride (TTC) (Figure 4.2A). Infarct size was measured as a percent of weight of the 
infarct to the area at risk, and was significantly larger in Malat1-/- mice as compared to 
WT controls (P<0.05, Figure 4.2B). The area at risk was not significantly different 
between the two groups (Figure 4.2C).  
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Figure 4.2. Malat1 deficiency increases infarct size after myocardial infarction. 
Myocardial ischemia was induced by occlusion of the left anterior descending coronary artery. A) 
Representative Evans blue and TTC stained heart sections 1 day post-MI. B) Infarct size 
expressed as a percent of the weight of the infarct to the area at risk. C) Area at risk after MI. 
Data are mean ± SEM, n = 6 mice per group. *P<0.05. 
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To evaluate cardiac function post-MI, left ventricular hemodynamic parameters 
were analyzed using a Millar pressure catheter. Apart from a small increase in left 
ventricular relaxation, there were no significant differences between WT and Malat1-/- 
mice under normal physiological conditions (Table 4.2). In mice subject to coronary 
artery ligation, there were no significant differences in heart rate (HR), mean arterial 
pressure (MAP), or left ventricular end diastolic pressure (LVEDP) 1 day post-MI. 
However, Malat1-/- mice showed a significant decrease in left ventricular function as 
determined by left ventricular end systolic pressure (LVSP), as well as left ventricular 
contractility (LV +dP/dt) and left ventricular relaxation (LV -dP/dt) (P<0.05, Table 4.2). 
These data indicate reduced cardiac function post-MI in Malat1-/- mice as compared to 
WT controls.   
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Table 4.2. Hemodynamic parameters of WT and Malat1
-/-
 mice 1 day after coronary 
artery ligation (MI) or sham operation. 
 Sham MI 
Parameters WT Malat1-/- WT Malat1-/- 
n 6 6 9 9 
HR (bpm) 414.0 ± 8.90 455.9 ± 22.4 409.5 ± 12.98 388.6 ± 7.14 
MAP (mmHg) 68.25 ± 3.04 67.67 ± 5.44 58.80 ± 1.96 51.33 ± 3.56 
LVSP 98.58 ± 5.30 89.45 ± 1.36 79.71 ± 1.95 68.82 ± 3.47* 
LVEDP 4.437 ± 1.30 3.199 ± 0.70 8.32 ± 1.56 9.306 ± 1.37 
LV +dP/dt 
(mmHg/s) 
7658 ± 516.4 9006 ± 475.6 6466 ± 395.2 4972 ± 523.1* 
LV -dP/dt 
(mmHg/s) 
7139 ± 291.7 8142 ± 331.8* 5762 ± 601.5 4249 ± 366.4* 
*P<0.05 as compared to respective WT controls. 
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To investigate the mechanisms responsible for reduced cardiac function by 
Malat1 deletion, the expression of several cardioprotective factors was measured in the 
peri-infarct area 1 day post-MI. Indeed, there was a significantly lower expression of 
bFGF, SDF-1 and TGF-β in Malat1-/- mice as compared to WT controls (P<0.05, Figure 
4.3). A trend indicates that the pro-survival and pro-angiogenic transcription factor 
hypoxia inducible factor (HIF-1α) was lower in Malat1-/- mice, however this difference 
was not significant. Thus, Malat1-/- mice have a reduced ability to up-regulate 
cardioprotective factors to prevent cardiac injury. 
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Figure 4.3. Malat1 deficiency significantly attenuates cardioprotective gene expression in the 
peri-infarct area post-MI. 
Real-time qPCR measurements of A) basic fibroblast growth factor (bFGF), B) transforming 
growth factor-beta (TGF-β), C) stromal derived factor-1 (SDF-1), and D) hypoxia inducible 
factor-1 alpha (HIF-1α). Data are mean ± SEM. n = 8-9 mice per group. *P<0.05, **P<0.01. 
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To determine the propensity for ischemia related acute damage in the 
myocardium, myocardial apoptosis was determined using caspase-3 and caspase-8 
activity assays. Both caspase-3 and caspase-8 activities were significantly higher in the 
infarct area of both WT and Malat1-/- mice as compared to sham operated WT controls 
(P<0.001 and P<0.01 for caspase-3 and caspase-8, respectively). However, to our 
surprise, there was no significant difference between the two MI groups (Figure 4.4).  
 
Figure 4.4. Malat1 deficiency did not affect caspase activity 1 day post-MI. 
Myocardial tissues were obtained from the infarct area of WT and Malat1
-/-
 mice 1 day post-MI 
with normal WT left ventricular myocardium serving as controls. Caspase-3 (A) and caspase-8 
(B) activity measured by caspase activity assay. Data are mean ± SEM. n = 3-8 mice per group. 
**P<0.05, ***P<0.001. 
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To further elucidate the mechanism causing increased infarct size in Malat1-/- 
mice, myocardial necrosis was assessed by propidium iodide (PI) staining. A significant 
increase in PI staining was observed in the infarct area of Malat1-/- mice as compared to 
controls one day post-MI (P<0.05, Figure 4.5). This suggests an increase in necrotic cell 
death in Malat1-/- mice post-MI. 
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Figure 4.5. Malat1 deficiency promotes necrotic cell death in the infarct area one day post-
MI. 
A) Representative images of propidium iodide (PI; red) and nuclear (Hoescht; blue) staining in 
the infarct area 1 day post-MI. B) Quantification of PI-labelled cells 1 day post-MI. Data are 
mean ± SEM. n = 6 mice per group. *P<0.05. 
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To determine whether necroptosis was altered in Malat1-/- mice in response to 
cardiac injury, TNF-α expression was measured 1 day post-MI by RT-qPCR. There was a 
significantly higher expression of TNF-α in the infarct area of Malat1-/- mice as 
compared to WT controls (P<0.001, Figure 4.6A). Expression of the downstream 
mediator of necroptosis, RIP3, was also measured 1 day post-MI. Similar to TNF-α 
expression, RIP3 mRNA levels were significantly higher in the infarct area of Malat1-/- 
mice as compared to WT controls (P<0.05, Figure 4.6B). To confirm this effect, Western 
blotting was performed to detect RIP3 protein levels (Figure 4.6C). Densitometric 
analysis shows that the ratio of RIP3 to GAPDH protein expression was significantly 
increased in Malat1-/- mice as compared to controls (P<0.001, Figure 4.6D). These 
results indicate an enhanced TNF-α/ RIP3 signaling pathway, leading to myocardial 
necroptosis in Malat1-/- mice post-MI. 
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Figure 4.6 Malat1 deficiency augments TNF-α and RIP3 expression 1 day post-MI. 
Real-time qPCR measurements of A) tumor necrosis factor alpha (TNF-α) and B) receptor-
interacting protein kinase 3 (RIP3) expression in infarct area of WT and Malat1
-/-
 mice 1 day 
post-MI. n = 4 mice per group. C) A representative Western blot for RIP3 and GAPDH protein 
levels in the infarct area of WT and Malat1
-/-
 mice. D) Densitometric analysis of RIP3 protein 
levels in relation to GAPDH protein expression, n = 4-5 mice per group. Data are mean ± SEM. 
*P<0.05, ***P<0.001. 
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Accumulating evidence indicates that lncRNAs are important regulators of 
physiological and pathological processes, however their potential importance in cardiac 
disease is only now emerging. While many lncRNAs have been demonstrated to be 
differentially expressed in cardiac disease, the mechanisms by which these lncRNAs 
regulate cardiac functional processes remain poorly understood.22 The present study was 
carried out to examine the role of the lncRNA Malat1 in cardiac injury from MI. Using a 
Malat1
-/- mouse, we demonstrate for the first time that Malat1 is important in mitigating 
cell death from cardiac ischemic injury. Deficiency of Malat1 was associated with 
increased myocardial infarct size and reduced cardiac function 1 day post-MI. To our 
surprise, this was not associated with an increase in apoptosis, but rather enhanced 
necrotic cell death. This likely occurred as a result of a reduced capacity for expression of 
cardioprotective factors, as well as higher TNF-α and RIP3 expression.  
Cardiac ischemic injury is known to consist of both apoptotic and necrotic cell 
death.23 In fact, necrosis may be responsible for the majority of damage not only from the 
initial infarct, but also contributing to long term deleterious remodelling.24 The 
contribution of necrosis to infarct-mediated cell death is confirmed in our study by the 
correlation between increased necrotic cell death and augmented infarct size in the 
Malat1
-/- group. While necrosis has been traditionally viewed as an un-regulated, passive 
form of cell death, recent evidence indicates that it can in fact be actively controlled by 
TNF-α signaling through a process termed necroptosis. Other reports have demonstrated 
the importance of necroptosis in mediating injury from MI.25 
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Inappropriate production of TNF-α is implicated in a wide spectrum of 
pathologies. TNF-α is a pleiotropic cytokine, and depending on environmental 
conditions, its signaling can cause one of three major processes: inflammation, apoptosis 
or necroptosis. Through the first pathway, TNF-α binding to its receptor TNFR1 causes 
ERK/MAPK and NF-κB mediated pro-inflammatory processes.26 However, in the 
absence of sufficient ERK/MAPK signaling, TNF-α becomes a potent inducer of cell 
death. In the second pathway, a complex of death domains forms with caspase-8, which 
causes apoptosis.27 However, if caspase activity is inhibited or RIP3 levels are high, a 
third signaling pathway ensues whereby the “necrosome” forms (containing RIP1 and 
RIP3) and causes necroptosis. The activity of RIP1 and RIP3 is critical to necroptosis as 
they phosphorylate downstream mediators which disrupt mitochondrial, lysosomal, and 
plasma membranes.28 This results in uncontrolled ion and solute passage, causing cell 
swelling and ultimately rupture - the dominant feature of necrosis. 
Malat1 is known to support the first ERK/MAPK pathway,29, 30 thus its absence 
may attenuate NF-κB signaling, and favor cell death. Additionally, knockdown of Malat1 
has been shown to potentiate the expression of TNF-α upon cell stimulation with 
lipopolysaccharide, suggesting a role for Malat1 in attenuating overall TNF-α 
signaling.31 In the present study, TNF-α and RIP3 expression was increased in the 
infarcted myocardium of Malat1-/- mice. Our results suggest that Malat1 inhibits TNF-
α/RIP3 signaling and myocardial necroptosis post-MI. 
The ubiquitous expression of Malat1 underscores its functional importance, 
however its exact mechanism of action is still unknown. Of the diverse roles of MALAT1, 
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it is suggested to mediate processes via binding and sequestration of molecules into 
nuclear speckles. Specifically, MALAT1 has been shown to regulate pre-mRNA splicing 
by bringing RNA-splicing factors to nuclear speckles for assembly, modification, and 
storage.32 Malat1 is also thought to play a cis-regulatory role by regulating expression of 
its neighbouring genes.18 Previous studies have demonstrated a role for Malat1 in 
suppressing apoptosis by regulating caspase levels and activity.33, 34 In 2016, Zhang et al. 
even confirmed the role of Malat1 in reducing cardiomyocyte apoptosis in the setting of 
diabetes.35 Although this group did not discern the mechanism of action, another study 
suggested that MALAT1 sponges or sequesters various miRNAs, and that in endothelial 
cells it modulates the expression of the chemokine receptor CXCR2 by competing with 
miR-22-3p, a promoter of apoptosis.14 Unexpectedly, Malat1 deficiency did not affect 
caspase activity in the present investigation. Instead, the Malat1-/- mice show augmented 
necroptotic cell death post-MI. While no study has demonstrated a direct relation of 
MALAT1 to necroptosis, it is known to downregulate miR-155, the suppression of which 
attenuates necroptosis.36, 37 The exact mechanism by which Malat1 mediates necroptosis 
in cardiac ischemic cells should be determined in future studies.  
In concordance with previous studies, we demonstrate that Malat1 expression is 
upregulated in response to ischemia.38 However, the results of the current study are in 
conflict with two previous reports of the role of Malat1 in cardiac injury. In one study, 
Malat1 reversed the cardioprotective effects of fentanyl in ischemia/reperfusion injury.39 
However, the authors only tested fentanyl and Malat1 co-administration and did not 
study any effect of Malat1 alone on ischemia/reperfusion injury. Thus, the effects of 
Malat1 on ischemic injury are unknown. In another study, Peters et al. showed that 
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Malat1 is dispensable during pressure overload-induced cardiac hypertrophy by thoracic 
aortic constriction (TAC) using a different Malat1-/- mouse line.40 Although cardiac 
ischemia may cause cardiac hypertrophy in the long term, this chronic effect was not 
tested in our study. In future, the role of Malat1 in long-term cardiac remodeling post-MI 
should be investigated. 
Cardioprotective factors also play an important role in the response to cardiac 
ischemia. Included in these factors are the ERK1/2 pro-survival kinases, as well as the 
PI3K/AKT signaling molecules. Upstream of these molecules are mediators of both acute 
and long term protection including protein tyrosine kinase ligands like bFGF and 
cytokines like SDF-1 and TGF-β.41-43 Exogenous administration of bFGF, SDF-1 and 
TGF-β have all been demonstrated to decrease myocardial cell death in the setting of 
acute ischemic injury.43-45 This is consistent with previous findings from our lab 
confirming the role of SDF-1 in myocardial injury.46 In the present investigation, we 
observed reduced expression of bFGF, SDF-1 and TGF-β in Malat1-/- mice, implicating 
Malat1 in the regulation of these cytoprotective factors in the heart. Insufficient 
cardioprotection in the setting of MI may have contributed to the observed increase in 
infarct size in Malat1-/- mice. The mechanisms by which Malat1 regulates expression of 
these cardioprotective factors require further investigation.  
In summary, our study suggests that Malat1 is critical in the regulation of necrotic 
cell death in cardiac ischemia. A Malat1 deficiency in the myocardium augments 
cardiomyocyte necroptosis, leading to increased infarct size and impaired cardiac 
function one day post-MI. Our results show a cardioprotective role of Malat1 post-MI, 
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and suggest that MALAT1 may have therapeutic potential to reduce cardiac injury in the 
setting of acute MI.  
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The overall objective of this thesis was to assess the capacity for cardiac 
regeneration in neonatal mice, and investigate the contributions of the primary cilium and 
the lncRNA Malat1 in responses to cardiac ischemic injury. Specifically, these studies 
aimed to determine the importance of Wt1 and Malat1 in neonatal cardiac regeneration, 
the role of the primary cilium in epicardial EMT, and the functional importance of 
Malat1 in cardiac cell death. To achieve this goal, experimental approaches included in 
vitro cell culture and in vivo animal studies. MI was used as a model of cardiac injury in 
both adult and neonatal mice. The regenerative capacity in the neonatal mouse was 
assessed by attempting to perturb regeneration through reductions in Wt1 and Malat1 
expression. The role of the primary cilium was investigated using an adenoviral construct 
containing shRNA for the Ift88 transport protein, while the importance of Malat1 in 
ischemic injury was studied using a Malat1-/- mouse.  
In Chapter 2, the effects of Wt1 knockdown and Malat1 deficiency on the 
cardiac regenerative response were investigated using a Wt1CreER mouse heterozygous for 
Wt1, and a Malat1-/- mouse line. A protocol to cause reproducible cardiac injury was 
established in neonatal mice. Critical to the implementation of this protocol is the control 
of mouse temperature during the surgical procedure such that the coronary vasculature is 
still perfused and is thus visible during hypothermic anesthesia. Reproducible cardiac 
injury was demonstrated by 100% infarction rate with a consistent infarct size of ~ 49% 
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of the area at risk. All mice subject to coronary artery ligation exhibited reduced cardiac 
function (EF and FS) measured by echocardiography. Complete cardiac regeneration was 
evident 21 days post-MI as demonstrated by a normal ventricular architecture and lack of 
scarring after Masson’s trichrome staining. Interestingly, neither Wt1 knockdown nor 
Malat1 deficiency affected the cardiac regenerative response; regardless of genotype, all 
mice exhibited 100% cardiac regeneration. These data further support the notion that the 
mammalian neonate possesses a powerful capacity for cardiac regeneration. 
EMT is a key regulator of the cardiac response to MI.1 In Chapter 3, the effects 
of primary ciliary disassembly on EMT and cardiac function post-MI were assessed. To 
carry out this aim, an adenoviral construct containing shRNA for Ift88 was employed to 
disassemble the primary cilium. In vitro cultures of epicardium derived cells (EPDCs) 
treated with Ad-shIft88 had fewer cells possessing cilia, and cilia that were present were 
shorter in length. The primary cilium is known to mitigate EMT and affect 
cardiogenesis,2, 3 however its role in epicardial activation in the adult heart has apparently 
never been investigated. We demonstrate for the first time that Ift88 knockdown 
potentiates epicardial activation and EMT both in vitro and in vivo post-MI. Molecular 
analysis demonstrated increased expression levels of the key EMT transcription factors 
Wt1, Snail, Slug and β-catenin in the peri-infarct area of hearts injected with Ad-shIft88. 
This resulted in improved neovascularization as compared to the control group. Overall, 
primary ciliary disassembly was associated with the attenuation of adverse remodeling 
post-MI, improved cardiac function, and reduced cardiomyocyte hypertrophy. 
Myocardial injury causing loss of functional cardiomyocytes within a few hours 
after ischemia produces pathological changes in the heart which may ultimately lead to 
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heart failure. In Chapter 4 the role of Malat1 in acute myocardial ischemia was 
investigated. To carry out this aim, a Malat1-/- mouse line was obtained for use in in vivo 
experiments. On initial experimental analysis, it was noted that 24 hours post-MI Malat1-
/- mice had larger infarcts than their WT counterparts. Importantly, this lead to reduced 
cardiac function. Surprisingly, myocardial apoptosis was not affected in this model, but 
rather Malat1-/- mice exhibited reduced expression of cardioprotective factors and 
augmented necrosis. We further demonstrated the involvement of regulated necroptotic 
signaling via TNF-α and RIP3 expression. Thus, we provide novel evidence that Malat1 
may affect the necroptosis pathway, and that its deficiency enhances injury from cardiac 
ischemia.  
In summary, we have validated the ability of neonates to recover from MI, and 
observed evidence of the involvement of the primary cilium and the lncRNA Malat1 as 
mediators of the damaging responses to this type of cardiac injury. Knockdown of the 
primary ciliary intraflagellar transport protein Ift88 enhances endogenous repair 
mechanisms by supporting EPDC EMT. This leads to neovascularization, which 
mitigates adverse cardiac remodeling post-MI. Contrastingly, deficiency of Malat1 
augments cell death from cardiac ischemic injury. These studies provide important 
information for developing novel strategies for both the treatment of MI, and identifying 
factors which may place patients at risk for increased damage in the face of MI. A 
summary of the findings from these studies is shown in Figure 5.1.  
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Figure 5.1. Summary of the cardiac response to myocardial infarction and the effects of 
primary ciliary disassembly and Malat1 deficiency. 
Myocardial infarction causes cell death, which results in cardiac dysfunction. An insufficient 
epithelial-to-mesenchymal transition (EMT) response to support neovascularization, coupled with 
collagen deposition and hypertrophy in remaining viable cardiomyocytes causes cardiac 
remodeling and heart failure. Effects of Ad-shIft88 and Malat1 deficiency are shown by purple 
and green arrows, respectively.  
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To evaluate the basic pathophysiological changes and potential therapies for any 
disease, it is necessary to simulate the human entity using a model that is both 
physiologically similar to humans, with conserved biological processes, and offers high 
throughput with minimal cost. The mouse genome has 99% homology with that of the 
human,4 and the use of mouse models offers the great advantage of possible genetic 
manipulation through knockout or overexpression mouse lines. Advancements in 
comparative genomics and the understanding of how small genetic mutations alter mouse 
response to disease may offer potential targets for therapeutics for humans and may be 
applied to identify individuals at risk for disease. However, the mouse genome does not 
completely recapitulate that of the human, and differences in gene isoform expression can 
cause major physiological changes. For example, the predominant ventricular sarcomeric 
protein in humans is β-myosin heavy chain (β-MyHC), whereas ventricular protein 
composition in mouse is >95% α-MyHC.5  Thus, genetic alterations may result in 
different physiological effects which may cause drastic phenotypic consequences in 
response to stressful stimuli in mice as compared to that in observed in humans with 
similar genetic mutations. 
Another advantage of murine disease modelling is the ability to ensure disease 
conditions are the same in all groups studied, while also observing phenomena at any 
time point in the disease process. The work presented here made use of an animal model 
of MI by surgically ligating the left anterior descending coronary artery (LAD). This is 
advantageous over other animal models of cardiac injury such as transverse aortic 
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constriction (TAC) or electrocautery as the effects on the myocardium are 
physiologically very similar to those which occur from a coronary artery block in 
humans. Furthermore, although harm from acute reperfusion injury invokes further 
myocyte cell death in the setting of ischemia/reperfusion,6 permanent occlusion of the 
LAD was chosen over an ischemia/reperfusion model in our studies. As duration of 
occlusion increases, the risk of stunned myocardium becoming infarcted increases, 
producing a larger, long lasting irreversible cardiac injury in the setting of permanent 
occlusion.7, 8 Thus, any beneficial effects demonstrated by shIft88 or Malat1 could be 
critically important, particularly for the development of therapeutics for patients who are 
unable to receive reperfusion therapy. 
Unfortunately, this approach does involve some inherent disadvantages. The most 
common cause of human MI is blockage of the LAD by rupture of an atherosclerotic 
plaque.9 Most patients with this form of MI carry a significant burden of comorbid 
conditions such as dyslipidemia, hypertension or diabetes.10 Many of these patients have 
already progressed to a late stage of cardiac disease, having already experienced angina, 
sometimes intermittent ischemia, and moderate cardiac remodeling by hypertrophy.11 
Furthermore, a disproportionately high percentage of patients experiencing coronary 
artery disease are older individuals.12 Thus, the myocardium of a typical MI patient is 
already moderately damaged, and the repair capabilities of this tissue would be inferior to 
that of a murine heart from our model of MI. Despite these short comings, cardiac 
research continues to depend heavily on mouse models of MI for the development of 
therapeutics and the understanding of molecular processes contributing to heart failure.  
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The ease with which the mouse genome can be manipulated makes it an 
invaluable model to study the mechanisms of cardiovascular disease. In this study, the 
Wt1CreER mouse heterozygous for the Wt1 allele was used. However, heterozygous 
deficiency of Wt1 may not be sufficient to perturb the regenerative capacity in neonates. 
Wt1 expression by the remaining endogenous allele could be responsible for the lack of 
any observable effects in Wt1CreER mice on cardiac regeneration. In 1993, Kreidberg et al. 
reported on the developmental deficiencies of mice with a homozygous deletion for 
Wt1.13 Even epicardial specific Wt1 mutants die from cardiovascular defects between 
E16.5 and E18.5.14 Although the Wt1 homozygous deletion cannot be used to study the 
role of Wt1 in the postnatal animal, Wt1 conditional knockout has been demonstrated in 
the study of glomerulosclerosis.15 
Interestingly, Wt1 mutations have been observed in the human population, and 
mutations in an exon from 11q13 causes Wilms’ tumors, a kidney tumor typically 
presenting in childhood.16 Larger mutations in this gene may cause WAGR syndrome, a 
more serious syndrome with a spectrum of defects including Wilms’ tumours, aniridia, 
genitourinary abnormalities and mental retardation, or Denys-Drash syndrome in which 
patients present with ambiguous genitalia, dysgenic gonads, nephropathy and Wilms’ 
tumors.17 Although mouse models of these syndromes using Wt1 deletion strategies 
identified the importance of Wt1 in the epicardium,18 cardiac abnormalities have only  
been reported in one patient with WAGR or Denys-Drash syndrome.19 However, 
Meacham syndrome is another rare multiple formation syndrome with an association to 
Wt1 mutations.19 Abnormalities, including congenital heart defects, have presented in 
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proepicardium derived tissues in these patients.19 Whether homozygous deletion of other 
parts of this gene in humans results in severe cardiac defects causing spontaneous 
abortion early in development has not been investigated.  
The differential effects observed in Wt1 mutant mice as compared to human 
patients with Wt1 mutations exemplifies a disadvantage of genetic knockout or 
knockdown mutant mice. Full genetic knockout or knockdown mutations may cause 
different phenotypes from point mutations in a gene. Proteins, such as Wt1, are created 
from multiple exons, and variants of a gene can produce different isoforms, causing 
differential effects on protein structure and function.20 Thus, while genetic knockouts 
may cause a drastic effect in development, point variants found in humans may have 
different consequences. 
 Like the lack of effect on cardiac regeneration in Wt1CreER neonatal mice, 
knockout of the lncRNA Malat1 had no observed effect on the cardiac regenerative 
capacity in the neonatal mouse. While there were no observable effects in the heart at this 
early time point in postnatal life, in Chapter 4 we did observe detrimental effects of 
Malat1 deficiency on cardiac function after MI in the adult. The differences in these 
studies underline the importance of differential gene expression signatures, causing 
interactions during development which are different from those in the adult mammal. For 
example, epigenetic regulators cause changes in expression profiles of proteins from 
development to post-natal life.21 Furthermore, Malat1 is known to be affected by 
methylation status, and while it is ubiquitously expressed in all tissues during early 
embryonic development, its expression varies markedly in adult tissue.22, 23  
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As Malat1 is expressed in numerous cell types, the effects observed in the whole 
body knockout could be the result of Malat1 deficiency in non-cardiac cells. Although no 
morphological differences between WT and Malat1-/- mice have been reported, we 
cannot definitively rule out that Malat1 deficiency in other cell types may have 
contributed to the effects observed in Chapter 4. TNF-α and other pro-inflammatory 
cytokines are known to play a role in the response to MI.24 It is possible that the role of 
Malat1 in TNF-α mediated inflammation could affect macrophage and neutrophil 
response to infarction. Neutrophil recruitment peaks 1 day post-infarction and contributes 
to the production of reactive oxygen species.25 It is possible that Malat1 deficiency in 
neutrophils may have altered the response to MI in our study. Other inflammatory cells 
such as macrophages are known to be recruited to the infarct region several days after 
MI.25 As such, it is unlikely that reduced Malat1 in these inflammatory cells is a major 
player in the responses observed at the early 1 day time point in this study. It would be 
interesting to observe the effects of a cardiac specific Malat1 knockout or Malat1 
knockdown in cardiomyocyte culture to further clarify these processes. In previous 
studies, siRNA has been used to knockdown Malat1 in a stable cardiomyocyte cell line in 
vitro.26 Furthermore, Malat1 expression has been reduced in the in vivo setting using 
antisense GapmeR reduction.27 However, a cardiac specific knockout or knockdown has 
yet to be published. 
 To the best of our knowledge, there are no reported cases of humans with 
MALAT1 null mutations. However, MALAT1 expression is known to be upregulated in 
various types of cancer.28 A recent study demonstrated that a genetic variant on the 
MALAT1 allele was associated with better survival for advanced lung adenocarcinoma 
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patients.29 It would be interesting to determine whether patients with this allele suffer 
worse outcomes in the face of an MI. Furthermore, the MALAT1 gene produces a very 
long transcript (6700 nt),30 thus, determining the structural and functional effects of this 
mutation should be the subject of future work. 
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In Chapter 3, the Ift88 transport protein was knocked down using an adenoviral 
construct containing short hairpin RNA. This approach has several pitfalls. Firstly, as 
noted in Chapter 3, uptake of the adenoviral construct was not restricted to epicardial 
cells. Thus, the observed effects could be partially the result of Ift88 knockdown in other 
cell types. This could be improved upon using an epicardial specific promoter (e.g., Wt1 
promoter) in future work. Secondly, an intramyocardial injection was used to deliver the 
Ad-shIft88 vector. This method would be suboptimal in the clinical setting as the 
myocardium is not directly approachable without opening of the thoracic cavity. 
Intravenous (IV) adenoviral delivery may be more a more clinically translatable method, 
as opening of the chest cavity would not be required. Tissue specific adenoviral targeting 
has been used previously to target the myocardium via IV injection.31 Catheter-based 
intramyocardial gene delivery by transendocardial injection is another superior approach 
which may be advantageous in the clinical setting. Using this less invasive approach, 
Kornowski et al. demonstrated that transgenes can be effectively delivered to precise 
regions of the myocardium.32  Finally, adenoviral administration can stimulate the 
immune system, causing activation of the interferon pathway.33 The safety profiles of 
adeno-associated viruses (AAVs) and biological nanoparticles (BNPs) have been 
demonstrated to be superior to those of adenoviral, retroviral and lentiviral vectors, and 
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may be more suitable approaches for clinical translation.34, 35 In fact, AAVs have been 
shown to have a higher and longer lasting infection efficiency than adenoviruses in the 
heart.36 
In addition to vector delivery, method of gene silencing can affect the efficiency 
of knockdown. While shRNA provides more efficient knockdown than other methods 
like siRNA, shRNA itself can cause unexpected cellular effects.37 Cell toxicity can arise 
from excess shRNA due to competition with normal cellular miRNA for processing 
machinery.38 This has been demonstrated by fatality in mice from oversaturation of the 
endogenous RNA processing machinery due to sustained high doses of shRNA via IV 
infusion.39 Thus, this type of cell injury should be controlled for in future work using 
another shRNA in combination with the control adenovirus. Other methods of RNA 
knockdown should also be considered. For example, CRISPR/Cas9 was recently 
demonstrated to efficiently knockdown Ift88 in zebrafish.40 
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This thesis demonstrated the extraordinary capacity for regeneration in neonatal 
cardiac tissue, and the roles of EMT, primary cilia and Malat1 in supporting repair and 
mitigating injury. However, other aspects of EMT signaling through the primary cilium 
and the mechanisms of action of Malat1 should be investigated in future studies to gain a 
further understanding of their roles in MI. 
In Chapter 2, the remarkable capacity of cardiac regeneration in neonatal mice 
was demonstrated; WT, Wt1CreER, and Malat1-/- neonates were able to completely 
regenerate their hearts post-MI. As mentioned above, the heterozygous deletion of Wt1 in 
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the Wt1CreER mouse may not be sufficient to perturb the regenerative response in the 
neonatal heart. Although conditional Cre-mediated Wt1 deletion is not 100% effective,14 
it is possible that the use of an inducible Wt1 knockout may provide superior Wt1 
knockdown and could thus resolve this issue. Furthermore, Malat1 was demonstrated to 
play a role in necroptosis mediated cell death in Chapter 4, however the effect of 
necroptosis in neonatal cardiac regeneration has not been investigated. It would be 
interesting to determine whether perturbing the necroptosis pathway by another 
downstream mediator would affect regenerative capacity. For example, overexpression of 
RIP3 is known to augment ischemic injury from MI,41 thus it is possible that RIP3 
overexpression would reduce the regenerative capacity in neonatal mice. 
In Chapter 3 of this thesis, knockdown of the primary cilium was demonstrated 
to augment EMT, neovascularization and cardiac repair post-MI. In addition to the 
suggested future work mentioned above, there are several experiments which could 
further support our findings. We demonstrated augmented EPDC EMT on a collagen gel 
in vitro by primary ciliary disassembly. When activated EPDCs are seeded next to 
cardiomyocytes in a transwell assay, they migrate towards the cardiomyocytes, reflecting 
their migratory capacity.42 To distinguish migratory ability from mesenchymal like 
differentiation, EPDCs could be treated with Ad-shIft88 in a transwell assay. 
Additionally, we demonstrated a significantly higher density of arterioles and capillaries 
in the peri-infarct area post-MI in our Ad-shIft88 treated group. To confirm the effect of 
shIft88 on neovascularization, an in vivo cardiac Matrigel plug assay could be performed 
to definitively establish an angiogenic response. Given the role of the primary cilium in 
EMT, it is expected that Ad-shIft88 administration with the Matrigel plug would enhance 
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vessel-like formation. Furthermore, to definitively establish whether EPDCs were 
responsible for the increased formation of vasculature, a lineage tracing study could be 
performed to track Wt1 positive cells. Our laboratory has previously demonstrated the 
contribution of Wt1 positive EPDCs to arteriogenesis using ROSAmTmG;Wt1CreER mice,42 
which express membrane-targeted tandem dimer Tomato (mT) globally prior to Cre-
mediated excision, and membrane-targeted enhanced green fluorescent protein (mG) 
upon Cre-mediated excision in Wt1 positive cells. If this study were to be performed, an 
adenoviral construct containing shIft88 without an eGFP tag would be required.  
In Chapter 4, deficiency of Malat1 was demonstrated to augment injury from MI. 
The protective role of Malat1 observed in our study conflicts with the report by Peters et 
al. which demonstrated that Malat1 was dispensable in cardiac hypertrophy.43 
Specifically, this group did not observe any effects of Malat1 deficiency in long term 
cardiac hypertrophic remodeling in response to pressure overload. The long term effects 
of MI induced cardiac remodeling and hypertrophy in Malat1-/- mice were not 
investigated in our study; this should be the subject of future work. Given the role of 
Malat1 in EMT and angiogenesis,27, 44 it is expected that Malat1 deficiency will attenuate 
neovascularization, augment deleterious remodeling, and enhance hypertrophy, thereby 
worsening cardiac function as compared to controls post-MI.  
Furthermore, to definitively discern the role of Malat1 in cardiac ischemic injury, 
the mechanism of action of Malat1 should be established. An attempt was made in the 
present investigation to determine the mechanism by which Malat1 affects cardiac cell 
death. Although we demonstrated the upregulation of mediators of necroptosis in Malat1-
/-
 mice, future work is required to study the molecular mechanism by which Malat1 
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regulates the necroptotic pathway. A model of hypoxic injury in cardiomyocytes in vitro 
may be helpful in elucidating this mechanism. Other studies have demonstrated a role for 
necroptosis in cardiomyocyte death in vitro, however the response to hypoxia in these 
cells was not studied.41  
Differential enzymatic processing of the MALAT1 transcript has recently been 
demonstrated to yield a small RNA molecule, mascRNA, which consists of 61 
nucleotides, and localizes to the cytoplasm.45 High levels of mascRNA have been 
demonstrated in human immunoregulatory cells.46 Gast et al.  further showed differential 
expression patterns of MALAT1 and mascRNA.46 Furthermore, in a monocyte cell line, 
anti-mascRNA treatment enhanced caspase activity and TNF-α expression. Interestingly, 
however, they demonstrate that mascRNA enhances innate immunity gene expression in 
cardiomyocytes. This suggests that the loss of mascRNA may contribute to the 
detrimental effects of Malat1 deficiency in our study. mascRNA levels should be 
measured in future work. 
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This thesis provides the first evidence for the roles of the primary cilium and 
Malat1 in cardiac ischemic injury. Knockdown of the primary cilium offers cardiac 
protection and improves cardiac repair post-MI, while Malat1 deficiency augments 
cardiac injury from MI. Although Malat1 and EMT were demonstrated to be important 
for mitigating injury from cardiac ischemia, perturbing their activity did not affect the 
capacity for neonatal cardiac regeneration (Chapter 2). Further investigation is required 
to determine the therapeutic potential of Ad-shIft88 in humans, however it is clear that 
primary ciliary disassembly and EMT are beneficial post-MI in the adult (Chapter 3). 
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This work has provided valuable insight into the mechanisms by which the primary 
cilium mitigates differentiation and migration of EPDCs. Furthermore, while future 
studies are required to determine the exact mechanism by which Malat1 affects 
cardiomyocyte viability, this work demonstrates its importance in mitigating injury from 
MI (Chapter 4). Whether MALAT1 expression may play a role in determining infarct 
size in human MI remains to be determined. Overall, the doctoral research presented 
herein has broadened the understanding of the primary cilium and the lncRNA Malat1 in 
the response to MI, and resultant cardiac function post-ischemic injury, and may open up 
new strategies in the development of therapeutics for the treatment of MI. 
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